05/13/16/ 16-C-N116
Abbreviated Title: PhI/II Bev Vorinostat GBM  
NCI Version Date: 04/29/2016 
MDACC Version Date: 09/22/2014  
Page i 
NCI APPENDIX  
Abbreviated Title: PhI/II Bev Vorinostat GBM  
NCI Protocol # : pending 
BTTC Protocol # : BTTC11-02 
Title: Phase I/II Adaptive Randomized Trial of Bevacizumab versus Bevacizumab plus Vorinostat 
in Adults with Recurrent Glioblastoma    
Coordinating Center:   NCI BTTC Coordinating Center, Center for Cancer Research  
NCI Principal Investigator:  [INVESTIGATOR_264250], M.D.  
Neuro Oncology Branch (NOB), CCR, NCI  
[ADDRESS_458523], Building 82, Room 235  
Bethesda, MD [ZIP_CODE]  
Phone: 301 -402-6383 
Fax: [PHONE_6168] 
Email: [EMAIL_5089]  
Associate Investigator:   Jing Wu, MD, NOB, CCR, NCI  
NCI Referral Contact(s):  Christine Bryla, RN, OCD, CCR, NCI  
NCI Study Coordinator (s): Christine Bryla, RN, OCD, CCR, NCI  
Neuro Oncology Branch (NOB), CCR, NCI  
[ADDRESS_458524], Building 82, Room 231  
Bethesda, MD [ZIP_CODE]  
Phone: 301 -443-3441 
Fax: [PHONE_6168] 
Email: [EMAIL_5842]   
Investigational Agents:  None 
Commercial Agents:   Vorinostat  and Bevacizumab  was supplied by [CONTACT_366921], [COMPANY_006] Sharp and Dohme Corp . and Genentech  
Abbreviated Title: PhI/II Bev Vorinostat GBM   
NCI Version Date: 04/29/2016 
MDACC Version Date: 09/22/2014  
           Page ii 
 BTTC Roles:  
 
ACADEMIC PI  
[INVESTIGATOR_366857] K. Puduvalli, MD  
Ohio State University  
Division of Neuro -Oncology  
[ADDRESS_458525], M410 
Starling Loving Hall  
Columbus OH [ZIP_CODE]  
Phone:614 -688-7592 
Email: 
[EMAIL_7030]  
FWA00007577  
 
 
ADMINISTRATIVE PI  
[INVESTIGATOR_75712] R. Gilbert, MD  
Neuro-Oncology Branch  
NCI/NINDS  
National Institutes of Health  
Bloch Bldg. 82, Rm. [ADDRESS_458526]  
Bethesda, MD [ZIP_CODE]  
Email:  [EMAIL_5089]   
BTTC BIOSTATISTICIAN  
Ying Yuan, Ph. D.  
UT MD Anderson Cancer 
Center 
Division of Quantitative 
Science 
[ADDRESS_458527].  
Unit 1411  
Houston, TX [ZIP_CODE] -4008 
Phone: 713 -563-4271 
Email: 
[EMAIL_7031]  
FWA00000363  
 
PATIENT OUTCOMES       
Terri S. Armstrong, PhD,  
ANP-BC, FAANP  
UT MD Anderson Cancer 
Center 
Neuro-Oncology, Unit 431  
[PO_BOX]  
Houston, TX  [ZIP_CODE] -1402 
Phone:  713 -745-4621 
Fax:   713 -794-4999 
Email:  
[EMAIL_7032]  
FWA00000363  
  
BTTC COORDINATING 
CENTER  
NCI BTTC Coordinating 
Center 
National Cancer Institute, 
National Institutes of Health  
[ADDRESS_458528], 
Room 211 
Bethesda, MD [ZIP_CODE]  
Phone: [PHONE_7587] 
Fax: [PHONE_5472] 
Email: 
[EMAIL_5091]  
 
 
AGENTS  
Name/s: Vorinostat &  
Bevacizumab  
 
 
A DISCLAIMER STATEMENT FOR BTTC PROTOCOLS  
This is a research protocol of the  Brain Tumor Trials Collaborative describing an experimental 
treatment procedure.  It is a privileged document and is not intended to be circulated or used for 
other purposes.  The Brain Tumor Trials Collaborative assumes no responsibility for its use 
outside of the constraints of this research protocol or by [CONTACT_366922].  
  
Abbreviated Title: PhI/II Bev Vorinostat GBM   
NCI Version Date: 04/29/2016 
MDACC Version Date: 09/22/2014  
           Page iii 
 PARTICIPATING INVESTIGATORS   
Mark Gilbert, MD  
Neuro-Oncology Branch, NCI/NINDS, NIH  
Email:    [EMAIL_5089]   
 
 
Vinay Puduvalli, MD  
Ohio State University Wexner Medical Center  
Email: [EMAIL_7033]    
FWA00007577  
 
Ivo Tremont, MD  
UT, MD Anderson Cancer Center  
Email:    [EMAIL_7034]  
FWA00000363  
 
Marta Penas Prado, MD  
UT, MD Anderson Cancer Center  ‚Äì PI 
[INVESTIGATOR_49852]:   [EMAIL_7035]  
FWA00000363  
 
Jeffrey Raizer, MD  
Northwestern University, Feinberg School of 
Medicine  
Email: [EMAIL_7036]  
FWA00018700  
 
Howard Colman, MD  
University of Utah Health System ‚Äì Huntsman 
Cancer Institute  
Email:  [EMAIL_7037]   
FWA00003745  
 
Karen Fink, MD  
Baylor Neuro -Oncology Associates  
Email: [EMAIL_7038]  
FWA00004415  
 
David Tran, MD  
Washington University School of Medicine  
Email:  [EMAIL_7039]   
FWA00002284  
 
 
 
 W.K. Alfred Yung, M D 
UT, MD Anderson Cancer Center  
Email: [EMAIL_7040]  
FWA00000363  
 
Terri S. Armstrong, APN, Ph.D.  
UT, MD Anderson Cancer Center  
Email:    [EMAIL_7041]  
FWA00000363  
 
John deGroot, MD  
UT, MD Anderson Cancer Center  
Email:    [EMAIL_7042]  
FWA00000363  
 
Monica Loghin, MD  
UT, MD Anderson Cancer Center  
Email:    [EMAIL_7043]  
FWA00000363  
 
Nicholas Avgeropoulos, MD  
MD Anderson Cancer Center - Orlando 
Email: 
[EMAIL_7044]  
FWA00022392  
 
Scott Lindhorst MD  
Medical University of South Carolina  
Hollings Cancer Center  
Email: [EMAIL_7045]   
FWA00001888  
 
Marc Chamberlain, MD 
University of Washington Medical Center  
Email:  [EMAIL_7046]  
FWA00002284  
 
Morris Groves, MD  
[LOCATION_007] Oncology -Austin Brain Tumor Center  
Email:  [EMAIL_7047]   
FWA00017020  
 
 
 
 
Abbreviated Title: PhI/II Bev Vorinostat GBM   
NCI Version Date: 04/29/2016 
MDACC Version Date: 09/22/[ADDRESS_458529] Health System  
Email:  [EMAIL_7048]  
FWA00005846  
 
Fabio Iwamoto, MD  
Columbia University  
Email: [EMAIL_7049]    
FWA00002636  
 
Ryan Merrell, MD  
Northshore University Health System  
Email: [EMAIL_7050]     
FWA00003000  
 
 Nina Paleologos, MD  
Rush University Medical Center  
Email:  [EMAIL_7051]   
FWA00000482  
 
David Peereboo m MD 
Cleveland Clinic  
Email: [EMAIL_3779]  
FWA00005367  
 
[LOCATION_009]s Collichio, MD  
University of North Carolina at Chapel Hill  
Email: [EMAIL_7052]  
FWA00004507  
 
 
 
  
Abbreviated Title: PhI/II Bev Vorinostat GBM   
NCI Version Date: 04/29/2016 
MDACC Version Date: 09/22/2014  
           Page v 
 PR√âCIS  
Background  
ÔÇ∑ Glioblastoma (GBM) is the most common primary brain tumor.  With optimal treatment, 
consisting of focal radiotherapy with concurrent chemotherapy, followed by [CONTACT_208592], median survival is 14.[ADDRESS_458530] evide nce of tumor 
progression within one year of diagnosis despi[INVESTIGATOR_2391].  At progression, treatment 
options are limited and mostly ineffective.  
ÔÇ∑ Given the importance of angiogenesis in GBM, anti -angiogenic therapy is a promising 
strategy in recurrent GBM. B evacizumab, the first angiogenesis inhibitor approved against 
cancer by [CONTACT_366923], has recently 
been studied in the GBM.  
ÔÇ∑ The present study aims to determine the potential of vorinostat, an HDAC inhibito r plus 
bevacizumab, versus bevacizumab alone, in an attempt to increase the anti -angiogenic 
effects of VEGF by [CONTACT_366924].  
Objectives  
ÔÇ∑ To determine the maximum tolerated dose (MTD) of vorinostat plus bevacizumab in adult 
patients with malignant glioma.  
 
ÔÇ∑ To determine the efficacy of vorinostat plus bevacizumab versus bevacizumab alone in 
patients with recurrent WHO grade IV glioma (glioblastoma and gliosarcoma) as 
determined by [CONTACT_3963] (PFS) using an adaptive randomization phase II 
trial design.  
Eligibility  
ÔÇ∑ Patients must have histologically proven glioblastoma, gliosarcoma or anaplastic glioma 
to be eligible for the Phase I component of this protocol. Anaplastic gliomas include 
anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO), anaplastic mixed 
oligoastrocytoma (AMO), or malignant glioma NOS (not otherwise speci fied). Patients 
will be eligible if the original histology was low -grade glioma and a subsequent histological 
diagnosis of a malignant glioma is made. Only patients with histologically proven or 
imaging proven recurrent glioblastoma or gliosarcoma will be eligible for the Phase II 
component.  
ÔÇ∑ Patients must have shown unequivocal evidence for tumor progression as determined by 
[CONTACT_366925].   
ÔÇ∑ No prior treatment with bevacizumab or Vorinostat  
 
 
 
Abbreviated Title: PhI/II Bev Vorinostat GBM   
NCI Version Date: 04/29/2016 
MDACC Version Date: 09/22/2014  
           Page vi 
 Design 
The phase I component will assess the MTD of Vorinostat in combination wi th Bevacizumab .  A 
conventional phase I design will be used and the MTD will be selected using a 3+3 accrual design 
at each dose level until MTD is determined.  A maximum of 18 patients will be recruited to this 
component of the study.  
The phase II component of the  trial compares  Bevacizumab to Vorinostat+ Bevacizumab in 
patients with recurrent GBM. The primary outcome is progression free survival. Patients will be 
randomized between the two arms using a Bayesian adaptive algorithm. Patients will be 
randomized fairly between the two arms at the start of the trial (for the first 20 patients).  
Thereafter, as the trial progre sses and data accrue, the randomization will become unbalanced in 
favor of the treatment that, on average, has better results in terms of failure time.  Therefore, 
each successive patient is more likely to receive the treatment with better results, on aver age. A 
minimum of 20 and a maximum of 90 patients will be accrued . 
  
$EEUHYLDWHG7LWOH3K, ,,%HY9RULQRVWDW*%0
1&,9HUVLRQ'DWH0'$&&9HUVLRQ'DWH
3 D J H  Y L L


7$%/(2)&217(176
35e&,6  Y  
 ,1752'8&7,21  YLLL 
 '$7$&2//(&7,21$1'(9$/8$7,21 YLLL  
 'DWD&ROOHFWLRQ  YLLL 
 'DWD6KDULQJ3ODQV YL LL 
 6$)(7<5(3257,1*5(48,5(0(176'$7$$1'6$)(7<021,725,1*3/$1
L [  
 'HILQLWLRQV  L[  
 $VVHVVLQJ&DXVDOLW\  [L 
 1&,,5%5HSRUWLQJ [L  
 *XLGHOLQHVIRU5HSRUWLQJ6HULRXV$GYHUVH(YHQWVWR%77& [LL  
 5HSRUWLQJWRWKH6WXG\'UXJ0DQXIDFWXUHUV [LY  
 'DWDDQG6DIHW\0RQLWRULQJ3ODQ [Y  
 &2//$%25$7,9($*5((0(176 [Y  
 $JUHHPHQW7\SH [Y L 
 +80$168%-(&763527(&7,216 [YL  
 5DWLRQDOHIRU6XEMHFW6HOHFWLRQ [YL  
 3DUWLFLSDWLRQRI&KLOGUHQ [YL  
 5LVNV%HQHILWV$QDO\VLV [YL  
 3+$50$&(87,&$/,1)250$7,21 [YLL  
$SSHQGL[$&&5352%/(05(3257)250 [YLLL  


$EEUHYLDWHG7LWOH3K, ,,%HY9RULQRVWDW*%0
1&,9HUVLRQ'DWH0'$&&9HUVLRQ'DWH
3 D J H  Y L L L


,1752'8&7,21  
7KHVWXG\LVFXUUHQWO\LQGDWDD QDO\VLVDWDOO%77&SDUWLFLSDWL QJLQVWLWXWLRQV7KHVWXG\ZLOOEH
RSHQHGDW1,+ZKLFKKDVUH SODFHG0'$QGHUVRQDVWKHFRRUGLQDWL QJFHQWHUIRUGDWDDQDO\VLV
RQO\
7KHPDLQERG\RIWKHVWXG\LVL QFOXGHGIRUKLVWRULFDOSXUSRVHV DQGUHPDLQVXQFKDQJHGZLWKWKH
H[FHSWLRQRISURFHGXUHVUH ODWHGWRGDWDFROOHFWLRQDQGUHSRUWLQ J
7KHIROORZLQJJXLGHOLQHVZLOOJRYHUQUHSRUWLQJRIGDWDDQGXQDQ WLFLSDWHGSUREOHPVGHYLDWLRQVWR
WKH1,+
DATA COLLECTION AND EVALUATION  
DATA COLLECTION  
'DWDZLOOEHFROOHFWHGUHSRUWHGLQDVHFX UHUHVHDUFKGDWDEDVH 7KH3,ZLOOEHUHVSRQVLEOHIRU
RYHUVHHLQJHQWU\RIGDWDDQGHQVXULQJGDWDDFFXUDF\FRQVLVWHQF \DQGWLPHOLQHVV7KHSULQFLSDO
LQYHVWLJDWRUDVVRFLDWHLQYHVWLJD WRUVUHVHDUFKQXUVHVDQGRUD FRQWUDFWHGGDWDPDQDJHUZLOODVVLVW
ZLWKWKHGDWDPDQDJHPHQWHIIRUWV
6LWHVZLOOHQWHUGDWDRQSDSHU&D VH5HSRUW)RUPVWKHQWUDQVIHU VWXG\GDWDWR1&,YLDID[PDLORU
6HFXUH(PDLODQG)LOH7UDQVIHU6HUYLFH6()7&RQWUDFWHG'DW D0DQDJHUVZLOOHQWHUWKHGDWD
LQWRDVHFXUHUHVHDUFKGDWDEDVH
8VLQJWKH6HFXUH(PDLODQG)LOH7U DQVIHU6HUYLFH6()7HQVXUH VWKHSURWHFWLRQRIDOOGDWDDQG
LQIRUPDWLRQEHLQJVHQWYLDHPDLO:KH QDQHPDLOLVVHQWWRDQ H[WHUQDOUHVHDUFKVLWHYLD6()7
WKHH[WHUQDOVLWHZLOOUHFH LYHDQHPDLOZLWKDOLQNWRWKH6()7 VLWHDQGWKHVSHFLILFHPDLO
(QGRIVWXG\SURFHGXUHV 'DWDZLOOEHVWRUHGDFFRUGLQJWR++6DQG)'$UHJXODWLRQVDV
DSSOLFDEOH
/RVVRUGHVWUXFWLRQRIGDWD 6KRXOGZHEHFRPHDZDUHWKDWDPDMRUEUHDFKLQRXUSODQWRSURWH FW
VXEMHFWFRQILGHQWLDOLW\DQGWULDOGDWDKD VRFFXUUHGWKH,5%ZL OOEHQRWLILHG

DATA SHARING PLANS  
+XPDQ'DWD6KDULQJ3ODQ
:KDWGDWDZLOOEHVKDUHG"
,ZLOOVKDUHKXPDQGDWDJHQHUDWHGLQWKLVUHVHDUFKIRUIXWXUHU HVHDUFKDVIROORZV
x'HLGHQWLILHGGDWDLQDQ1,+IXQG HGRUDSSURYHGSXEOLFUHSRVLWR U\
x'HLGHQWLILHGGDWDLQ%75,6DXWRP DWLFIRUDFWLYLWLHVLQWKH&O LQLFDO&HQWHU
x'HLGHQWLILHGRULGHQWLILHGGDWDZ LWKDSSURYHGRXWVLGHFROODERU DWRUVXQGHUDSSURSULDWH
DJUHHPHQWV

+RZDQGZKHUHZLOOWKHGDWDEHVKDUHG"
'DWDZLOOEHVKDUHGWKURXJK
x$Q1,+IXQGHGRUDSSURYHGSXEOLFUHSRVLWRU\,QVHUWQDPHRUQD PHVFOLQLFDOWULDOVJRY
$EEUHYLDWHG7LWOH3K, ,,%HY9RULQRVWDW*%0
1&,9HUVLRQ'DWH0'$&&9HUVLRQ'DWH
3 D J H  L [

x%75,6DXWRPDWLFIRUDFWLYLWL HVLQWKH&OLQLFDO&HQWHU
x$SSURYHGRXWVLGHFROODERUDWRUVXQGHUDSSURSULDWHLQGLYLGXDODJU HHPHQWV
x3XEOLFDWLRQDQGRUSXEOLFSUHVHQWDWLRQV

:KHQZLOOWKHGDWDEHVKDUHG"
x%HIRUHSXEOLFDWLRQ
x$WWKHWLPHRISXEOLFDWLRQRUVKRUWO\WKHUHDIWHU

*HQRPLF'DWD6KDULQJ3ODQ
8QOLQNHGJHQRPLFGDWDZLOOEHGH SRVLWHGLQSXEOLFJHQRPLFGDWDE DVHVVXFKDVGE*D3LQ
FRPSOLDQFHZLWKWKH1,+*HQRPLF'DWD6KDULQJ3ROLF\

SAFETY REPORTING REQUIREMENTS/DATA AND SAFETY MONITORING 
PLAN  
$WWLPHRIWUDQVLWLRQWR1,+DFF UXDOLVFRPSOHWHDQGWKHVWXG\ VWDWXVLVORQJWHUPIROORZXS
7KHIROORZLQJUHTXLUHPHQWVDQGSODQDUHIRUHYHQWVGXULQJORQJ WHUPIROORZXSDQGLQFLGHQWDOWR
GDWDFROOHFWLRQXSRQWUDQVLWLRQWR1,+
DEFINITIONS  
$GYHUVH(YHQW
$QDGYHUVHHYHQWLVGHILQHGDVD Q\UHDFWLRQVLGHHIIHFWRUXQ WRZDUGHYHQWWKDWRFFXUVGXULQJWKH
FRXUVHRIWKHFOLQLFDOWULDO DVVRFLDWHGZLWKWKHXVHRIDGUXJ LQKXPDQVZKHWKHURUQRWWKHHYHQW
LVFRQVLGHUHGUHODWHGWRWKH WUHDWPHQWRUFOLQLFDOO\VLJQLILFDQ W)RUWKLVVWXG\$(VZLOOLQFOXGH
HYHQWVUHSRUWHGE\WKHSDWLHQWDVZ HOODVFOLQLFDOO\VLJQLILFD QWDEQRUPDOILQGLQJVRQSK\VLFDO
H[DPLQDWLRQRUODERUDWRU\HYDOXDWLRQ$QHZLOOQHVVV\PSWRPV LJQRUFOLQLFDOO\VLJQLILFDQW
ODERUDWRU\DEQRUPDOLW\RUZRUVH QLQJRIDSUHH[LVWLQJFRQGLWLRQ RUDEQRUPDOLW\LVFRQVLGHUHGDQ
$($OO$(VPXVWEHUHFRUGHGRQWKH$(FDVHUHSRUWIRUP
$OO$(VLQFOXGLQJFOLQLFDOO\VLJQLILFDQWDEQRUPDOILQGLQJVRQ ODERUDWRU\HYDOXDWLRQVUHJDUGOHVV
RIVHYHULW\ZLOOEHIROORZHGXQWLOUHWXUQWREDVHOLQHRUVWDEL OL]DWLRQRIHYHQW
6HULRXVDGYHUVHHYHQWVWKDWRFF XUPRUHWKDQGD\VDIWHUWKHO DVWDGPLQLVWUDWLRQRI
LQYHVWLJDWLRQDODJHQWLQWHUYHQWL RQDQGKDYHDQDWWULEXWLRQRID WOHDVWSRVVLEO\UHODWHGWRWKH
DJHQWLQWHUYHQWLRQVKRXOGEHUHFRUGH GDQGUHSRUWHGDVSHUVHFWL RQVDQG
$QDEQRUPDOODERUDWRU\YDOXHZLO OEHFRQVLGHUHGDQ$(LIWKHOD ERUDWRU\DEQRUPDOLW\LV
FKDUDFWHUL]HGE\DQ\RIWKHIROORZLQJ
x5HVXOWVLQGLVFRQWLQXDWLRQIURPWKHVWXG\
x,VDVVRFLDWHGZLWKFOLQLFDOVLJQVRUV\PSWRPV
x5HTXLUHVWUHDWPHQWRUDQ\RWKHUWKHU DSHXWLFLQWHUYHQWLRQ
x,VDVVRFLDWHGZLWKGHDWKRUDQRWKHU VHULRXVDGYHUVHHYHQWLQFO XGLQJKRVSLWDOL]DWLRQ
x,VMXGJHGE\WKH,QYHVWLJDWRUWREHRIVLJQLILFDQWFOLQLFDOLPS DFW
$EEUHYLDWHG7LWOH3K, ,,%HY9RULQRVWDW*%0
1&,9HUVLRQ'DWH0'$&&9HUVLRQ'DWH
3 D J H  [

x,IDQ\DEQRUPDOODERUDWRU\ UHVXOWLVFRQVLGHUHGFOLQLFDOO\VLJQ LILFDQWWKHLQYHVWLJDWRUZLOO
SURYLGHGHWDLOVDERXWWKHDFWLRQWDNHQZLWKUHVSHFWWRWKHWHVW GUXJDQGDERXWWKHSDWLHQW¬∂V
RXWFRPH
6XVSHFWHGDGYHUVHUHDFWLRQ
6XVSHFWHGDGYHUVHUHDFWLRQPHDQVD Q\DGYHUVHHYHQWIRUZKLFKWK HUHLVDUHDVRQDEOHSRVVLELOLW\
WKDWWKHGUXJFDXVHGWKHDGYHUVHHYH QW)RUWKHSXUSRVHVRI,1' VDIHW\UHSRUWLQJ¬µUHDVRQDEOH
SRVVLELOLW\¬∂PHDQVWKHUHLVH YLGHQFHWRVXJJHVWDFDXVDOUHODWL RQVKLSEHWZHHQWKHGUXJDQGWKH
DGYHUVHHYHQW$VXVSHFWHGDGYHUV HUHDFWLRQLPSOLHVDOHVVHUGH JUHHRIFHUWDLQW\DERXWFDXVDOLW\
WKDQDGYHUVHUHDFWLRQZKLFKPHDQVDQ\DGYHUVHHYHQWFDXVHGE\ DGUXJ
8QH[SHFWHGDGYHUVHUHDFWLRQ
$QDGYHUVHHYHQWRUVXVSHFWHGDGYH UVHUHDFWLRQLVFRQVLGHUHG¬≥X QH[SHFWHG¬¥LILWLVQRWOLVWHGLQ
WKHLQYHVWLJDWRUEURFKXUHRULVQRWOLVWH GDWWKHVSHFLILFLW\R UVHYHULW\WKDWKDVEHHQREVHUYHGRU
LIDQLQYHVWLJDWRUEURFKXUHLVQR WUHTXLUHGRUDYDLODEOHLVQR WFRQVLVWHQWZLWKWKHULVNLQIRUPDWLRQ
GHVFULEHGLQWKHJHQHUDOLQYHVWL JDWLRQDOSODQRUHOVHZKHUHLQW KHFXUUHQWDSSOLFDWLRQ
8QH[SHFWHG¬¥DOVRUHIHUVWRDGYH UVHHYHQWVRUVXVSHFWHGDGYHUVH UHDFWLRQVWKDWDUHPHQWLRQHGLQ
WKHLQYHVWLJDWRUEURFKXUHDVRFFXUULQJZLWKDFODVVRIGUXJVRU DVDQWLFLSDWHGIURPWKH
SKDUPDFRORJLFDOSURSHUWLHVRIWKH GUXJEXWDUHQRWVSHFLILFDOO \PHQWLRQHGDVRFFXUULQJZLWKWKH
SDUWLFXODUGUXJXQGHULQYHVWLJDWLRQ
6HULRXV
$Q8QDQWLFLSDWHG3UREOH PRU3URWRFRO'HYLDWLRQLVVHULRXVLILW PHHWVWKHGHILQLWLRQRID6HULRXV
$GYHUVH(YHQWRULILWFRPSURPLVHVWKHVDIHW\ZHOIDUHRUULJKW VRIVXEMHFWVRURWKHUV
6HULRXV$GYHUVH(YHQW
$QDGYHUVHHYHQWRUVXVSHFWHGDGYH UVHUHDFWLRQLVFRQVLGHUHGVH ULRXVLILQWKHYLHZRIWKH
LQYHVWLJDWRURUWKHVSRQVRULWUHVXOWVLQDQ\RIWKHIROORZLQJ 
x'HDWK
x$OLIHWKUHDWHQLQJDGYHUV HGUXJH[SHULHQFH
x,QSDWLHQWKRVSLWDOL]DWL RQRUSURORQJDWLRQRIH[LVWLQJKRVSLWDOL ]DWLRQ
x3HUVLVWHQWRUVLJQLILFDQWLQFDSDFLW\RUVXEVWDQWLDOGLVUXSWLRQ RIWKHDELOLW\WRFRQGXFW
QRUPDOOLIHIXQFWLRQV
x$FRQJHQLWDODQRPDO\ELUWKGHIHFW
x,PSRUWDQWPHGLFDOHYHQWVW KDWPD\QRWUHVXOWLQGHDWKEHOLIH WKUHDWHQLQJRUUHTXLUH
KRVSLWDOL]DWLRQPD\EHFRQVLGHUHG DVHULRXVDGYHUVHGUXJH[SHUL HQFHZKHQEDVHGXSRQ
DSSURSULDWHPHGLFDOMXGJPHQWWKH\ PD\MHRSDUGL]HWKHSDWLHQWR UVXEMHFWDQGPD\UHTXLUH
PHGLFDORUVXUJLFDOLQWHUYHQWLRQWRSUHYHQWRQHRIWKHRXWFRPHV OLVWHGLQWKLVGHILQLWLRQ
'LVDELOLW\
$VXEVWDQWLDOGLVUXSWLRQRIDSHUVRQ¬∂VDELOLW\WRFRQGXFWQRUPD OOLIHIXQFWLRQV
$EEUHYLDWHG7LWOH3K, ,,%HY9RULQRVWDW*%0
1&,9HUVLRQ'DWH0'$&&9HUVLRQ'DWH
3 D J H  [ L


/LIHWKUHDWHQLQJDGYH UVHGUXJH[SHULHQFH
$Q\DGYHUVHHYHQWRUVXVSHFWHGD GYHUVHUHDFWLRQWKDWSODFHVWKH SDWLHQWRUVXEMHFWLQWKHYLHZRI
WKHLQYHVWLJDWRURUVSRQVRUDWLPP HGLDWHULVNRIGHDWKIURPWK HUHDFWLRQDVLWRFFXUUHGLHLW
GRHVQRWLQFOXGHDUHDFWLRQWKDWKDGLW RFFXUUHGLQDPRUHVHYH UHIRUPPLJKWKDYHFDXVHGGHDWK
3URWRFRO'HYLDWLRQ1,+'HILQLWLRQ
$Q\FKDQJHGLYHUJHQFHRUGHSDUWXUHIURPWKH,5%DSSURYHGUHVH DUFKSURWRFRO
1RQFRPSOLDQFH1,+'HILQLWLRQ
7KHIDLOXUHWRFRPSO\ZLWKDSSOLFD EOH1,++XPDQ5HVHDUFK3URWHF WLRQV3URJUDP+533
SROLFLHV,5%UHTXLUHPHQWVRUUHJXODWRU\UHTXLUHPHQWVIRUWKH SURWHFWLRQRIKXPDQUHVHDUFK
VXEMHFWV
8QDQWLFLSDWHG3UREOHP
$Q\LQFLGHQWH[SH ULHQFHRURXWFRPHWKDW
x,VXQH[SHFWHGLQWHUPVRIQDWXUHVHYHULW\RUIUHTXHQF\LQUH ODWLRQWR
DWKHUHVHDUFKULVNVWKDWDUH GHVFULEHGLQWKH,5%DSSURYHGU HVHDUFKSURWRFRODQG
LQIRUPHGFRQVHQWGRFXPHQW,QYHVWL JDWRU¬∂V%URFKXUHRURWKHUVWX G\GRFXPHQWVDQG
EWKHFKDUDFWHULVWLFVRIWKH VXEMHFWSRSXODWLRQEHLQJVWXGLHG $1'
x,VUHODWHGRUSRVVLEO\UHODWHGWRSDUWLFLSDWLRQLQWKHUHVHDUFK $1'
x6XJJHVWVWKDWWKHUHVHDUFKSODFHVVXEMHFWVRURWKHUVDWD JUHDWHUULVNRIKDUP LQFOXGLQJ
SK\VLFDOSV\FKRORJLFDOHF RQRPLFRUVRFLDOKDUPWKDQZDVSUH YLRXVO\NQRZQRU
UHFRJQL]HG
ASSESSING CA[LOCATION_003]LITY  
,QYHVWLJDWRUVDUHUHTXLUHGWRDVVHVVZKH WKHUWKHUHLVDUHDVRQD EOHSRVVLELOLW\WKDWWKHVWXG\DJHQWV
FDXVHGRUFRQWULEXWHGWR DQDGYHUVHHYHQW7KHIROORZLQJJHQHU DOJXLGDQFHPD\EHXVHG
<HV ,IWKHWHPSRUDOUHODWLRQVKLSRIWKHFOLQLFDOHYHQWWRWKHVWXG \DJHQWV
DGPLQLVWUDWLRQPDNHVDFD XVDOUHODWLRQVKLSSRVVLEOHDQGRWKHU GUXJVWKHUDSHXWLF
LQWHUYHQWLRQVRUXQGHUO\LQJFRQGLWLRQVGRQRWSURYLGHDVXIILFL HQWH[SODQDWLRQIRUWKH
REVHUYHGHYHQW
1R ,IWKHWHPSRUDOUHODWLRQVKLSRIWKHFOLQLFDOHYHQWWRWKHVWXG \DJHQWV
DGPLQLVWUDWLRQPDNHVDFD XVDOUHODWLRQVKLSXQOLNHO\RURWKHUG UXJVWKHUDSHXWLF
LQWHUYHQWLRQVRUXQGHUO\LQJF RQGLWLRQVSURYLGHDVXIILFLHQWH[S ODQDWLRQIRUWKHREVHUYHG
HYHQW
NCI-IRB  REPORTING  
1&,,5%([SHGLWHG5HSRUWLQJRI 8QDQWLFLSDWHG3UREOHPVDQG'HDWK V
7KHDGPLQLVWUDWLYH3,ZLOOUHSRUWWRWKH1&,,5%
x$OOGHDWKVH[FHSWGHDWKVGXHWRSURJUHVVLYHGLVHDVH
x$OO3URWRFRO'HYLDWLRQV
$EEUHYLDWHG7LWOH3K, ,,%HY9RULQRVWDW*%0
1&,9HUVLRQ'DWH0'$&&9HUVLRQ'DWH
3 D J H  [ L L

x$OO8QDQWLFLSDWHG3UREOHPV
x$OOVHULRXVQRQFRPSOLDQFH
5HSRUWVPXVWEHUHFHLYHGE\WKH1&,, 5%ZLWKLQZRUNLQJGD\VR I3,DZDUHQHVVYLDL5,6
1&,,5%5HTXLUHPHQWVIRU3,5HSRUWLQJDW&RQWLQXLQJ5HYLHZ
7KHDGPLQLVWUDWLYH3,ZLOOUHSRUWWRWKH1&,,5%
$VX[COMPANY_003]U\RIDOOSURWRFROGHYLDWLRQVLQDWDEXODUIRUPDWWRLQF OXGHWKHGDWHWKHGHYLDWLRQ
RFFXUUHGDEULHIGHVFULSW LRQRIWKHGHYLDWLRQDQGDQ\FRUUHFWL YHDFWLRQ
$VX[COMPANY_003]U\RIDQ\LQVWDQFHVRIQRQFRPSOLDQFH
$WDEXODUVX[COMPANY_003]U\RIWKHIROORZLQJDGYHUVHHYHQWV
x$OO*UDGH XQH[SHFWHG HYHQWVWKDWDUHSRVVLEO\SUREDEO\RUGHILQLWHO\UHODWHGWRWK H
UHVHDUFK
x$OO*UDGHDQGHYHQWVWKDWDUHSRVVL EO\SUREDEO\RUGHILQLW HO\UHODWHGWRWKH
UHVHDUFK
x$OO*UDGHHYHQWVUHJD UGOHVVRIDWWULEXWLRQ
x$OO6HULRXV(YHQWVUHJDUGOHVVRIDWWULEXWLRQ
127(*UDGHHYHQWVDUHQRWUHTXLU HGWREHUHSRUWHG
0XOWL,QVWLWXWLRQDO*XLGHOLQHV
,5%$SSURYDOV
7KH$GPLQLVWUDWLYH3,ZLOOSURYLGHWKH1& ,,5%DQG&HQWUDO5HJL VWUDWLRQ2IILFHZLWKDFRS\RI
WKHSDUWLFLSDWLQJLQVWLWXWLRQ¬∂VDSSURYHG\HDUO\FRQWLQXLQJUHYL HZ5HJLVWUDWLRQZLOOEHKDOWHGDW
DQ\SDUWLFLSDWLQJLQVWLWXWLRQLQZKLFKDFXUUHQWFRQWLQXLQJDSS URYDOLVQRWRQILOHDWWKH1&,,5%
$PHQGPHQWV
7KH$GPLQLVWUDWLYH3,ZLOOSURYLGHWKH 1&,,5%ZLWKFRSLHVRID OODPHQGPHQWVDQGDSSURYDOV
IURPHDFKSDUWLFLSDWLQJLQVWLWXWLRQ
*8,'(/,1(6)25 5(3257,1* 6(5,286$'9(56((9(17672 %77&  
:KDWWR5HSRUW" :KHQWR5HSRUW"
$OO'HDWKVH[FHSWWKDWGXHWR
SURJUHVVLYHGLVHDVHRFFXUULQJIURPWKH
WLPHWKHFRQVHQWLVVLJQHGWKURXJK
GD\VDIWHUWKHODVWGD\RIDFWLYH
WUHDWPHQW:LWKLQ ZRUNLQJGD\KRXUVIURPWKH
WLPHWKHUHVHDUFKWHDP EHFRPHVDZDUHRI
HYHQW
$EEUHYLDWHG7LWOH3K, ,,%HY9RULQRVWDW*%0
1&,9HUVLRQ'DWH0'$&&9HUVLRQ'DWH
3 D J H  [ L L L

:KDWWR5HSRUW" :KHQWR5HSRUW"
2WKHU6HULRXV8QH[SHFWHG6XVSHFWHG
$GYHUVH5HDFWLRQV WKDWGLGQRWUHVXOW
LQGHDWKRFFXUULQJIURPWKHWLPHWKHFRQVHQWLVVLJQHGDQGIRUWKHGXUDWLRQRIWKHVXEMHFW¬∂VSDUWLFLSDWLRQRQWKH
VWXG\:LWKLQ ZRUNLQJGD\VIURPWKHWLPHWKH
UHVHDUFKWHDP EHFRPHVDZDUHRIHYHQW
$OOSURWRFROGHYLDWLRQVQRQ
FRPSOLDQFHDQGXQDQWLFLSDWHG
SUREOHPV:LWKLQ ZRUNLQJGD\VIURPWKHWLPHWKH
UHVHDUFKWHDP EHFRPHVDZDUHRIHYHQW
3UHJQDQF\DOWKRXJKQRWLWVHOIDVHULRXV
DGYHUVHHYHQWVKRXOGDOVREHUHSRUWHGRQDVHULRXVDGYHUVHHYHQWIRUPDQGEH
IROORZHGXSWRGHWHUPLQHRXW FRPH
LQFOXGLQJVSRQWDQHRXVRUYROXQWDU\WHUPLQDWLRQGHWDLOVRIELUWKDQGWKH
SUHVHQFHRUDEVHQFHRIDQ\ELUWK
GHIHFWVRUFRQJHQLWDODEQRUPDOLWLHV:LWKLQ ZRUNLQJGD\VIURPWKHWLPHWKH
UHVHDUFKWHDP EHFRPHVDZDUHRIHYHQW
7KH&&5SUREOHPUHSRUWIRUPZLOO EHXVHGWRVXEPLWDGYHUVHHYHQ WVWR%77&6HH $SSHQGL[$ 
3DUWLFLSDWLQJFHQWHUVPXVWDOVRVXEP LWWKHUHSRUWWRWKHLU,5% LQDFFRUGDQFHZLWKWKHLU
LQVWLWXWLRQDOSROLFLHV
7KH%77&&RRUGLQDWLQJ&H QWHUZLOOPDLQWDLQGRFXPHQWDWLRQRIDOO 6HULRXV$GYHUVH(YHQWVIURP
HDFKLQVWLWXWLRQ7KH%77&&RRUGLQDWLQJ &HQWHUZLOOQRWLI\DOO LQYHVWLJDWRUVRIDQ\VHULRXVDQG
XQH[SHFWHGDGYHUVHH[SHULHQ FHVWKDWDUHSRVVLEO\UHODWHGWRWKH VWXG\DJHQWV7KHLQYHVWLJDWRUV
DUHWRILOHDFRS\ZLWKWKHLUSURWRFROILOHDQGVHQGDFRS\WR WKHLU,5%DFFRUGLQJWRWKHLUORFDO
,5%¬∂VSROLFLHVDQGSURFHGXUHV
*XLGHOLQHV	3URFHGXUHVIRU UHSRUWLQJ'HYLDWLRQVDQG8QDQWLFLSD WHG3UREOHPV 
1HLWKHUWKH)'$QRUWKH,&+*&3JXLGHOLQHVGHILQHWKHWHUP¬≥SUR WRFROGHYLDWLRQ¬¥7KHGHILQLWLRQ
LVRIWHQOHIWWRWKH/HDG,QVWLWXWLRQ,5%$FFRUGLQJO\VLQFH 1&,&HQWHUIRU&DQFHU5HVHDUFKLV
WKH&RRUGLQDWLQJ&HQWHUDQGWKH $GPLQLVWUDWLYH3,PXVWDGKHUHW RWKRVHSROLFLHVVHWE\WKH1&,
,5%WKHGHILQLWLRQVIRUXQDQWL FLSDWHGSUREOHPDQGSURWRFROGHY LDWLRQDVGHVFULEHGE\WKH1&,,5%
ZLOOEHDSSOLHGIRUUHSRUWLQJSXUSRVHVIRUDOOLQVWLWXWLRQVSDU WLFLSDWLQJLQWKH1&,&HQWHUIRU&DQFHU
5HVHDUFK0XOWLFHQWHU3URMHF W'HILQLWLRQVDUHOLVWHGLQVHFWLR Q
3URWRFRO'HYLDWLRQVRU8QDQWLFLSDWHGSUREOHPVRFFXUULQJDWDSD UWLFLSDWLQJLQVWLWXWLRQZLOOEH
VXEPLWWHG WR WKDW LQVWLWXWLRQ¬∂V RZQ ,5% LQ DFFRUGDQFH ZLWK ORFD O SROLFLHV DQG SURFHGXUHV
+RZHYHUWKHSDUWLFLSDWLQJLQVWLW XWLRQPXVWVXEPLWDUHSRUWWR WKH%77&&RRUGLQDWLQJ&HQWHUHYHQ
LQLQVWDQFHVZKHUHWKHORFDO,5%GRHVQRWUHTXLUHDUHSRUW
'HYLDWLRQVRU8QDQWLFLSDWHGSUREOHPVPXVWEHVXEPLWWHGWRWKH1 &,%77&&RRUGLQDWLQJ&HQWHU
ZLWKLQZRUNLQJGD\VDIWHUWKHRULJLQDOVXEPLVVLRQWRWKH,5% RUDIWHUEHFRPLQJDZDUHRIWKH
HYHQWLIQRWUHSRUWDEOHWRWKHORFDO,5%:KHQ'HYLDWLRQVRU 8QDQWLFLSDWHG3UREOHPVDUHUHSRUWHG
WR%77&EXWWKHORFDO,5%GRHVQRWUHTXLUHDUHSRUWWKHUHSR UWWKDWLVVXEPLWWHGWRWKH1&,%77&
$EEUHYLDWHG7LWOH3K, ,,%HY9RULQRVWDW*%0
1&,9HUVLRQ'DWH0'$&&9HUVLRQ'DWH
3 D J H  [ L Y

&RRUGLQDWLQJ&HQWHUPXVWEHDFFRPSDQLHGE\DIRUPDOPHPRH[SODL QLQJWKHORFDOSROLF\DQGWKH
UDWLRQDOHIRUQRWUHSRUWLQJWKHHYHQWWRWKHORFDO,5%
'HYLDWLRQRU8QDQWLFLSDWHGSUREOHP5H SRUWVDQGDQ\DFFRPSDQ\LQJ GRFXPHQWDWLRQWRLQFOXGH
WKHORFDO,5%DFNQRZOHGJHPHQWRIWKHHYHQWZKHQDSSOLFDEOHDUH WREHVXEPLWWHGWRWKH1&,
%77&&RRUGLQDWLQJ&HQWHUXVLQJWKHSUREOHPUHSRUWIRUPLQ $SSHQGL[$ YLDID[DW

1&,&HQWHUIRU&DQFHU5HVHDUFK&RRUGLQDWLQJ&HQWHU8SRQUHFHL SWRIWKHGHYLDWLRQXQDQWLFLSDWHG
SUREOHPUHSRUWIURPWKHSDUWLFLSDWLQJL QVWLWXWLRQWKH1&,%77& &RRUGLQDWLQJ&HQWHUZLOOVXEPLW
WKHUHSRUWWRWKH$FDGHPLF3,IRUUHYLHZ6XEVHTXHQWO\WKHSDU WLFLSDWLQJLQVWLWXWLRQ¬∂V,5%
GHYLDWLRQXQDQWLFLSDWHGSUREOHPUH SRUWZLOOEHVXEPLWWHGWRWKH 1&,,5%IRUUHYLHZ

5(3257,1*727+( 678'<'58*0$18)$&785(56 
7KH1&,%77&&RRUGLQDWLQJ&HQWH UZLOOIRUZDUGDOO6$(UHSRUWVW RWKHOHDG,5%YLDWKHOHDG
LQYHVWLJDWRU)'$ZKHQDSSOLFDEOH DQG*HQHQWHFK'UXJ6DIHW\ DQG0HUFN6KDUSDQG'RKPH
&RUS:RUOGZLGHVDIHW\
*HQHQWHFK'UXJ6DIHW\DQG0HUFN6KDUS DQG 'RKPH &RUS:RUOGZLGH6DIHW\
)'$0HG:DWFK GD\$OHUW
5HSRUW
*HQHQWHFK'UXJ6DIHW\ 
)D[  RU

8VLQJWKHVDIHW\UHSRUWLQJID[FRYHU
VKHHWDWWDFKHGWRWKLVGRFXPHQW 

0HUFN6KDUSHDQG'RKPH&RUS 
$WWQ:RUOGZLGH3URGXFW6DIHW\
)D[


$1'

6WXG\&RRUGLQDWLRQ&HQWHU3ULQFLSDO
,QYHVWLJDWRU 
&RQWDFW,QIRUPDWLRQDQGID[
DQG
3KRQH)'$
)$;)'$ RUE\PDLOWR
0HG:DWFK 
&HQWHUIRU%LRORJLFV(YDOXDWLRQDQG
5HVHDUFK
)RRGDQG'UXJ$GPLQLVWUDWLRQ 
6XLWH15RFNYLOOH3LNH 
5RFNYLOOH0' 
)$;)'$ RUE\PDLOWR
0HG:DWFK )RRG DQG 'UXJ$GPLQLVWUDWLRQ

)LVKHUV/DQH5RFNYLOOH0'


$EEUHYLDWHG7LWOH3K, ,,%HY9RULQRVWDW*%0
1&,9HUVLRQ'DWH0'$&&9HUVLRQ'DWH
3 D J H  [ Y


6$(VZLOOEHIRUZDUGHGWR *HQHQWHFK'UXJ6DIHW\DQG 0HUFN6KDUSDQG'RKPH&RUS
:RUOGZLGH6DIHW\YLDWK H1&,%77&&RRUGLQDWLQJ&HQWHULQDFFRUG DQFHZLWKWKH
IROORZLQJ 
$OOVHULRXVDGYHUVHHYHQWVVKRXOGEHUH SRUWHGWR*HQHQWHFK'UXJ 6DIHW\DQG0HUFN6KDUSDQG
'RKPH&RUS:RUOGZLGH6DIHW\ ZLWKLQKRXUV,QWKHHYHQWRID Q6$(WKHLQYHVWLJDWRUVKRXOG
UHIHUWRWKH3KDUPDFRYLJLODQFH VHFWLRQRIWKHFRQWUDFWIRUUHSR UWLQJSURFHGXUHV,QEULHI
7KH,QYHVWLJDWRU6SRQVRUPD\UHS RUWVHULRXVDGYHUV HGUXJUHDFWL RQV
6$'5VXVLQJHLWKHU 
$0HG:DWFKIRUPDYDLO DEOHDWKWWSZZZIGDJRYPHGZDWFK

2FFDVLRQDOO\%77&PD\FRQWDFWWKHUHSRUWHUIRUDGGLWLRQDOLQIRU PDWLRQFODULILFDWLRQRUFXUUHQW
VWDWXVRIWKHVXEMHFWIRUZKRPDQDGYHUVH HYHQWZDVUHSRUWHG
'$7$$1' 6$)(7<021,725,1* 3/$1
3ULQFLSDO,QYHVWLJDWRU5HVHDUFK7HDP
7KHFOLQLFDOUHVHDUFKWHDPZLOOKD YHDWHOHFRQIHUHQFHHYHU\RWK HUZHHNZKHQSD WLHQWVDUHEHLQJ
DFWLYHO\WUHDWHGRQWKHWULDOW RGLVFXVVHDFKSDWLHQW'HFLVLRQ VDERXWGRVHOHYHOHQUROOPHQWDQG
GRVHHVFDODWLRQLIDSSOLFD EOHZLOOEHPDGHEDVHGRQWKHWR[LFLW \GDWDIURPSULRUSDWLHQWV
$OOGDWDZLOOEHFROOHFWHGLQDWLPHO\ PDQQHUDQGUHYLHZHGE\W KH3ULQFLSDOLQYHVWLJDWRURUDOHDG
DVVRFLDWHLQYHVWLJDWRU$GYHUVHHYH QWVZLOOEHUHSRUWHGDVUHTX LUHGDERYH$Q\VDIHW\FRQFHUQV
QHZLQIRUPDWLRQWKDWPLJKWDIIHFWHLWKHU WKHHWKLFDODQGRUVFL HQWLILFFRQGXFWRIWKHWULDORU
SURWRFROGHYLDWLRQVZLOOEHLPPHGLDWHO\U HSRUWHGWRWKH,5%XVL QJL5,6
7KH3ULQFLSDO,QYHVWLJDWRUZLO OUHYLHZDGYHUVH HYHQWDQGUHVSRQ VHGDWDRQHDFKSDWLHQWWRHQVXUH
VDIHW\DQGGDWDDFFXUDF\7KH 3ULQFLSDO,QYHVWLJDWRUZLOOSHUVR QDOO\FRQGXFWRUVXSHUYLVHWKH
LQYHVWLJDWLRQDQGSURYLGHDSSURSULD WHGHOHJDWLRQRIUHVSRQVLELO LWLHVWRRWKHUPHPEHUVRIWKH
UHVHDUFKVWDII
'DWD6DIHW\0RQLWRULQJ%RDUG
7KH0'$QGHUVRQ'60%PHWDQGUH YLHZHGWKHUHSRUWRISURJUHVVDQ GDGYHUVHHYHQWVRIWKH
DERYHOLVWHGSURWRFRO%DVHGRQWKHLQIRUPD WLRQUHYLHZHGWKH 0'$QGHUVRQ'60%KDVPDGH
WKHIROORZLQJGHWHUPLQDWLRQ
x7KH&RPPLWWHHDSSURYHGWRHQGD FWLYH'60%PRQLWRULQJRIWKHWUL DO
x5HOHDVHWKHGDWDWRWKH3,
x3URYLGHDILQDOUHSRUWWR WKH'60%ZKHQDOOGDWDLVFROOHFWHG

COLLABORATIVE AGREEMENTS  
$EEUHYLDWHG7LWOH3K, ,,%HY9RULQRVWDW*%0
1&,9HUVLRQ'DWH0'$&&9HUVLRQ'DWH
3 D J H  [ Y L


AGREEMENT TYPE 
7KHUHLVD%77&FRQVRUWLDDJUHH PHQWLQSODFHEHWZHHQDOORIWKH SDUWLFLSDWLQJLQVWLWXWLRQVOLVWHG
RQWKHWLWOHSDJHRIWKLVVWXG\

HUMAN SUBJECTS PROTECTIONS 
RATIONALE FOR SUBJECT SELECTION  
7KLVVWXG\ZDVGHVLJQHGWRLQFOXGHZRPHQDQGPLQRULWLHVEXWZD VQRWGHVLJQHGWRPHDVXUH
GLIIHUHQFHVRILQWHUYHQWLRQHII HFWV0DOHVDQGIHPDOHVZLOOEH UHFUXLWHGZLWKQRSUHIHUHQFHWR
JHQGHU1RH[FOXVLRQWRWKLVVW XG\ZLOOEHEDVHGRQUDFH0LQ RULWLHVZLOODFWLYHO\EHUHFUXLWHGWR
SDUWLFLSDWH*OLREODVWRPDVRFF XULQSDWLHQWVRIDOOUDFHVDQG DOWKRXJKWKHUHLVDVOLJKW
SUHGRPLQDQFHLQPHQWKLVL VDGLVHDVHWKDWLVDOVRIRXQGLQZR PHQ7KHPROHFXODUWDUJHWVRI
EHYDFL]XPDEDQGYRULQRVWDWZLWKLQWKHWXPRUDUHQRWNQRZQWREH GLIIHUHQWDPRQJSDWLHQWVEDVHG
RQJHQGHURUUDFHKHQFHWKLVVWXG\ZLOOEHRSHQWRDOODGXOWV 
PARTICIPATION OF CHILDREN  
,QGLYLGXDOVXQGHUWKHDJHRI ZLOOQRWEHHOLJLEOHWRSDUWLFL SDWHLQWKLVVWXG\EHFDXVHWKH\DUH
XQOLNHO\WRKDYHJOLREODVWRPDDQGEHFDXVHRIXQNQRZQWR[LFLWLH VRIWKHVWXG\DJHQWVLQWKH
SHGLDWULFSDWLHQW)XUWKHUPRUH WKHWDUJHWVRIEHYDFL]XPDEDQG YRULQRVWDWDUHQRWDVSUHYDOHQWLQ
SHGLDWULFJOLREODVWRPDDQGWKHU HIRUHWKHHIILFDF\RIWKLVUHJL PHQZLOOEHLQLWLDOO\GHWHUPLQHGLQ
WKHDGXOWSRSXODWLRQEHIRUHFRQVLGHUDWLRQRILWVXVHLQSHGLDWU LFV
1,+,QIRUPHG&RQVHQW
*LYHQWKHDFFUXDOFRPSOHWLRQD QGIROORZXSVWDWXVRIWKHVWXG\ VXEMHFWVZLOOQRWEHUH
FRQVHQWHG
RISKS/BENEFITS ANALYSIS  
 %HQHILWV
7KHUHLVQRGLUHFWEHQHILWWRSDWL HQWVSUHYLRXVO\HQUROOHGRQW KLVVWXG\&RPSOHWLRQRIGDWD
DQDO\VLVLVOLNHO\WR\LHOGJHQHUDOL]DEOHNQRZOHGJHDERXWWKHW UHDWPHQWRIVXEMHFWVZLWKUHFXUUHQW
JOLREODVWRPDLQFOXGLQJDGHWHUPL QDWLRQDVWRZKHWKHUWR[LFLWLH VRFFXUULQJRQWKLVVWXG\ZRXOG
SUHFOXGHIXWXUHLQYHVWLJDWLRQVRIWKLVDJHQWV
5LVNV
7KHFXUUHQWVWXG\DW1&,LVOLPL WHGWRGDWDDQDO\VLVRQO\7KL VGDWDKDVDOUHDG\EHHQREWDLQHG
DQGWKXVSRVHQRULVNWRWKHLQGLYLGXDO ZLWKUHJDUGWRREWDLQLQ JWKHP
6LQFHVLWHVZLOOEHWUDQVPLWWLQJ SDSHU&5)VZLWKVWXG\VXEMHFW QXPEHUVRQO\WKHUHLVQRULVNRID
EUHDFKRISDWLHQW¬∂VPHGLFDOUH FRUGV7KHVWXG\GDWDREWDLQHGGX ULQJWKHFRQGXFWRIWKHSURWRFRO
ZLOOEHNHSWLQVHFXUHQHWZRUNGULYH VRULQDSSURYHGDOWHUQDWLY HVLWHVWKDWFRPSO\ZLWK1,+
VHFXULW\VWDQGDUGV2QFHWKHGDWDLVWUDQVIHUUHGWR1&,WKHSU LPDU\DQGILQDODQDO\]HGGDWDZLOO
KDYHLGHQWLILHUVVRWKDWUHVHDUFKGD WDFDQQRWEHDWWULEXWHGWR DQLQGLYLGXDOKXPDQVXEMHFW
SDUWLFLSDQW$GGLWLRQDOLQIRUPDWLRQLVIRXQGLQ'DWD&ROOHFWLR Q6HFWLRQ 
$EEUHYLDWHG7LWOH3K, ,,%HY9RULQRVWDW*%0
1&,9HUVLRQ'DWH0'$&&9HUVLRQ'DWH
3 D J H  [ Y L L


5LVNV%HQHILWV$QDO\VLV
7KHSRWHQWLDOEHQHILWVRIFRPSOHWLQJGDWDDQDO\VLVDUHWKH\LHO GLQJRIJHQHUDOL]DEOHLQIRUPDWLRQ
DERXWWKHFRQGLWLRQXQGHUVWXG\*LYHQWKHHIIRUWVWRPLQLPL] HULVNRIWUDQVIHUULQJWKH
LQIRUPDWLRQWKLVSURWRFROSRVHVULVNQRJUHDWHUWKDQPLQLPDOU LVN

3+$50$&(87,&$/,1)250$7,21
$VQRSDWLHQWVUHPDLQRQVWXG\WUHDWPHQWDWDQ\VLWHQRVWXG\ GUXJZLOOEHDGPLQLVWHUHG
7KLVVWXG\PHHWVWKHFULWHULDIRU H[HPSWLRQIRUDQ,1'DVWKLV LQYHVWLJDWLRQLVQRWLQWHQGHGWR
VXSSRUWDQHZLQGLFDWLRQIRUXVHRUDQ \RWKHUVLJQLILFDQWFKDQJ HWRWKHODEHOLQJWKHGUXJVDUH
DOUHDG\DSSURYHGDQGPDUNH WHGDQGWKHLQYHVWLJDWLRQLVQRWLQWH QGHGWRVXSSRUWDVLJQLILFDQW
FKDQJHLQDGYHUWLVLQJDQGWKHLQYHVWLJDWLRQGRHVQRWLQYROYHD URXWHRIDGPLQLVWUDWLRQRUGRVDJH
OHYHOLQXVHLQDSDWLHQWSRSXODWLRQRURWKHUIDFWRUWKDWVLJQL ILFDQWO\LQFUHDVHVWKHULVNVRU
GHFUHDVHVWKHDFFHSWDELOLW\ RIWKHULVNVDVVRFLDWHGZLWKWKHX VHRIWKHGUXJSURGXFW

Abbreviated Title: PhI/II Bev Vorinostat GBM   
NCI Version Date: 04/29/2016 
MDACC Version Date: 09/22/2014  
           Page xviii 
 APPENDIX A: CCR PROBLEM REPORT F ORM  
NCI Protocol #:  Protocol Title:  
 
 Report version: (select one)  
____Initial Report  
____Revised Report 
____Follow -up  
Site Principal Investigator:  
   
[INVESTIGATOR_264319]:     Location of problem: (e.g., patient‚Äôs home, 
doctor‚Äôs office)  
Date PI [INVESTIGATOR_366858]: __/__/____  
If delay in reporting to IRB (> 5 days for serious 
events; > 14 days for not serious events), please 
explain: 
 
 
Who identified the problem? (provide role (not name [CONTACT_52943]): nurse, investigator, monitor, 
etc‚Ä¶) 
 
Brief Description of Subject  (if 
applicable)   
(Do NOT include personal 
identifiers)   Sex:  ___ Male  ___ Female  Age:   
 ___ Not applicable (more than one subject is involved)  
 
Diagnosis under study:   
Name [CONTACT_131839]: (select all that apply)    
[  ] Adverse drug reaction   
[  ] Abnormal lab value   
[  ] Death   
[  ] Cardiac Arrest/ code  
[  ] Anaphylaxis  
[  ] Sepsis/Infection   
[  ] Blood product reaction  
[  ] Unanticipated surgery/procedure   
[  ] Change in status (e.g. increased level of care required)    
[  ] Allergy (non -medication)  
[  ] Fall  
[  ] Injury/Accident (not fall)  
[  ] Specimen collection issue   
[  ] Informed consent issue   
[  ] Ineligible for  enrollment   
[  ] Breach of PII  
[  ] Tests/procedures not performed on schedule  
[  ]  Other, brief  [ADDRESS_458531] description: _________________________  
 
Abbreviated Title: PhI/II Bev Vorinostat GBM   
NCI Version Date: 04/29/2016 
MDACC Version Date: 09/22/2014  
           Page xix 
 Detailed Description of the problem: (Include any relevant treatment, outcomes or pertinent 
history): 
 
 
*Is this problem unexpected? (see the definition of unexpected in the protocol))   __YES __NO  
Please explain:  
 
 *Is this problem related or possibly related to participation in the research?  __YES __NO  
Please explain:  
 
*Does the problem suggest the research places subjects or others at a greater risk of harm 
than was previously known or recognized?     __YES __NO      Please explain:  
 
 
Is this problem?  (select all that apply ) 
[  ] An Unanticipated Problem* that is:       [  ] Serious        [  ] Not Serious  
[  ] A Protocol Deviation that is:                [  ] Serious        [  ] Not Serious  
[  ] Non-compliance  
*Note if the 3 criteria starred above are answered, ‚ÄúYES‚Äù, then this event is also a UP.  
Is the problem also (select one)   [  ] AE  [  ] Non-AE 
Have similar problems occurred on this protocol at your site? __YES __NO       
If ‚ÄúYes‚Äù, how many?  ____      Please describe:  
Describe what steps you have already taken as a result of this problem:  
 
 
In addition to the NCI IRB, this problem is also being reported to: (select all that apply ) 
[  ] Local IRB  
[  ] Study Sponsor  
[  ] Manufacturer : ____________________   
[  ] Institutional Biosafety Committee  
[  ] Data Safety Monitoring Board  
[  ] Other: ____________________________________   
[  ] None of the above, not applicable  
INVESTIGATOR‚ÄôS SIGNATURE:   
 [CONTACT_81619]:   
 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 1 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
1 
  BRAIN TUMOR TRIALS COLLABORATIVE (BTTC)  
 
BTTC11-02: Phase I/II Adaptive Randomized Trial of Bevacizumab versus Bevacizumab  
plus Vorinostat in Adults with Recurrent Glioblastoma   
 
  PAGE 
1.0 OBJECTIVES AND STUDY DESIGN  4 
2.0 BACKGROUND  6 
3.0 DRUG INFORMATION  19 
4.0 ELIGIBILITY CRITERIA  26 
5.0 STRATIFICATION/DESCRIPTIVE FACTORS  [ADDRESS_458532]., Unit  431  
Houston, TX [ZIP_CODE]  
Phone: 713 -792-4008 
Email: [EMAIL_7053]  
 
CO-INVESTIGATOR  
Jing Wu MD  
University of North Carolina, Chapel 
Hill 
Department of Neurosurgery  
Chapel Hill, NC [ZIP_CODE] -1374 
Phone: 919 -966-1374 
Email: [EMAIL_7054]  BTTC BIOSTATISTICIAN  
Ying Yuan, Ph. D . 
MD Anderson Cancer Center  
Division of Quantitative Science  
[ADDRESS_458533]., Unit 1411  
Houston, TX [ZIP_CODE] -4009 
Phone: 713 -563-4271 
Email: [EMAIL_7031]  
 
QUALITY OF LIFE CHAIR  
Terri S. Armstrong, Ph. D,  ANP-BC, 
FAANP 
MD Anderson Cancer Center  
Neuro-Oncology Department  
[ADDRESS_458534]., Unit 431  
Houston, TX [ZIP_CODE]  
Phone: 713 -745-4621 
Email: [EMAIL_7055]  
 ACADEMIC CHAIR (BTTC LEAD)  
Vinay K. Puduvalli, MD  
The Ohio State  University  Wexner 
Medical Center  
Div.of  Neuro-Oncology,D ept of Surgery  
320 W 10th Av enue, Starling Loving Hall 
Suite M410  
Columbus,  OH [ZIP_CODE]  
Phone: 614 -688-7592 
Email : [EMAIL_7030]  
 
BTTC COORDINATING CENTER  
Office of Multicenter Clinical Research  
MD Anderson  Cancer Center  
[ADDRESS_458535]., Unit 1664,  
Houston, TX [ZIP_CODE]  
Phone: 713 -792-8519 
Fax: [PHONE_7588] 
Email: [EMAIL_7056]  
A DISCLAIMER STATEME NT FOR BTTC PROTOCOL S 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 2 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
2 
  
This is a research protocol of the Brain Tumor Trials Collaborative describing an experimental treatment procedure.  
It is a privileged document and is not intended to be circulated or used for other purposes.  The Brain Tumor Trials 
Collaborative assumes no responsibility for its use o utside of the constraints of this research protocol or by 
[CONTACT_264321].  
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 3 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
3 
 PARTICIPATING INVESTIGATORS   
 
Vinay Puduvalli, MD  
Ohio State University We xner Medical Center  
Email: [EMAIL_7033]    
 
Mark Gilbert, M.D.  
UT, MD Anderson Cancer Center  
Email:    [EMAIL_7053]  
 
Charles Conrad, M.D.  
UT, MD Anderson Cancer Center  
Email:    [EMAIL_7057]  
 
Ivo Tremont, M.D.  
UT, MD Anderson Cancer Center  
Email:    [EMAIL_7034]  
 
Marta Penas Prado, M.D.  
UT, MD Anderson Cancer Center  
Email:   [EMAIL_7035]  
 
Jeffrey Raizer, M.D.  
Northwestern University, Feinberg School of Medicine  
Email: [EMAIL_7036]  
 
Karen Fink, MD  
Neuro-Oncology Associates  
Email: [EMAIL_7038]  
 
Jing Wu, MD  
University of North Carolina - Chapel Hill  
Email:  [EMAIL_7054]  
 
Pamela New, MD  
The Methodist Hos pi[INVESTIGATOR_366859]:  [EMAIL_7058]  
 
David Tran, MD  
Washington University School of Medicine  
Email:  [EMAIL_7039]  
 
Tobias Walbert, MD  
Henry Ford Health System  
Email;  [EMAIL_7048]  
 
Fabio Iwamoto, MD  
Columbia University  
Email: [EMAIL_7049]    
 
 W.K. Alfred Yung, M.D.  
UT, MD Anderson Cancer Center  
Email: [EMAIL_7040]  
 
Terri S. Armstrong, APN, Ph.D.  
UT, MD Anderson Cancer Center  
Email:    [EMAIL_7041]  
 
John deGroot, M.D.  
UT, MD Anderson Cancer Center  
Email:    [EMAIL_7042]  
 
Monica Loghin, M.D.  
UT, MD Anderson Cancer Center  
Email:    [EMAIL_7043]  
 
Nicholas Avgeropoulos, MD  
MD Anderson Cancer  Center - Orlando 
Email: [EMAIL_7044]  
 
 Scott Lindhorst MD  Medical University of South 
Carolina Hollings Cancer Center  
Email:   [EMAIL_7045]  
 
Howard Colman, MD  
University of Utah Health System ‚Äì Huntsman Cancer 
Institute 
Email:  [EMAIL_7037]   
 
Marc Chamberlain, MD  
University of Washington Medical Center  
Email:  [EMAIL_7046]  
 
 Morris Groves, MD  
[LOCATION_007] Oncology -Austin Brain Tumor Center  
Email:  [EMAIL_7047]  
 
Nina Paleologos, MD  
Rush Univers ity Medical Center  
Email:  [EMAIL_7051]   
 
Ryan Merrell, MD  
Northshore University Health System  
Email: [EMAIL_7050]     
 
David Peereboom M.D  
Cleveland Clinic  
Email: [EMAIL_3779]  
 
 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 4 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
4 
 1.0 OBJECTIVES AND STUDY DESIGN  
 
1.1 OBJECTIVES  
 
Primary endpoint:  
 
Phase I 
 
ÔÇ∑ To determine the maximum tolerated dose (MTD) of vorinostat plus bevacizumab in adult 
patients with malignant glioma.  
 
Phase II 
 
ÔÇ∑ To determine the efficacy of vorinostat plus bevacizumab versus bevacizumab alone in 
patients with recurrent WHO grade IV glioma (glioblastoma and gliosarcoma) as determined 
by [CONTACT_3963] (PFS) using an adaptive randomization phase II trial des ign. 
 
Secondary endpoint:  
 
Phase II 
 
ÔÇ∑ To determine the radiological response, TTP and OS in the treatment arms.  
 
ÔÇ∑ To determine the efficacy and safety of combination of Vorinostat and Bevacizumab 
including in a subset of patients whose tumors exhibit a mese nchymal-pro-angiogenic 
phenotype associated with poor outcome.   
 
ÔÇ∑ To determine the effects of bevacizumab with and without vorinostat upon biomarkers of 
angiogenesis.  
 
ÔÇ∑ To evaluate the occurrence of symptoms and correlate to disease progression and tolerance to 
treatment using the MD Anderson Symptom Inventory -Brain Tumor Module (MDASI -BT) 
self-reporting tool.  
 
1.2 STUDY DESIGN  
 
1.2.1 Description of the Study  
 
Phase 1 component:  
 
A conventional Phase I design will be used and the MTD will be selected using a 3+3 accrual 
design at each dose level until MTD is determined.   
 
Phase II component:  
 
This is a randomized phase II trial  of the combination of bevacizuma b plus vorinostat compared 
with bevacizumab alone in patients with recurrent grade IV malignant glioma.  The primary 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 5 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
5 
 endpoint is progression free survival. Patients will be randomized between the two arms using a 
Bayesian adaptive algorithm. Patients will be randomized fairly between the two arms at the start 
of the trial (for the first 20 patients). Thereafter, as the trial progresses and data accrue, the 
randomization will become unbalanced in favor of the treatment that, on average, has better 
results in terms of failure time. Therefore, each successive patient is more likely to receive the 
treatment with better results, on average. A minimum of [ADDRESS_458536] patient is accrued. Based on an 
anticipated accrual rate between 3 and 5 patients per month, the maximum trial accrual period 
will be between 12 and 24 months.  
 
The operating characteristics of the design are detailed in section 11.0 in the detailed table 
provided. The historical median progression free survival used for this study will be 4 months. 
This is in keepi[INVESTIGATOR_366860]; median PFS in that study for single agent bevacizumab was 4.2 months 
(95% CI, 2.9, 5.8). The calculations used for the current assume an accrual rate of either 3 or 5 
patients per month. The trial will be s topped early and a treatment selected as being ‚Äúbetter‚Äù if the 
probability that one treatment‚Äôs median PFS is larger than the other‚Äôs PFS exceeds 0.995. If the 
trial does not stop early and the maximum 90 patients are accrued, a treatment is selected as be ing 
‚Äúbetter‚Äù if the probability that one treatment‚Äôs median PFS is larger than the other‚Äôs PFS exceeds 
0.975. The ‚Äúnumber of patients treated‚Äù row is the average number of patients treated on a given 
arm under the given scenario. When the medians are equal , the probability of selecting either of 
the two arms (i.e., a false positive result) is 9% for both accrual rates. The probability of selecting 
the better treatment (i.e., a true positive result) for a doubling in the median PFS is 85% for 3 per 
month and  83% for [ADDRESS_458537] the ability to randomize patients, update the current patients‚Äô status. The results of 
randomization are displayed for the user to review.  
    
1.2.2 Rationale for Study Design  
 
Phase I component:  
 
A recent phase I trial tested the combination of vorinostat with bevacizumab and CPT -11 in 
patients with recurrent glioblastoma. The MTD of vorinostat has bee n established at a dose of 400 
mg daily given on days 1 -7 and 15-21 on a 4 week cycle when combined with CPT -11 (125 
mg/m2) and bevacizumab (10 mg/kg) given on days [ADDRESS_458538] to date included fatigue, diarrhea, muco sitis and hematological toxicities.  Common 
toxicities of the combination included fatigue and diarrhea. DLTs included fatigue, 
hypertension/hypotension, and central nervous system ischemia  (Chinnaiyan et al 2012).  
  
Given that our study proposes to use bevacizumab and vorinostat only, we anticipate less toxicity 
than seen in the 3 -drug combination utilized in the trial described above.  These results provide a 
rationale for our starting dose of 400 mg/day on days 1 -7 and 15-21 of vorinostat in combinatio n 
with bevacizumab at 10 mg/kg on days 1 and 15.  We will incorporate dose escalation of 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 6 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
6 
 vorinostat by [CONTACT_366926] 500 mg and also provide two dose de -escalation levels at 300 and 200 
mg/day in the unlikely event that the starting dose level is above MTD.  
 
Phase II component:   
 
To assess the activity of a new treatment regimen, conventional phase II designs use either a 
single arm design compared with historical controls or a randomized design with a control arm of 
standard treatment, if such a standard is  identified. For patients with recurrent GBMs, there are no 
extant standards of care. In a paradigm such as the one being studied in the proposed trial, testing 
each combination against historical controls would involve separate trials, a process that will  not 
provide timely answers to the question at hand nor allow utilization of resources in an efficient 
manner. To overcome some of these hurdles and test these combinations against each other as 
well as historical controls, this study proposes to utilize a  Bayesian adaptive randomization 
design, which will pit the two treatment regimens against each other. This will result in 
progressive bias of randomization towards the best of the two regimens in a single trial. The 
"winner" of these two regimens will be considered the best regimen for further testing in a larger 
trial if it compares favorably with historical controls (Berry and Eick, 1994; Thall et al., 2002; 
Wong et al., 1999).     
 
 
2.[ADDRESS_458539] common and aggressive malignant primary brain tumor, accoun ting more than half of 
the primary brain tumor with approximately 4 ‚Äì6 per 100,000 people per year (Gurney and 
Kadan-Lottick, 2001) . Malignant gliomas are the second leading cause of cancer death in patients 
under 35 years of age and the fourth leading cause in those patients younger than 45 yrs.  
 
Histologically, glioblastomas display high mitotic index, cellular pleomorphism, extensive 
vascular proliferation or necrosis. They are characterized by [CONTACT_345032], high 
morbidity and mortality. Despi[INVESTIGATOR_366861], 
radiation therapy and cytotoxic chemotherapeutic agents, the prognosis of patients with GBM is 
only 14.6 month (Stupp et al., 2005)  in newly diagnosed GBM. Recurrent GBM has an even more 
dismal prognosis with a median overall survival of~25 weeks (Wong et al., 1999)  and PFS6 15%. 
Recent studies of bevacizumab either as a single agent or in combination with irinotecan have 
demonstrated a significant improvement in response rate compared to h istorical agents. Single -
agent Bevacizumab treatment was associated with an overall response rate of 28.2% with a 
median duration of response was 5.6  months.  Six-month PFS and median overall survival (OS) 
were 42.6% and 9.2 months, respectively; based on the response rate, bevacizumab was recently 
granted FDA approval for use in patients with recurrent GBM. However, progression after 
Bevacizumab therapy is often dramatic and associated with poor prognosis. Hence, there remains 
an unmet need for development  of new approaches against these tumors and their characteristic 
biologic heterogeneity  
 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 7 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
[ADDRESS_458540] non -overlappi[INVESTIGATOR_366862].  
 
2.2 BEVACIZUMAB CLINICAL  EXPERIENCE     
 
Bevacizumab has been studied in a multitude of Phase I, II, and III clini cal trials in more than 
5000 patients and in multiple tumor types. In addition, data are available from 3,863 patients 
enrolled in two postmarketing studies in metastatic colorectal cancer (CRC). Approximately 
130,[ADDRESS_458541] or in clinical trials.  
The following discussion summarizes bevacizumab‚Äôs safety profile and presents some of the 
efficacy results pertinent to this particular trial. Please refer to Investigator‚Äôs Brochure of 
bevacizumab for desc riptions of all completed Phase I, II, and III trials reported to date.  
 
In a large phase III study (AVF2107g) in patients with metastatic colorectal cancer, the addition 
of bevacizumab, a monoclonal antibody directed against vascular endothelial growth factor 
(VEGF), to irinotecan/5 -fluorouracil/leucovorin (IFL) chemotherapy resulted in a clinically and 
statistically significant increase in duration of survival, with a hazard ratio of death of 0.67 
(median survival 15.6 vs. 20.3  months; p  < 0.001).  Simi lar increases were seen in progression -
free survival (6.2 vs. 10.6 months; p  < 0.001), overall response rate (35% vs. 45%; p  < 0.01) and 
duration of response (7.1  vs. 10.4 months; p  < 0.01) for the combination arm versus the 
chemotherapy only arm (bevacizu mab, Investigator Brochure, October 2005).  
 
Based on the survival advantage demonstrated in Study AVF2107g, bevacizumab was designated 
for priority review and was approved on [ADDRESS_458542] -line 
treatment in combination wit h IV 5-FUÔÄ≠based chemotherapy for subjects with metastatic 
colorectal cancer.  
 
Additional data from Phase III trials in metastatic CRC (E3200), non ÔÄ≠small cell lung cancer 
(NSCLC; E4599), and  metastatic breast cancer (E2100) have also demonstrated clinical benefit 
from bevacizumab when added to chemotherapy.  In Study E3200, the addition of bevacizumab 
to FOLFOX chemotherapy resulted in improved overall survival compared with FOLFOX alone 
(13.0 vs. 10.8  months, respectively, HR  ÔÄΩ 0.75; p ÔÄº 0.01) in a populat ion of previously treated 
CRC patients.   
 
There was also improved overall survival in first -line NSCLC patients (E4599) treated with 
carboplatin/paclitaxel  ÔÄ´ bevacizumab compared with chemo therapy alone (12.3 vs. 10.3 months, 
respectively; HR  ÔÄΩ 0.80; p = 0.003).  The results from this trial were the basis for FDA approval 
of bevacizumab for use in combination with carboplatin  ÔÄ´ paclitaxel as first -line treatment of 
patients with unresectable , locally advanced, recurrent or metastatic, non -squamous NSCLC in  
October 2006.  Finally, patients with untreated metastatic breast cancer (E2100) who received 
bevacizumab in combination with weekly paclitaxel had a marked improvement in PFS compared 
with chemotherapy alone (13.3 vs. 6.7  months, respectively; HR  ÔÄΩ 0.48; p ÔÄº 0.0001) (see the 
bevacizumab Investigator Brochure for additional details).  
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 8 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
8 
  
A Phase II, open -label, multicenter, randomized, non -comparative study (AVF3708g, BRAIN), 
evaluated the efficacy and safety of Bevacizumab alone, or in combination with irinotecan in 167 
glioblastoma (GBM) patients with progressive disease following prior therapy.  For single -agent 
Bevacizumab (n=85), ORR was 28.2% and median duration of response was 5.6  months.  Six-
month PFS and median overall survival (OS) were 42.6% a nd 9.2 months, respectively; median 
PFS was 4.2 months (95% CI 2.9, 5.8).  Based on these data, Bevacizumab, as a single agent, was 
approved by [CONTACT_366927]. 
 
a. Bevacizumab  Safety Profile  
 
In the initial Phase I and II clinical trials, four potential bevacizumab -associated safety 
signals were identified: hypertension, proteinuria, thromboembolic events, and hemorrhage.  
Additional completed Phase II and Phase III studies of bevacizumab as we ll as spontaneous 
reports have further defined the safety profile of this agent. Bevacizumab -associated adverse 
events identified in phase III trials include congestive heart failure (CHF) primarily in 
metastatic breast cancer, gastrointestinal perforation s, wound healing complications, and 
arterial thromboembolic events (ATE). Visceral arterial ischemia and disseminated 
intravascular coagulation resulting in death was reported in a single case recently.  These and 
other safety signals are described in furth er detail as follows and in the bevacizumab 
Investigator Brochure.  
 
Hypertension : An increased incidence of hypertension has been observed in patients treated 
with bevacizumab.  Grade [ADDRESS_458543] included hypertensive crisis, hypertensive encephalopathy, and 
reversible posterior leukoencephalopathy syndrome (RPLS) (Glusker et al., 2006; Ozcan et 
al., 2006) .  
 
There is no information on the effect of bevacizumab in patients with uncontrolled 
hypertension at the time of initiating bevacizumab therapy.  Therefore, caution should be 
exercised before initiating bevacizumab therapy in these patients.  Monitoring of blood 
pressure is recommended during bevacizumab therapy.  Optimal control of blood pressur e 
according to standard public health guidelines is recommended for patients on treatment with 
or without bevacizumab.   
 
Temporary interruption of bevacizumab therapy is recommended in patients with 
hypertension requiring medical therapy until adequate co ntrol is achieved.  If  hypertension 
cannot be controlled with medical therapy, bevacizumab therapy should be permanently 
discontinued.  Bevacizumab should be permanently discontinued in patients who develop 
hypertensive crisis or hypertensive encephalopath y. 
 
Proteinuria :  An increased incidence of proteinuria has been observed in patients treated 
with bevacizumab compared with control arm patients.  In the bevacizumab -containing 
treatment arms of clinical trials (across all indications), the incidence of p roteinuria (reported 
as an adverse event) was up to 38% (metastatic CRC Study  AVF2192g). The severity of 
proteinuria has ranged from asymptomatic and transient events detected on routine dipstick 
urinalysis to nephrotic syndrome; the majority of proteinuri a events have been grade 1. NCI -
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 9 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
9 
 CTC Grade 3 proteinuria was reported in up to 3% of bevacizumab -treated patients, and 
Grade 4 in up to 1.4% of bevacizumab -treated patients. The proteinuria seen in bevacizumab 
clinical trials was not associated with renal i mpairment and rarely required permanent 
discontinuation of bevacizumab therapy.  Bevacizumab should be discontinued in patients 
who develop Grade 4 proteinuria (nephrotic syndrome)  
 
Patients with a history of hypertension may be at increased risk for the d evelopment of 
proteinuria when treated with bevacizumab.  There is evidence from the dose -finding, Phase 
II trials (AVF0780g, AVF0809s, and AVF0757g) suggesting that Grade 1 proteinuria may be 
related to bevacizumab dose.  
 
Proteinuria will be monitored by [CONTACT_39701]:creatinine (UPC) ratio at least every 6 weeks.  
If the UPC ratio is not available, a dipstick urinalysis may be used to allow treatment to 
proceed. 
 
Thromboembolic Events : Both venous and arterial thromboembolic (TE) events, ranging in 
severity from catheter -associated phlebitis to fatal, have been reported in patients treated with 
bevacizumab in the colorectal cancer trials and, to a lesser extent, in patients treated with 
bevacizumab in NSCLC and breast cancer trials.  
 
Venous thromboembolis m (including deep venous thrombosis, pulmonary embolism, 
and thrombophlebitis : In the phase III pi[INVESTIGATOR_47273], there was a slightly 
higher rate of venous TE events in patients treated with bevacizumab plus chemotherapy 
compared with chemo therapy alone (19% vs. 16%).  
 
In Study AVF2107g, a Phase III, pi[INVESTIGATOR_47273], VTE events, including deep 
venous thrombosis, pulmonary embolism, and thrombophlebitis, occurred in 15.2% of 
patients receiving chemotherapy alone and 16.6% of patients receiving 
chemotherapy  ÔÄ´ bevacizumab.  
 
The incidence of NCI -CTC Grade ÔÇ≥ 3 venous VTE events in one NSCLC trial (E 4599) was 
higher in the bevacizumab -containing arm compared to the chemotherapy control arm (5.6% 
vs. 3.2%).  One event (0.2%) was fatal in the bevacizumab -containing arm; not fatal events 
were reported in the carboplatin/paclitaxel arm (see Bevacizumab Investigator Brochure).  
In metastatic CRC clinical trials, the incidence of VTE events was similar in patients 
receiving chemotherap y ÔÄ´ bevacizumab and those receiving the control chemotherapy alone.  
 
In clinical trials across all indications the overall incidence of VTE events was 2.8% ÔÄ≠17.3% 
in the bevacizumab -containing arms compared with 3.2% ÔÄ≠15.6% in the chemotherapy 
control arms.   The use of bevacizumab with chemotherapy does not substantially increase the 
risk of VTE event compared with chemotherapy a lone.  However, patients with metastatic 
CRC who receive bevacizumab and experienced a VTE event may be at higher risk for 
recurrence of VTE event.  
 
Arterial Thromboembolic Events: An increased incidence of ATE events was observed in 
patients treated with bevacizumab compared with those receiving control treatment. ATE 
events include cerebrovascular accidents, myocardial infarction, t ransient ischemic attacks 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 10 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
10 
 (TIAs), and other ATE events. In a pooled analysis of data from five randomized Phase II and 
III trials (mCRC [AVF2107g, AVF2192g, AVF0780g]; locally advanced or metastatic 
NSCLC [AVF0757g]; metastatic breast cancer [AVF2119g]), t he incidence rate of ATE 
events was 3.8% (37 of 963) in patients who received chemotherapy  ÔÄ´ bevacizumab 
compared with 1.7% ( 13 of 782) in patients treated with chemotherapy alone. ATE events led 
to a fatal outcome in 0.8% (8 of 963) of patients treated wi th chemotherapy  ÔÄ´ bevacizumab 
and 0.5% (4 of 782) of patients treated with chemotherapy alone. Cerebrovascular accidents 
(including TIAs) occurred in 2.3% of patients treated with chemotherapy  ÔÄ´ bevacizumab and 
0.5% of patients treated with chemotherapy al one.  Myocardial infarction occurred in 1.4% of 
patients treated with chemotherapy  ÔÄ´ bevacizumab compared with 0.7% of patien ts treated 
with chemotherapy alone (see the Bevacizumab Investigator Brochure for additional details).  
 
Aspi[INVESTIGATOR_33930] a standard thera py for primary and secondary prophylaxis of arterial 
thromboembolic events in patients at high risk of such events, and the use of aspi[INVESTIGATOR_248] ‚â§ [ADDRESS_458544] to 
metastatic colorectal cancer patients were presented at ASCO 2005 (Hambleton et al., 2005). 
Further analyses of the effects of concomitant use of bevacizumab and aspi[INVESTIGATOR_366863].  
 
Gastrointestinal perfora tion: Patients with metastatic carcinoma may be at increased risk 
for the development of gastrointestinal perforation and fistula when treated with bevacizumab 
and chemotherapy. Bevacizumab should be permanently discontinued in patients who 
develop gastroi ntestinal perforation. A causal association of intra -abdominal inflammatory 
processes and gastrointestinal perforation to bevacizumab treatment has not been established. 
Nevertheless, caution should be exercised when treating patients with intra -abdominal 
inflammatory processes with bevacizumab. Gastrointestinal perforation has been reported in 
other trials in non -colorectal cancer populations (e.g., ovarian, renal cell, pancreas, breast, 
and NSCLC) and may be higher in incidence in some tumor types.   
 
Fistula: Bevacizumab use has been associated with serious cases of fistulae including events 
resulting in death. Fistulae in the GI tract are common (1% ‚Äì10% incidence) in patients with 
metastatic CRC, but uncommon (0.1% ÔÄ≠1%) or rare (0.01% ‚Äì0.1%) in other indica tions. In 
addition, fistulae that involve areas of the body other than the GI tract (e.g., 
tracheoesophageal, bronchopleural,  urogenital, biliary) have been reported uncommonly 
(0.1%‚Äì1%) in patients receiving bevacizumab in clinical studies and postmarketi ng reports. 
Events were reported at various timepoints during treatment, ranging from 1  week to ÔÄæ [ADDRESS_458545] 6  months of 
therapy. 
 
Permanently discontinue bevacizumab in patients with tracheoesophageal fistulae or any 
Grade 4 fistula.  Limited information is available on the continued use of bevacizumab in 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 11 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
[ADDRESS_458546], 
discontinuation of bevacizumab should be considered.  
 
Wound healing complications:  Wound healing complications such as wound dehiscence 
have been reported in patients receiving bevacizumab. In an analysis of pooled data from two 
trials in metastatic colorectal cancer, patients undergoing surge ry 28-60 days before study 
treatment with 5 -FU/LV plus bevacizumab did not appear to have an increased risk of wound 
healing complications compared to those treated with chemotherapy alone (Scappaticci et al., 
2005). Surgery in patients currently receiving bevacizumab is not recommende d. No 
definitive data are available to define a safe interval after bevacizumab exposure with respect 
to wound healing risk in patients receiving elective surgery; however, the estimated half life 
of bevacizumab is 21 days. Bevacizumab should be discontinu ed in patients with severe 
wound healing complications.  
 
If patients receiving treatment with bevacizumab require elective major surgery, it is 
recommended that bevacizumab be held for 4 ‚Äì8 weeks prior to the surgical procedure. 
Patients undergoing a major surgical procedure should not begin or restart bevacizumab until 
4 weeks after that procedure (in the case of high -risk procedures such as liver resection, 
thoracotomy, or neurosurgery, it is recommended that chemotherapy be restarted no earlier 
than 6 wee ks and bevacizumab no earlier than 8 weeks after surgery).  
 
Hemorrhage : Overall, grade 3 and 4 bleeding events were observed in 4.0% of 1132 patients 
treated with bevacizumab in a pooled database from eight Phase I, II, and III clinical trials in 
multiple tumor types (bevacizumab Investigator Brochure, October 2005). The hemorrhagic 
events that have been observed in bevacizumab clinical studies were predominantly tumor -
associated hemorrhage (see below) and minor muco -cutaneous hemorrhage.  
 
Tumor-Associated  Hemorrhage:  Major or massive pulmonary hemorrhage or hemoptysis 
has been observed primarily in patients with NSCLC. Life -threatening and fatal hemoptysis 
was identified as a bevacizumab -related adverse event in NSCLC trials. These events 
occurred suddenly  and presented as major or massive hemoptysis.  Among the possible risk 
factors evaluated (including squamous cell histology, treatment with 
anti-rheumatic/anti -inflammatory drugs, treatment with anticoagulants, prior radiotherapy, 
bevacizumab therapy, pre vious medical history of atherosclerosis, central tumor location, and 
cavitation of tumors during therapy), the only variables that showed statistically significant 
correlations with bleeding were bevacizumab therapy and squamous cell histology.  
 
GI hemorr hages, including rectal bleeding and melena have been reported in patients with 
CRC, and have been assessed as tumor -associated hemorrhages.  
 
Tumor-associated hemorrhages were also seen rarely in other tumor types and locations, 
including a case of CNS bleeding in a patient with hepatoma with occult CNS metastases and 
a patient who developed continuous oozing of blood from a thigh sarcoma with necrosis.  
 
Mucocutaneous Hemorrhage:  Across all bevacizumab clinical trials, mucocutaneous 
hemorrhage has been s een in 20% -40% of patients treated with bevacizumab. These were 
most commonly NCI -CTC Grade 1 epi[INVESTIGATOR_214743] 5 minutes, resolved without 
medical intervention and did not require any changes in bevacizumab treatment regimen.  
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 12 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
[ADDRESS_458547] al so been less common events of minor mucocutaneous hemorrhage in other 
locations, such as gingival bleeding and vaginal bleeding.  
 
Reversible Posterior Leukoencephalopathy Syndrome:  There have been rare reports of 
bevacizumab -treated patients developi[INVESTIGATOR_366864], 
a rare neurologic disorder that can present with the following signs and symptoms (among 
others):  seizures, headache, altered mental status, visual disturbance, or cortical blindness, 
with or without associa ted hypertension.  Brain imaging is mandatory to confirm the 
diagnosis of RPLS. In patients who develop RPLS, treatment of specific symptoms, including 
control of hypertension, is recommended along with discontinuation of bevacizumab.  The 
safety of reinit iating bevacizumab therapy in patients previously experiencing RPLS is not 
known (Glusker et al., 2006; Ozcan et al., 2006) .   
 
Congestive heart failure:  In clinical trials CHF was observed in all cancer indications 
studied to date, but predominantly in patients with metastatic breast cancer.  In the Phase III 
clinical trial of metastatic breast cancer (AVF2119g), 7 (3%) bevacizumab -treated patients 
experienced CHF, compared with two (1%) control arm patients.  These  events varied in 
severity from asymptomatic declines in left ventricular ejection fraction (LVEF) to 
symptomatic CHF requiring hospi[INVESTIGATOR_47276].  All the patients treated with 
bevacizumab were previously treated with anthracyclines (doxorubicin cumulative dose of 
240ÔÄ≠360 mg/m2).  Many of these patients also had prior radiotherapy to the left chest wall.  
Most of these patients showed improved symptoms and/or left ventricular functio n following 
appropriate medical therapy (Miller et al., 2005) . 
 
In a randomized, Phase III trial of pati ents with previously untreated metastatic breast cancer 
(E2100), the incidence of LVEF decrease (defined as NCI -CTC Grade 3 or 4) in the 
paclitaxel  ÔÄ´ bevacizumab arm was 0.3% versus 0% for the paclitaxel alone arm  
 
No information is available on patients with preexisting CHF of [LOCATION_001] Heart Association 
(NYHA) Class II ÔÄ≠IV at the time of initiating bevacizumab therapy, as these patients were 
excluded from clinical trials.  
 
Prior anthracyclines exposure and/or prior radiotherapy to the chest wall may be pos sible risk 
factors for the development of CHF. Caution should be exercised before initiating 
bevacizumab therapy in patients with these risk factors.  
 
A Phase II trial in patients with refractory acute myelogenous leukemia reported 5  cases of 
cardiac dysfu nction (CHF or LVEF decrease to ÔÄº 40%) among 48  patients treated with 
sequential cytarabine, mitoxantrone, and bevaci zumab. All but one of these patients had 
significant prior exposure to anthracyclines as well (Karp et al., 2004) .  
 
Other studies in patients with various tumor types and either a history of anthracycline 
exposure or concomitant use with bevacizumab are ongoing.  
 
Patients rec eiving concomitant anthracyclines or with prior exposure to anthracyclines should 
have a baseline MUGA scans or echocardiograms (ECHOs) with a normal LVEF.  
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 13 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
13 
  
Neutropenia:  Increased rates of severe neutropenia, febrile neutropenia, or infection with 
severe neutropenia (including some fatalities) have been observed in patients treated with 
some myelotoxic chemotherapy regimens plus bevacizumab in comparison to chemotherapy 
alone (Sandler et al. 2006).  
 
Additional Adverse Events:   See the bevacizumab Investigat or Brochure for additional 
details regarding the safety experience with bevacizumab.  
 
2.3 Vorinostat clinical experience  
 
As of 07-May-2008, vorinostat has been orally administered to more than 1899 patients in Ph I, II 
and III clinical studies. These studies were sponsored by [CONTACT_366928], Sharp and Dohme 
Corp.the US National Cancer Institute (NCI) or the [COMPANY_006] Investigator initiated studies program 
(IISP).  The clinical development program being conducted by [CONTACT_44873], Sharp and Dohme Corp. 
for vorinostat includes: Seventeen (Mastronardi et al., 1998)  Phase I, II and III studies conducted 
with vorinostat in monotherapy and eleven  (Duvic et al., 2005) Phase I, II and III studies 
conducted with vorin ostat in combination therapy.  
 
Zolinza¬Æ (vorinostat) was approved by [CONTACT_941] U.S. Food and Drug Administration (FDA) on [ADDRESS_458548] progressive, persistent or recurrent disease on or following two systemic 
therapi[INVESTIGATOR_014].  The efficacy of vorinostat in CTCL has been demonstrated in a pi[INVESTIGATOR_366865] a 
supportive Phase IIa study. A total of 107 individual patients with CTCL, 89 of who had Stage 
IIB or higher disease, were treated in these studies.  In this refractory population, the response 
rates for all patients treated with vorinostat at 400 mg orally once daily, the dose and schedule 
approved for clinical use in patients with CTCL, were 30.8% and 29.7% for the overall 
population in these two studies.  For patients with Stage IIB and higher CTCL, the response rates 
were 36.4% and 29.5% respectively.  For patients with Sezary syndrome, the respo nse rate was 
33.3% in both studies.  More information can be found in the prescribing information for 
vorinostat.  
 
Phase I and II clinical studies of vorinostat sponsored by [CONTACT_44873], Sharp and Dohme, Corp. and the 
NCI have demonstrated confirmed anti -tumor activity in patients with acute myeloid leukemia 
(AML), advanced multiple myeloma, B -cell non-Hodgkin‚Äôs lymphoma, squamous cell laryngeal 
carcinoma, thyroid carcinoma, breast carcinoma, non -small cell lung carcinoma, glioblastoma 
multiforme and myelodysplas tic syndrome.  Studies are ongoing to further evaluate whether these 
observations translate into clinical benefit.  
 
a.  Safety Profile  
 
The total daily oral dose of vorinostat administered in these studies ranges from 200 mg to 
900 mg. The tolerability of oral vorinostat appears to be determined by [CONTACT_366929]. The maximum tolerated dose (MTD) for continuous 
daily dosing without a rest period is 400 mg once a day or 200 mg twice a day (200 mg 
b.i.d.). The MT D for intermittent dosing is [ADDRESS_458549]. Dose -limiting toxicities (DLTs) 
are mainly non -hematologic (anorexia, dehydration, diarrhea and weight loss). Hematolo gic 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 14 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
[ADDRESS_458550] possibly related to 
vorinostat reported as of 07 -May-2008 by ‚â•10 % of patients across all [COMPANY_006], Sharp and 
Dohme Corp.& Co., Inc. sponsored vorinostat clinical studies are summarized below by 
[CONTACT_366930] (MedDRA), system organ class (SOC) and 
preferred term:  
 
SOC 
 Reported Possible Related Adverse 
Experiences in ‚â•10 % Overall Patients  
Blood and Lymphatic System  
Disorders  Thrombocytopenia, anemia  
Gastrointestinal disorders  Nausea diarrhea, vomiting, constipation  
General disorders and 
Administration Site Conditions  Fatigue 
Investigations Blood creatinine increased, weight 
decreased, hemoglobin decreased  
Metabolism and Nutritional 
Disorders  Anorexia, dehydration, hyperglycemia  
Nervous System Disorders  Dysgeusia  
 
The types of adverse experiences observed in clinical trials of vorinostat were those usually 
associated with chemotherapy. No new or unique adverse experiences were commonly 
observed. The three major clinical categories of adverse experiences attributable  to vorinostat 
include a constellation of gastrointestinal symptoms, constitutional complaints, and 
cytopenias. Most of the adverse experiences were manageable. In fact, most of the very 
common adverse experiences were reversible and could be managed using  conventional 
supportive care for chemotherapy.  There does not seem to be an increased incidence of 
venous thromboembolic disease in patients treated with vorinostat. There are no statistically 
significant data to suggest that vorinostat increases the QTc  to > 500 ms or induces a change 
from baseline of > [ADDRESS_458551] of a single 
dose of vorinostat on the QTc  interval in patients with advanced cancer was completed and 
showed a single supratherapeutic dose of vorinostat was not associated with prolongation of 
the QTc interval. (Munster et al., 2009)  
 
Vorinostat should be taken approximately [ADDRESS_458552] 2 liters of fluid orally, daily. If 
patients are experiencing dysgeusia, popsicles or electrolyte fluid replacement drinks may be 
recommended. If diarrhea occurs it should be managed with loperamid e according to 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 15 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
[ADDRESS_458553], a 
corticosteroid and fosaprepi[INVESTIGATOR_366866]/or aprepi[INVESTIGATOR_366867]/therapeutic indication for each compound.  
 
Vorinostat should not be administered concomitantly with other HDAC inhibitors (e.g., 
valproic acid) as cl ass-specific adverse reactions may be additive. Severe (Grade 4) 
thrombocytopenia with associated gastrointestinal bleeding and anemia has been reported 
with the concomitant use of vorinostat and valproic acid.  
 
b.  HDAC inhibitors and gliomas  
 
HDAC inhibitors have shown preclinical inhibition of glioma cell lines in vitro and in vivo. In 
particular, vorinostat upregulates p21, decreases VEGF levels and increases apoptosis in 
various glioma cell lines. Also, in vivo glioma xenograft studies demon strate an increased 
survival time in rats treated with vorinostat. Other HDAC inhibitors, such as trichostatin A, 
FK228 and sodium butyrate, show similar effects in vitro. Ugur et al showed that intracranial 
administration of vorinostat inhibits tumor growth in a orthotopic glioma model; more 
relevant to this study, they also demonstrated that vorinostat significantly inhibited vessel 
formation in a endothelial cell tube f orming matrigel assay. In addition, a 30% decrease in 
microvessel density was noted in addition to direct antitumor effects in glioma xenografts 
isolated from vorinostat treated animals resulting in increased survival of the animals (Ugur 
et al, 2007).  On going clinical studies are testing anti -tumor activity of vorinostat either as a 
single agent or in combination with temozolomide in gliomas. Final results of a phase II trial 
of vorinostat as a single agent against recurrent glioblastoma were reported (Ga lanis et al. 
2009) and showed that in a cohort of 66 patients, 9 of the 52 evaluable patients were 
progression free at 6 months. From an intent to treat analysis, 15.2% of patients were alive 
and progression free at 6 months which was considered superior t o historical controls and 
thus met the trial‚Äôs primary efficacy endpoint  The study  also showed upregulation of E -
cadherin in a subgroup who received vorinostat prior to surgery, indicating a biologic effect 
of the HDAC inhibitor on the glioblastoma tumor s.  
 
2.4 Study Rationale   
 
a)  Angiogenesis, a critical biological feature of GBM  
 
Since the notion of tumor angiogenesis was brought by [INVESTIGATOR_124]. Folkman in 1971 (Folkman, 
1971), angiogenesis has been studied widely. Most solid tumors are angiogenesis -dependent 
(Folkman, 2006)  and angiogenesis is the key feature in GBM (Jain et al., 2007) . A 
mesenchymal/angiogenic gene expression signature [CONTACT_366988] [CONTACT_366931] (Phillips et al., 2006; Tso et al., 2006) . GBM 
frequently shift to mesenchym al phenotype at the time of their recurrence. A robust 38 -gene 
profile, which is associated with mesenchymal/angiogenesis genes, was identified to predict 
survival in GBM (Colman et al., 2007, 2009). This gene set was subsequently narrowed down 
to a 9-gene set which when expressed as  a metagene score was confirmed to be independent 
predictor of outcome in GBM. Because the proposed trial is expected to modify the 
angiogenic phenotype, analysis of improved outcome in patients with a poor metagene score 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 16 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
16 
 (from the 9 -gene signature) could potentially indicate efficacy of the treatment proposed in 
our study.  
 
b)  Anti-angiogenic therapy in GBM  
 
Given the importance of angiogenesis in GBM, anti -angiogenic therapy is a promising 
strategy in recurrent GBM. Bevacizumab, the first angiogenesis in hibitor approved against 
cancer by [CONTACT_366923], has recently 
been studied in the GBM. In a prospective phase II trial, 35 patients with recurrent GBM 
were treated with bevacizumab and Irinotecan. The resp onse rate was 57%, PFS 6 was 43%, 
2 year OS 15% (Vredenburgh et al., 2007) . A subsequent Phase II, open -label, multicenter, 
randomized, non -comparative study (AVF3708g, BRAIN), evaluated  the efficacy an d safety 
of Bevacizumab alone, or in combination with irinotecan in 167 glioblastoma (GBM) patients 
with progressive disease following prior therapy.  For single -agent Bevacizumab (n=85), 
ORR was 28.2% and median duration of response was 5.6  months.  Six-month PFS and 
median overall survival (OS) were 42.6% and 9.2 months, respectively; Median PFS for the 
bevacizumab alone arm was 4.2 months.  Based on these data, Bevacizumab, as a single 
agent, was approved by [CONTACT_366932].  
 
However, it has become evident recently despi[INVESTIGATOR_366868], 
there is an increased risk of tumor infiltration on brain MRI suggesting development of 
resistance and leading to treat ment failure; (Norden et al., 2008) ; Zuniga et al. 2008; Lassman 
et al., 2008).  
 
c)  Resistance to anti -VEGF therapy  
 
The pattern of tumor stasis and then tumor growth seen in the clinical trials with bevacizumab 
as monotherapy or in combination with other cytotoxic agents highly suggests development 
of resistance to anti -VEGF therapy. Studies in animal models provide evi dence that tumor 
cells develop the capability to re -grow in the face of VEGF/VEGFR blockade (Casanovas et 
al., 2005) . Both intrinsic and adaptive resistance have been proposed as mechanisms for 
resistance to anti -angiogenic agents (Bergers and Hanahan, 2008) . After the initial response 
to anti-VEGF therapy denoted by [CONTACT_366933], alternative 
pro-angiogenic factors/signal ing pathways are activated, such as fibroblast growth factor 
(FGF), angiopoietin , platelet-derived growth factor (PDGF), VEGF and placenta growth 
factor (PI[INVESTIGATOR_12252]) (Batchelor et al., 2007; Casanovas et al., 2005; Fernando et al., 2008) . The 
upregulation and activation of these pro -angiogenic signa ling pathways can further cause 
revascularization and tumor progression. Furt her, various bone marrow derived cells 
(BMDC) that consists of vascular progenitor cells and vascular modulator cells can be 
recruited secondary to the hypoxia which was induced by [CONTACT_14181] -VEGF therapy (Du et al., 
2008). HIF-1Œ±, upregulated under such hypoxic condition is the key factor by [CONTACT_366934] -
angiogenic BMDCs via stromal cell -derived factor (SDF) 1Œ± to facilitate revascularization 
(Du et al., 2008) . In addition, many pericytes can survive the anti -VEGF therapy and support 
the endothelial cell survival as well (Bergers et al., 2003; Mancuso et al., 2006) . Finally, 
tumor cells escape from their inability to induce neoangiogenesis in the face of initial anti -
VEGF therapy by [CONTACT_366935] g more invasive by [CONTACT_366936] (Lamszus et al., 2003) . 
Therefore, resistance to anti -VEGF therapy is complex multi -step process. An agent targeting 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 17 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
17 
 these multiple pathways of resista nce will potentiate the effects of anti -VEGF therapy and 
repress mechanisms that attempt to by[CONTACT_366937]. 
 
d)  Rationale of combining HDAC inhibitors and bevacizumab  
 
HDAC inhibitors are known to impact several pathways related to angiogenesis. HDAC are 
enzymes responsible for regulation DNA transcription via deacetylation of the lysine tails of 
histones. As transcriptional repressors, there is increasing evidence that HDAC activity is 
altered in many cancers, including gliomas (Marks et al., 2004) . Since epi[INVESTIGATOR_366869] y all cellular pathways that have been associated to 
tumorigenesis, it is not surprising that as epi[INVESTIGATOR_366870], HDAC inhibito rs display 
pleiotropic activities. The anti -angiogenic properties of HDAC inhibitors have been 
associated with decreased expres sion of pro -angiogenic genes, such as VEGF, bFGF, 
angiopoeitin and tunica intima endothelial kinase 2 (TIE2) (Bolden et al., 2006) . More 
importantly, it als o has been shown to regulate HIF 1Œ± transcriptional activity (Kim et al., 
2001; Mahon et al., 2001) , which is a key factor in mediating anti -VEGF resistance. HDAC 
inhibitors can largely down -regulate HIF -1Œ± express ion in both tumor cells and endothelial 
cells. HDAC not only upregulate HIF -1Œ± through down -regulating p53 and VHL suppressor 
gene, but also directly regulate the stability and transcription activity via interaction with 
oxygen-dependent degradation domain (ODDD) of HIF -1Œ± (Kim et al., 2007) . There is also 
evidence of HDAC  inhibitor decrease chemokine receptor 4 (CXCR4) expression in human 
endothelial cells (Qian et al., 2004) . HDAC inhibition also reported to resulted in impaired 
endothelial progenitor cell differentiation (Rossig et al., 2005) . Resistance to bevacizumab is 
thought to be related to escape of tumor endothelium from dependency on VEGF. Glioma 
xenografts from animals treated with bevacizu mab show increased expression of HIF -[ADDRESS_458554] than bevacizumab alone (Rapi[INVESTIGATOR_57177]).  Thus combining a strategy that using 
vorinostat to inhibit HIF -[ADDRESS_458555] of the pro -angiogenic 
signals that contribute to evasion resistance of anti -VEGF therapy. It down regulates HIF -1Œ±, 
the factor helps recruiting the pro -angiogenic BMDCs, and further block the 
revascularization. It may overcome the evasive resistance and improve the ant i-angiogenic 
therapy. This lead us to propose the present study which aim to determine the potential of 
vorinostat, an HDAC inhibitor plus bevacizumab, versus bevacizumab alone, in an attempt to 
increase the anti -angiogenic effects of VEGF by [CONTACT_366938].   
 
e)  Rationale for dosing schedule  
 
Induction of hypoxia has been described in tumors which have been treated a variety of 
angiogenesis inhibitors (Yu et al., 2002) . A study by [CONTACT_366939] (as detected by [CONTACT_21173][INVESTIGATOR_366871]); however, this  
rapi[INVESTIGATOR_366872]; the authors suggested that persistent subtle hypoxia may 
be the factor that maintain the VEGF independent angiogenic stimulus. (Casanovas et al., 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 18 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
18 
 2005) Therefore, we hypothesize that the HIF 1 induced upregulation of other pro -angiogenic 
factors such as FGF, SDF, PDGF, PI[INVESTIGATOR_366873] 1 and likely the low level persistent 
hypoxia wh ich can be abrogated by [CONTACT_366940]. Based on these facts, we 
schedule bevacizumab infusion on day 1 and administer vorinostat on days 1 - 7. Again, the 
second infusion of bevacizumab of the same cycle on day 15 will be followed by 7 days of 
vorinostat. This dosing schedule is designed to block the upstream of the cascade of evasive 
mechanism of resistance to anti -angiogenic therapy.  
 
f)  Rationale for obtaining exploratory data  
 
Identification of markers that are associated with tumor during anti angiogenic therapy alone 
or in combination with other therapi[INVESTIGATOR_366874]. A big challenge in 
bevacizumab therapy is lack of identified and valid ated biomarkers during the treatment. 
HIF1Œ± has been found to stimulate neovascularization by [CONTACT_133239] a variety of pro -
angiogenic factors, such as VEGF, VEGFR, PDGF, FGF and angiopoetin (Calvani et al., 
2006; Holash et al., 1999; Okuyama et al., 2006) . Neo-angiogenesis depends on the 
recruitment of BMDC cells, which includes endothelial progenitor cells and pericyte 
progenitor cells (Kopp et al., 2006) .The most important factors in helpi[INVESTIGATOR_366875]1Œ±, SDF and VEGF (Ceradini et al., 2004; Petit et al., 2007) .  To study 
these important biomarker during bevacizumab treatment, we propose to measure level of 
VEGF, PI[INVESTIGATOR_12252], bFGF, SDF1Œ±, angiopoeitin 1 and 2 by [CONTACT_366941] 1 pretreatment, cycle 1 
day 2, day 15 (pre - and post-infusion) and cycle 2 (pre-infusion) in both treatment arms, 
bevacizumab alone and bevacizumab with vorinostat. Level of circulating endothelial cells 
(CEC) and circulating endothelial progenitor cells (CEPC) will also be measured at the same 
time. 
 
MR imaging study is one of t he most commonly used techniques for monitoring tumor 
growth. Analysis of MRI studies at different stages of therapy could potentially be used for 
correlation between disease prognosis and treatment response. Ultimately the goal would be 
that MRI could be used as an imaging correlate to predict the disease prognosis. To do that, 
we propose to use unique MRI sequences in addition to conventional contrast -enhanced (CE) 
MRI to evaluate the tumor response to bevacizumab with and without vorinostat. In this 
context, increased cell density, vascular proliferation and necrosis are the key features of 
higher grade malignant gliomas. Traditional CE -MRI does not adequately reflect the complex 
biology of the malignant glioma. Angiogenesis, the major mean for tumor to s urvival and 
proliferate, gives dilated, tortuous and hyperpermeable vessels. Anti -angiogenic therapy leads 
to decreased permeability and vascular regression. The traditional CE -MRI is dependent on 
blood brain barrier permeability to the MR contrast agent u sed as well as on tumor vascular 
density. Thus the amount of contrast entering the tumor decreases in the setting of 
antiangiogenic treatment regardless of changes in the tumor itself. This makes CE -MRI 
unreliable in evaluating tumor growth in the setting of anti-angiogenic therapy. This trial will 
use DCE-MRI to measure permeability, DSC -MRI measure the CBV and CBF, and DWI to 
measure the cell density with ADC maps and DTI to supplement this information. We expect 
that this will overcome the limitation of the traditional CE -MRI in evaluating the tumor 
growth. It will improve the understanding of the imaging changes related to anti -angiogenic 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 19 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
[ADDRESS_458556] the tumor pr ogression and disease prognosis.  
 
 
3.0 DRUG INFORMATION  
 
3.1  BEVACIZUMAB DRUG INFORMATION  
 
3.1.1  Drug Name : [CONTACT_366989]  
 
3.1.2 Appearance : Bevacizumab is a clear to slightly opalescent, colorless to pale brown, 
sterile liquid concentrate for solution for intravenous (IV) infusion.     
 
3.1.3 How supplied : Bevacizumab will be supplied by [CONTACT_366942] 20 -cc (400-mg) glass 
vials containing 16 mL bevacizumab (25 mg/mL).   Vials contain bevacizumab with 
phosphate, trehalose, polysorbate 20, and Sterile Water for Injection (SWFI), USP.   Vials 
contain no preservative and are suitable for single use only.  
 
For further details, see the bevacizumab Investigator Brochure.  
 
3.1.4 Storage and Stability : Upon receipt of the study drug, vials are to be ref rigerated at 
2ÔÇ∞C‚Äì8ÔÇ∞C (36ÔÇ∞F‚Äì46ÔÇ∞F) and should remain refrigerated until just prior to use. DO NOT 
FREEZE.  DO NOT SHAKE.  Vials should be protected from light.  
 
Opened vials must be used within [ADDRESS_458557] be administered within 8 hours.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.1.5 Human Toxicity : 
 
Likely (occurring in more than 20% of patients)  
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 20 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
20 
 high blood pressure  
pain  
headache 
dizziness 
hair loss 
abdominal pain  
vomiting loss of appetite  
constipation  
diarrhea  
sores in the mouth   
bleeding in the digestive 
system 
upset stomach  taste disorder  
failure of the ovaries to 
produce hormones, which may 
be permanent (possible 
stopped menstrual cycle)  
weakness  
increased proteins in the urine 
(possible kidney damage)  
airway infection  
nosebleeds  
difficulty breathing  
 
Bevacizumab may likely cause low white blood cell counts.  This means that while you 
take the drug, there is more of a chance of getting an infection, including pneumonia.  
 
Common (occurring in 3 -20% of patients)       
 
low blood pressure  
fatigue  
nerve damage (possible 
numbness, tingling, 
and/or burning)  
confusion  
unusual manner of 
walking 
dry skin 
shedding and scaling of 
the skin (possible fatal 
loss of bodily fluids)  
skin discoloration  
nail disorder  
fainting 
low potassium blood 
levels (possible 
weakness) low sodium blood levels 
(possible headache, 
confusion, seizures, and/or 
coma)  
gas  
weight loss  
nausea 
dry mouth  
inflammation of the intestines  
decreased intestinal function 
(possible vomiting, swelling, 
and/or pain)  
dehydration  
frequent urination  strong need to urinate  
vaginal bleeding  
fever, infection, and low 
white blood cell counts  
bleeding  
high levels of bile in the blood  
muscle and/or bone pain  
teary eyes  
voice changes  
lung inflammation  
build-up in the lung tissues  
infection 
infusion rea ctions 
 
Bevacizumab may commonly cause low blood cell counts (red blood cells and platelets).  
You may become anemic and/or have problems with bleeding, bruising, fatigue, and/or 
shortness of breath.  You may need a blood transfusion.  
 
Bevacizumab may commonly cause blood clots.  The clots can occur in the veins or 
arteries that supply blood to the brain, heart, lungs, or other organs, which may cause 
stroke and/or heart attack.  
 
Bevacizumab may commonly cause the development of a hole through the entir e 
thickness of the wall of the stomach, small intestine or large intestine, which can cause 
leakage of the contents of these organs and lead to infection.  
 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 21 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
21 
 Rare but serious (occurring in fewer than 3% of patients)        
 
heart failure  
heart attack  
chest pain due to heart 
trouble  
severe increase in blood 
pressure  
bleeding in the brain, 
causing stroke  
stroke 
bleeding in the space 
surrounding the brain  
bleeding gums  pockets of infected fluid in 
the abdomen  
death of tissue in the 
intestines  
intestinal blockage  
vein blockage in the 
abdomen 
destruction of the jaw bone  
eye infection  
blurry vision  
kidney damage  
hole between the nostrils  
coughing up blood  bleeding in the lung  
increased pressure in the 
blood vessel that leads to 
the lungs (possible 
shortness of breath)  
opening of a healed 
wound 
sudden, rapid loss of a 
skin graft (a patch of 
transplanted skin tissue) 
or other grafted tissue  
wound healing problems  
 
 
Bevacizumab may rarely cause brain damage (encephalopathy), including reversible 
posterior leukoencephalopathy syndrome, a medical condition related to leakiness of 
blood vessels in the brain, which can cause confusion, blindness or vision changes, 
seizure, changes in brain scans, and/or other symptoms.  Leukoencephalopathy may 
occur up to [ADDRESS_458558] dose of study drug.  
 
Bevacizumab may rarely cause an abnormal opening that develops between one area of 
the body and another (for example, an abnormal connection and opening in one or more 
places between the trachea [breathing tube] and  esophagus, which may interfere with 
swallowing, digestion, and/or choking).  This may result in death.  
 
Other Information about Bevacizumab  
 
Rarely (in about 1 -2% of patients), bevacizumab may cause bleeding in the brain in 
patients who have received beva cizumab for the treatment of primary brain tumors. You 
will be monitored for this complication and removed from the study if this were to occur.  
 
In most patients, blood pressure can be controlled with routine medications taken by 
[CONTACT_366943] i s continued.  However, uncontrolled high blood pressure and 
high blood pressure resulting in disturbance of organ function may occur.  
 
Bevacizumab may also worsen any pre -existing heart or cerebrovascular disease 
(abnormality of the brain resulting from blood vessel problems).  
 
The impact of bevacizumab on future fertility is currently unknown.  However, it is 
possible that treatment with bevacizumab may affect fertility and decrease the likelihood 
of becoming pregnant in the future.  
 
If you are older tha n 65, you may have an increased risk of blood vessel problems such as 
stroke and/or heart attack. You also may have a higher chance of low white blood cell, 
low platelet counts, diarrhea, nausea, headache, and/or fatigue.  
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 22 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
22 
 If you are taking Coumadin (warfar in) or other blood -thinning drugs, you may be at 
higher risk of blood clots and/or bleeding.  
 
3.1.6 Administration :  
 
Bevacizumab 10mg/kg will be administered on day 1 and 15 intravenously on a 28 day 
cycle in both arms. Dilute bevacizumab according to the  manufacturer package insert 
and/or institutional standards regarding bevacizumab storage, handling, dose preparation, 
and administration.   Administration will be as a continuous IV infusion.  Anaphylaxis 
precautions should be observed during study drug ad ministration.   It is not necessary to 
correct dosing based on ideal weight.  . 
 
The initial dose will be delivered over 90 ÔÇ±[ADDRESS_458559] infusion is tolerated 
without infusion -associated adverse events (fever and/or chills), the second infusion  may 
be delivered over 60 ÔÇ±10 minutes.  If the 60 -minute infusion is well tolerated, all 
subsequent infusions may be delivered over 30 ÔÇ±[ADDRESS_458560] experiences an infusion ‚Äìassociated adverse event, he or she may be pre -
medicated for the next s tudy drug infusion; however, the infusion time may not be 
decreased for the subsequent infusion.  If the next infusion is well tolerated with 
premedication, the subsequent infusion time may then be decreased by 30 ÔÇ±[ADDRESS_458561] experiences an 
infusion-associated adverse event with the 60 -minute infusion, all subsequent doses 
should be given over 90 ÔÇ±[ADDRESS_458562] experiences an 
infusion-associated adverse event with the 30 -minute infusion, all subsequent doses 
should be given over 60 ÔÇ±10 minutes. 
 
3.1.7 Supplier: Bevacizumab is supplied by  [CONTACT_366944]  
  
3.2 VORINOSTAT DRUG INFORMATION  
 
3.2.1 Drug Name : [CONTACT_366990]  (Zolinza¬Æ) 
 
3.2.2 Appearance : Vorinostat is supplied as a white, opaque gelatin, size 3 capsule, containing 
100 mg of vorinostat . 
 
3.2.3  How supplied : Vorinostat is supplied as a white, opaque gelatin, size 3 capsule, 
containing 100 mg of vorinostat. The inactive ingredients contained in each capsu le are 
microcrystalline cellulose, sodium croscarmellose, and magnesium stearate. Vorinostat 
will be supplied in the marketed package (Zolinza¬Æ).  
 
3.2.4 Storage and Stability : Vorinostat capsules should be stored at room temperature (do not 
store above 30 ¬∞C) in a dry, limited -access area. Care should be taken to maintain 
acceptable storage temperature. Vorinostat capsules should not be opened or crushed and 
must be administered whole.  
 
The shelf-life of the 100 mg capsule is 2 years.  
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 23 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
23 
  
3.2.5 Human Toxicity :  
 
 Likely (occurring in more than 20% of patients)  
 
fatigue 
high blood sugar 
(possible diabetes)  
diarrhea   
nausea  
changes in taste  dry mouth  
weight loss  
loss of appetite  
decreased appetite  
vomiting  
difficulty breathing  increased proteins in the 
urine (possible kidney 
damage) 
increased creatinine blood 
level (possible kidney 
problems)  
 
Vorinostat may likely cause low platelet counts. You may become anemic and/or have 
problems with bleeding, bruising, fatigue, and/or shortness of breath. You may need a 
blood transfusion if a problem with bleeding occurs.  
 
Common (occurring in 3 -20% of patients)      
 
arm and/or leg swelling  
irregular heartbeat   
chills  
dizziness  
headache  fever  
hair loss  
itching 
dehydration  
constipation  muscle spasm  
cough 
airway infection  
blood clots in the lung  
squamous cell carcinoma 
(skin cancer)  
 
Vorinostat may commonly cause low red blood cell counts. You may become anemic, 
fatigued, and/or short of breath. You may need a blood transfusion.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rare but serious (occurring in fewer than 3% of patients)   
 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 24 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
[ADDRESS_458563] pain  
blood clots in a vein  
high blood pressure  
heart attack  
stroke 
fainting  
swelling 
shedding and scaling of 
the skin (possible fatal 
loss of bodily fluids)   
low blood levels of 
calcium (possible 
weakness and/or 
crampi[INVESTIGATOR_007])  low blood levels of 
sodium (possible 
headache, confusion, 
seizures, and/or coma)  
low blood levels of 
potassium (possible 
weakness)  
bleeding in the digestive 
system 
inflammation of the 
gallbladder  
blockage in the tubes 
that drain u rine from the 
kidneys 
inability to urinate  severe blood infection  
bacterial infection in the 
bloodstream  
blood vessel inflammation 
(possible fever and/or 
fatigue) 
spi[INVESTIGATOR_366876] 
T-cell lymphoma (cancer of 
the lymph nodes)  
 
Vorinostat may rarely cause low white blood cell counts. This means that while you take 
the drug, there is more of a chance of getting an infection, including pneumonia.  
 
Vorinostat can interact with many drugs.  Be sure to tell your study doctor or nurse about 
all drugs that you are currently taking, including any over -the-counter or herbal products.  
While on study, please check with your study doctor or nurse before you start any new 
prescription dr ugs or over -the-counter or herbal products.  
 
3.2.6 Administration : Vorinostat 400mg/day will be administered on day [ADDRESS_458564] be administered whole. It is recommended that Vorinostat be 
administered with food, but not high fat meal. A pi[INVESTIGATOR_366877].  
 
Special Handling Requirements : Vorinostat is an anticancer drug. Spi[INVESTIGATOR_366878]. The af fected area must be washed at least [ADDRESS_458565] occurs, wash 
thoroughly. Vorinostat capsules should be stored at room temperature (do not store above 
30¬∞C) in a dry, limited -access area. Care should be taken to maintain acceptable storage 
temperature. Vorinostat capsules should not be opened or crushed and must be 
administered whole.  
 
For further detail s and molecule characterization, see the vorinostat Investigator 
Brochure.  
 
3.2.7 Supplier: Vorinostat is supplied by [CONTACT_44873], Sharp and Dohme Corp.  
 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 25 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
25 
  
3.3 Study Agent Distribution  (for the Phase II Multi -Center component) :  
 
3.3.1 Ordering Study Agent/s :  
 
Bevacizumab and vorinostat may be requested by [CONTACT_079] (or their 
authorized designees) at each participating institution.   
All regulatory document requirements (including a Pharmacy Initiation Worksheet), as 
described in the BTTC Operations Manual, must be current and up to date in the BTTC 
Coordinating Center. The participating institution must have received an Activation 
memo from the OMCR prior to requesting study agents.  A Study Drug Order form and 
Pharmacy Initiation Worksheet will be provided to the sites by [CONTACT_366945].  
 
Signed and Dated Drug requests should be emailed to:  
Uintavision  
Attn: Michelle DuBois  
Email: [EMAIL_7059]  
 
When a number of investigators are participating on a clinical study at the same 
institution, one investigator should be considered or designated the principal or lead 
investigator under whom all investigational agents for that protocol should be ordered.  
 
3.3.2 Agent Storage and Accountability :  
 
 The investigator is responsible for the proper and secure physical storage and 
 record keepi[INVESTIGATOR_264297]. 
 Specifically, the investigator must:   
ÔÇ∑  Maintain a careful record of the receipt, use and final disposition of all 
 investigational agents received, using the NCI Agent Accountability Record 
 Form (DARF), http://ctep.cancer.gov/forms/index.html .   
ÔÇ∑  Store the agent in a secure location, accessible to only authorized personnel, 
 preferably in the pharmacy.  
ÔÇ∑   Maintain appropriate storage of the investigational agent to ensure the stability 
 and integrity of the agent.  
ÔÇ∑   Return or destroy any unused investigational agents at the completion of the 
 study or upon notification that an agent is being withdrawn.  
 
The intent of the agent accountability procedures described in this section is to assist the 
investigator in making certain that agents received from BTTC are used only for patients 
entered onto an approved protocol. The record keepi[INVESTIGATOR_366879]. Investigators are responsible for the use of 
investigational agents shipped in their name. Even if a pharmacist or chemotherapy nurse 
has the actual task of handling these agents upon receipt, the investigator is the  
responsible individual and has agreed to accept this responsibility by [CONTACT_366946] 
1572, http://www.fda.gov/opacom/morechoices/fdaforms/FDA -1572.doc. 
 
3.3.3 Returning or destroying unused and/or defective Agent :  
 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 26 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
26 
 Investigators/Designees should make every effort to minimize the amount of 
agent ordered and returned unused, (e.g. limit inventories to an 8 week supply or 
less). The BTTC Operations Manual describes a generic  Policy for returning or 
destroying supplied study agents. Procedures specific to this study are described 
here.  
 
Agent Return/Destruction Procedure   
 
All unused or expi[INVESTIGATOR_366880] . The on site destruction of unused or expi[INVESTIGATOR_366881] , and forward ed to BTTC  Coordinating 
center which in turn will notify Genentech and [COMPANY_006] Sharp and Dohme along with 
documentation of lot numbers and number of vials destroyed.  
 
Destroy opened, partially used or unused  vials/bottles. Do NOT return opened or 
partially used vials/bottles unless specifically requested otherwise in the protocol.  
 
 
4.[ADDRESS_458566] be registered with the Brain Tumor 
Trials Collaborative via the Office of Multicenter Clinical Research ( MD ANDERSON 
CANCER CENTER  OMCR) at the University of [LOCATION_007], MD Anderson Cancer Center  prior to 
receiving treatment with study drug .  The OMCR‚Äôs registration procedures are described in the 
Multicenter Procedures section of this protocol. Patients must initiate study treatment with in 
[ADDRESS_458567] histologically proven glioblastoma, gliosarcoma or anaplastic glioma 
to be eligible for the Phase I component of this protocol. Anaplastic gliomas include 
anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO), anaplastic mixed 
oligoastrocytoma (AMO), or malignant glioma NOS (not otherwise specified). Patients 
will be eligible if the original histology  was low-grade glioma and a subsequent 
histological diagnosis of a malignant glioma is made. Only patients with histologically 
proven or imaging proven recurrent glioblastoma or gliosarcoma will be eligible for the 
Phase II component. Wafer acceptable if recurrence is confirmed.  
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 27 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
[ADDRESS_458568] a Karnofsky performance status  (KPS) equal or greater than  60 (See 
Appendix   18.2). 
 
4.5 At the time of registration:   
4.5.[ADDRESS_458569] recovered from the toxic effects of prior therapy to < grade 2 
toxicity per CTC version  4 (except deep vein thrombosis ‚Äì see section 6.1. 4  
ÔÇ∑ 28 days from any investigationa l agent, 
ÔÇ∑ 4 weeks ( 28 days) from prior cytotoxic therapy,  
ÔÇ∑ 2 weeks ( 14 days) from vincristine,  
ÔÇ∑ 6 weeks ( 42 days) from nitrosoureas,  
ÔÇ∑ 3 weeks ( 21 days) from procarbazine administration,  
ÔÇ∑ >1 week ( 7 days) for non-cytotoxic agents, e.g., interferon, tamoxifen, 
thalidomide, cis -retinoic acid, etc. (radiosensitizer does not count).   
4.5.2  Patients who receive anticance r agents for non -therapeutic purposes unrelated to 
this study (such as presurgically for obtaining pharmacology data for the agent) 
will be eligible to enter the study provided they have recovered from the toxic 
effects of the agent if any. Any questions r elated to the definition of non -
cytotoxic agents should be directed to the Study Chair.  
 
4.[ADDRESS_458570] adequate bone marrow function (ANC > 1,500/mm3, platelet count of 
> 100,000/mm3), adequate liver function ( SGPT < 3 times upper limit normal and 
alkaline phosphatase < 2 times upper limit normal, total bilirubin < 1.5mg/dl, ‚ÄúPatients 
with high bilirubin levels related to known diagnosis of benign hyperbilirubinemia 
(Gilbert‚Äôs syndrome) will be eligible ‚Äú. , and adequa te renal function ( BUN < 1.5 times 
institutional normal and Creatinine  < 1.5 mg/d l) prior to registration .  These tests must be 
performed within [ADDRESS_458571] confirmation of true progressive disease rather than radiation 
necrosis using the local institutional standards for such determination including advanced 
imaging or surgery.  .  
 
4.8  The baseline on -study MRI scan should be performed within 14 days (+ 3 working days) 
prior to registration but before starting treatment and on a steroid dose that has been 
stable or decreasing for at least 5 days. If the steroid dose is increased between the date of 
imaging and registration (or at that time), a new baseline MR I is required. The same type 
of scan, i.e., MRI must be used throughout the period of protocol treatment for tumor 
measurement.  
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 28 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
28 
  
4.9  Patients having undergone recent resection of recurrent or progressive tumor will be 
eligible as long as all of  the following conditions apply:  
 
a) At least 4 weeks (28 days  ) have elapsed from the date of surgery and the patients 
have recovered from the effects of surgery.  
 
b) Evaluable or measureable disease following resection of recurrent Malignant 
Glioma is not mandated for eligibility into the study.   
 
c) To best assess the extent of residual disease post -operatively, a MRI should be 
done no later than [ADDRESS_458572] an interval of greater than 
or equal to 12 weeks (84  days) from the completion of radiation therapy to study entry  
except if there is unequivocal evidence for tumor recurrence (such as histological 
confirmation or advanced imaging data such as PET scan) in which case at least 4 weeks 
(28 days) from completion of radiation therapy will suffice (Note: for patients who h ave 
undergone surgery to confirm recurrence after radiation therapy, guidelines in 4.9a 
should be followed) . 
 
4.[ADDRESS_458573] confirmation of true progressive disease rather than radiation 
necrosis based upon either PET or Thallium scanning, MR spectroscopy or 
surgical/pathological  documentation of disease.  
 
4.[ADDRESS_458574] practice adequate contraception  
(please refer to Appendix   18.11 for details and definitions ‚Äì woman of childbearing 
potential; adequate methods of contraception)  for the duration of the study, and for [ADDRESS_458575] dose of study 
medication (please refer to Appendix 18.11 for definition of adequate methods of 
contraception).  
 
4.[ADDRESS_458576] be able to tolerate the procedures required in this study including periodic 
blood sampling, study related assessments, and management at the treating institution for 
the duration of the study.  
 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 29 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
29 
 4.15 Patients receiving treatment with any antiepi[INVESTIGATOR_366882] 
(because of its HDAC inhibitory activity) can be included in the study.  Vorinostat is not 
metabolized by [CONTACT_13439] P450 3A4 (CYP 3A4); howev er, Vorinostat may potentially 
suppress CYP 3A4 activity. Therefore, patients should preferably be treated with non -
enzyme inducing anti -epi[INVESTIGATOR_366883]. If enzyme -
inducing antiepi[INVESTIGATOR_366884], monitoring of th ese drug levels should be 
considered, as considered clinically appropriate by [CONTACT_1963] (See Appendix  
18.3). 
 
4.16. For the Phase II portion of the study, patients may have had treatment for no more than 2 
prior relapses.  There is no limit to  the number of relapses for the phase I portion of the 
study provided the functional status and other eligibility criteria for enrollment are met. 
Relapse is defined as progression following initial therapy (i.e. radiation+/ - chemo if that 
was used as init ial therapy).  The intent therefore is that patients had no more than 3 prior 
therapi[INVESTIGATOR_014] (initial and treatment for 2 relapses).  If the patient had a surgical resection for 
relapsed disease and no anti -cancer therapy was instituted for up to [ADDRESS_458577] relapse  
 
General Exclusion Criteria  
 
4.17  Inability to comply with protocol or study procedures (for example, an inability to 
swallow tablets).  
 
4.18  Prior treatment with bevacizumab or Vorinostat.  
 
4.19  Patients receiving valproic acid (VPA), an anticonvulsant drug with HDAC inhibitor 
properties, will be excluded, unless they are switched to an alternative agent prior to 
treatment initiation. A [ADDRESS_458578] from providing informed consent.  
 
4.21  Any condition, including the presence of clinically significant laboratory abnormalities, 
which places the p atient at unacceptable risk if he/she were to participate in the study or 
confounds the ability to interpret data from the study. These would include  
 
a) Active infection (including persistent fever) including known AIDS or Hepatitis C 
infection 
 
b) Diseases or conditions that obscure toxicity or dangerously alter drug metabolism    
 
c) Serious intercurrent medical illness (e.g. symptomatic congestive heart failure).  
 
4.22  Current, recent (within 4 weeks (28 days) of t he first infusion of this study , or planned 
participation in an experimental antitumor drug study (other than the current one).  
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 30 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
30 
  
4.23  Patients with a history of any other cancer (except non -melanoma skin cancer or 
carcinoma in -situ of the cervix or bladder), unless in complete remission and off of all 
therapy for that disease for a minimum of 3 years are ineligible.  
 
4.24    Patients with spi[INVESTIGATOR_366885]  (metastasis)  and/or leptomeningeal disease will not be allowed 
in the study.  
 
 
Bevacizumab -Specific Exclusion Criteria  
 
4.25  Inadequately controlled hypertension (defined as systolic blood pressure > 140 mmHg 
and/or diastolic blood pressure > 90 mmHg).  
 
4.26  Prior history of hypertensive encephalopathy.  
 
4.27  [LOCATION_001] Heart Association (NYHA) Grade II or greater congestive heart failure (s ee 
Appendix 18.9 ). 
 
4.28  History of myocardial infarction or unstable angina within 6 months prior to Day 1 . 
 
4.29   History of stroke or transient ischemic attack within 6 months prior to Day1 . 
 
4.30  Significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or recent 
peripheral arterial thrombosis) within 6 months prior to Day 1 . 
 
4.31  History of hemoptysis ( ÔÇ≥ 1/2 teaspoon of bright red blood per epi[INVESTIGATOR_1865]) within 1  month 
prior to Day 1 . 
 
4.32  Evidence of bleeding diathesis or signif icant coagulopathy (in the absence of therapeutic 
anticoagulation) . 
 
4.33  Major surgical procedure, open biopsy, or significant traumatic injury within 28  days 
prior to Day 1 or anticipation of need for major surgical procedure during the course of 
the study.  ‚ÄúPatients with recent resection will be eligible for entry into the surgical arm 
of the study but will follow guidelines as in section 4.9‚Äù .  
 
4.34  Core biopsy or other minor surgical procedure, excluding placement of a vascular access 
device, within 7 days prior to Day 1 . 
 
4.35  History of abdominal fistula or gastrointestinal perforation within 6 months prior to Day 
1. 
 
4.36  Serious, non -healing wound, active ulcer, or untreated bone fracture . 
 
4.37  Proteinuria as demonstrated by:  
ÔÇ∑ Urine prot ein: creatinine (UPC) ratio  ÔÇ≥ 1.0 (Appendix  18.10) at screening OR  
 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 31 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
31 
 ÔÇ∑ Urine dipstick for proteinuria ‚â• 2+ (patients discovered to have ‚â•2+ proteinuria on 
dipstick urinalysis at baseline should undergo a [ADDRESS_458579] 
demonstrate ‚â§ 1g of protein in 24 hours to be eligible).  
 
4.38  Known hypersensitivity to any component of bevacizumab . 
 
4.39  Pregnancy (positive pregnancy test) or lactation. Use of effective means of contraception 
(men and women) in subjects of child -bearing potential  is required  for study treatment.  
 
 
5.0 STRATIFICATION/DESCRIPTIVE FACTORS  
 
See section 11.[ADDRESS_458580] be registered with the Brain Tumor Trials 
Collaborative  Office of Multicenter Clinical Research  (MD ANDERSON CANCER CENTER  
OMCR) at the University of [LOCATION_007], MD Anderson Cancer Center (UT MD ANDERSON 
CANCER CENTER ).  Patients must initiate study treatment within 96 hours after registration.  
 
6.1.1 Patients will be monitored for hematologic or serologic evidence of myelosuppression, 
hepatic injury, renal injury, and electrolyte disturbances and for clinical evidence of other 
toxicity as is described in section 8.0.  
 
6.1.2 G-CSF Administration  
 
G-CSF and erythropoietin administration: Routine prophylactic use is not permitted. 
However, therapeutic use in patients with complications (severe neutropenia with fever or 
anemia), may be considered at the investigator‚Äôs discretion . 
 
6.1.[ADDRESS_458581], and discontinued if possible.  
 
b. Anti-seizure medications  should be used as indicated. Treatment with valproic acid is 
not allowed. Patients should preferably be t reated with non -enzyme inducing 
antiepi[INVESTIGATOR_366886]. For 
patients on treatment with enzyme -inducing antiepi[INVESTIGATOR_006], clinically relevant 
monitoring of drug levels is recommended, as considered a ppropriate by [CONTACT_30780]  
 
c. Febrile neutropenia  may be managed according to the local institution's Infectious 
Disease guidelines.  Measures may include appropriate laboratory testing, including 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 32 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
[ADDRESS_458582]-spectrum antibiotics.  If a source 
for the fever is not identified or the fever resolves when the neutrophil count 
recovers, antibiotics may be discontinued and the patient observed.  
 
d.  Antiemetics:  prophylactic and therapeutic use is allowed . 
 
e. Other Concomitant Medications  
 
Therapi[INVESTIGATOR_264271]-being of the patient may be given at the 
discretion of the treating physician . All concomitant medications must be recorded.  
 
f. Other Anticancer or Experimental Therapi[INVESTIGATOR_366887] (including chemotherapy, radiation, hormonal treatment 
or immunotherapy) of any kind is permitted during the study period. No other 
antitumor drugs under investigation may be used concomitantly with the study drug.  
 
g. Surgery 
 
If neurosurgical management is required for reasons not due to tumor progression, 
these procedures must be documented, including the indications for surgery, the 
surgical operative note and pathology report.  
 
6.1.4  Definition of dose limiting toxicities ( DLT) (Phase I portion)  
 
All patients in the phase I study will be evaluable for assessment of toxicity in order to 
define DLT.  Toxicities will be graded according to the Common Terminology Criteria 
for Adverse events (CTCAE) Version  4.0.  If multiple toxi cities are seen, the presence of 
DLT should be based on the most severe toxicity experienced. DLT will be defined as 
any of the following events occur ring in the first cycle of treatment (4 weeks) and 
attributable to the study drugs:  
ÔÇ∑ Any grade 4 hematologi cal toxicity except neutropenia and thrombocytopenia, as 
indicated below  
-  febrile neutropenia defined as grade 3 -4 neutropenia with fever ‚â•38.5¬∫C and/or 
infection requiring antibiotic or antifungal treatment OR any grade 4 neutropenia 
lasting 5 days or m ore is considered a DLT  
-  Grade 4 thrombocytopenia OR platelet count <25,000/ul of any duration is 
considered a DLT;  
 
ÔÇ∑ Any non-hematologic grade 3 or 4 toxicity, except the following   
‚Äì nausea or vomiting that responds to symptomatic therapy  
-  fatigue that responds to symptomatic therapy  
-  alopecia 
-  lymphopenia,  
-  weight gain (in patients on steroids),  
-  venous thromboembolic disease*.  
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 33 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
33 
 -  In case of isolated laboratory abnormalities that may not reach clinical 
significance, a determination wil l be made in consultation with the IRB on a case 
by [CONTACT_366947].  
 
ÔÇ∑ Failure to recover from treatment related toxicities to be eligible for re -treatment 
within [ADDRESS_458583] dose of the drugs.   
 
*Non-Relevant T oxicities for Brain Tumor Protocols  
 
Lymphopenia is a common finding among patients with primary brain tumors and is 
directly attributable to concurrent use of corticosteroids.  To date, even Grade III 
lymphopenia has not been associated with a worsening o f clinical outcome.  Therefore, 
we will not consider this parameter in the determination of optimal dosing of drugs.  
 
Weight gain is a common finding among patients with primary brain tumors.  This too is 
directly attributed to the concurrent use of corticosteroids. Doses of steroids or study 
agents will not be modified as a consequence of weight gain.  Corticosteroid dosage will 
be based on maintenance of control of edema in the brain and the standard clinical 
practice to use the minimal effective do se of corticosteroids will be employed.  
 
Alopecia is a common occurrence in patients with brain tumors as a consequence of 
cranial radiotherapy.  Alopecia will not be recorded or graded as toxicity.  
 
Venous thromboembolic disease is a common complication occurring in up to 30% of 
patients with malignant gliomas (Wen and Marks, 2002; Semrad et al., 2006). In this 
study, patients who develop deep vein thrombosis may receive anticoagulation and 
resume therapy once they are stable on anticoagulation. Grade III  deep vein thrombosis 
will not be considered a DLT for the phase I portion.  
 
 
The routine use of filgrastim or other white cell growth factors is not permitted during 
cycle 1 of the Phase I portion unless clinically indicated (see section 6.1. 2), but it ma y be 
used beyond this period or once the assessment of DLT has been completed.   
 
6.2 Phase I Treatment Plan  
The Phase I study has been completed in MDACC. The Phase II dose has been determined.  Brief 
details of the phase I study are included in this section to indicate the doses explored and the final 
phase II dose identified.  
 
6.2.1 Drug Dose/s:  
 
In this component, the combination treatment arm was tested and several dose levels 
planned.. The starting dose was bevacizumab 10mg/kg administered on day 1 and 15 
intravenously and vorinostat at 400 mg/day orally on days 1 to 7 and days 15 to 21 .  This 
dose of vorinostat is also the recommended dose for combination trials based on other 
ongoing studies.     
 
 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 34 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
34 
 6.2.2 Dose Escalations and definition of maximum tolerated dose  (MTD): 
 
A conventional Phase [ADDRESS_458584] cohort, the next 3 patients would be enrolled to level  1. If no DLT 
was noticed after dose escalation to level 1, this dose was to be  used for Phase II 
component of the study. If 1/3 of the patients experience DLT, the cohort was to be 
expanded to 3 more patients; if 1/6 patients experience DLT, the MTD was to be 
considered reached and this dose would be used for the phase II part of the study. If 2/[ADDRESS_458585] cohort at 400 mg/daily of vorinostat and  
10 mg/kg of bevacizumab. One patient experienced a grade 3 ALT elevation and grade 3 
hyperglycemia which were designated as possibly  related to vorinostat ‚Äì these toxicities 
constituted a DLT for this dose level.  The cohort was hence expanded by [ADDRESS_458586] cycle.  Per protocol 
guidelines as noted in section 6.2.2, given that 1/6 patients experienced DLT at the 
starting dose level and because this dose level was also the recommended dose for 
combination studies based on other ongoing trials, the starting dose level of bevacizumab 
and vorinostat  was declared the Phase II dose.        
 
6.3 Phase II Treatment Plan  
 
6.3.1 Drug Dose/s:  
 
The dose for phase II study of the combination has been identified as follows:  
bevacizumab 10mg/kg administered on day 1 and 15 intravenously and vorinostat at 400 
mg/day orally on days 1 to 7 and days 15 to 21 . On cycle 1 day 1, vorinostat should be 
taken prior to the bevacizumab infusion.  
 
6.3.2  Non- Surgical Arm : 
 
In this component, patients will be randomized between two competing treatment arms: 
Vorinostat + bevacizumab versus bevacizumab alone using an adaptive randomization 
design (see Statistical Section). The dosage for the vorinostat + bevacizumab arm as 
derived from the MTD of the combination determined in the phase I component of the 
study is as described in section 6.3.1 . The treatment schedule will be identical to that 
described above in the phase I component, with each course comprising 28 days. Patients 
will continue treatment until tumor progression or unacceptable toxicity occurs.  
 
6.3.3 Surgical Arm :  
 
Patients who need a surgical resection for their recurrent tumors are eligible for this part 
of the study. These patients will be primarily accrued in M D Anderson Cancer Center. 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 35 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
35 
 Other interested  sites may participate on the surgical arm provided  there are available 
local resources  for appropriate sample collection and shipment . This will be decided on 
an institution specific manner after d iscussion with the Study Chair. Such participating 
institutions are expected to ensure that participation of such subjects as well as shipment 
of tissue to MDACC are in compliance with institutional and federal human subjects 
protection guidelines. Based on prior experience with such accrual  it is anticipated that no 
more than 10 patients will be accrued into this portion of the study. Tumor tissue from 
the resection will be sent for qRT -PCR assessment of a prognostic 9 gene profile (Aldape 
and Colman, unpublished data). This profile distinguishes between an angiogenic (poor 
prognosis) mesenchymal group and a proneural (good prognosis) group. We hypothesize 
that the current treatment can modify the poor prognosis of the mesenchymal subgroup 
and improve their PFS and  OS; this will be preliminarily tested in this study. Patients on 
this arm will be eligible after surgery to be randomized to two treatment arms  (as 
described above  in section 6.3.2 ) using a Bayesian adaptive algorithm after a 4 week  
recovery period.  PFS in patients in the surgical arm will be determined from the date of 
randomized to the treatment arms and not from the date of registration in the trial. Tissue 
will also be collected from all patients (including from the nonsurgical arm) from their 
original or most recent resection for this assessment.  
 
[IP_ADDRESS] Pre and Post -operative evaluations as a result of this part of the study will consist of 
history and physical examination, laboratory studies, baseline toxicity assessments and 
postsurgical symptoms  assessment  as described in sections 7.0 and 8.0.   
 
[IP_ADDRESS] Once patients have recovered from the effects of surgery, they will embark upon the 
phase II component of the study.  Patients are not required to have residual disease to 
continue onto the phase II component.  
 
[IP_ADDRESS] Following surgery, a MRI scan should be done no later than 96 hours  after surgery; given 
that patients are required to be at least 4 weeks after surgery to begin treatment in the 
adaptive randomized portion of the trial , the MRI shou ld be repeated prior to initiation of 
treatment and on a steroid dose that is stable or decreasing. Treatment with bevacizumab 
or bevacizumab+vorinostat post-operatively should start no later  than 14 days after the 
scan.  
 
6.4 Dose Modifications:   
 
Treatment cycles are 28 days  (+3 days if needed for scheduling around holidays ); treatment will 
be continued if there is no tumor progression and patients recovered from treatment -related 
adverse events associated with the prior cycle. Recovery has occurre d once all the following 
conditions have been met:  
 
1. ANC > 1000/ml; 
2. Platelet > 100,000/ml;  
3. All drug associated non - hematological toxicity have recovered to grade 0 or 1 (except for 
DVT as below).  
 
If recovery has not occurred by [CONTACT_2006] 28 (+ 3 days) , the subsequent cycle will be delayed until 
these criteria have been met. If the patient has not recovered within [ADDRESS_458587], he/she will be 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 36 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
36 
 taken off  treatment  However, if the patient develops a lower extremity deep venous thrombosis 
and requires a nticoagulation or intervention (grade 3 toxicity), treatment may be restarted after a 
[ADDRESS_458588] period if the patient is stably anticoagulated and is judged medically stable to begin 
chemotherapy, in the opi[INVESTIGATOR_021]. (Please note: D VT is graded in the CTC 
version 4.0 as grade 1=  superficial thrombosis , grade 2= DVT , medical intervention indicated , 
grade 3=  uncomplicated pulmonary embolism, medical intervention indicated, grade 4=life -
threatening pulmonary embolism, cerebrovascular ev ent, arterial insufficiency, urgent 
intervention indicated ). 
 
The dose of Vorinostat will be initiated at MTD dose from the phase I part of the trial. The same 
dose will be continued unless > or = grade 3 drug related toxicity occurs; treatment will be hel d 
until toxicity resolves to less than grade 2.  The dose for next cycle will be reduced to one level 
below the dose that cause d the grade 3 toxicity. If grade 3 toxicity occurs again at lower dose, the 
dose will be further reduced to the next lower level.  A maximum of 2 dose reductions will be 
allowed for vorinostat.  
  
There is no dose reduction for bevacizumab. If any drug related adverse event occurs that 
necessitate holding bevacizumab, the dose will remain unchanged once treatment resumes. The 
maximum allowable length of treatment interruption is 4 weeks.  
  
6.4.1 Bevacizumab Dose Modification and Toxicity Management  
 
 There are no reductions in the bevacizumab dose. If adverse events occur that require 
holding bevacizumab, the dose will remain the same once treatment resumes  provided 
these events do not require discontinuation of the agent (Tab le 1). 
 
 Any toxicity associated or possibly associated with bevacizumab treatment should be 
managed according to standard medical practice. Discontinuation of bev acizumab will 
have no immediate therapeutic effect. Bevacizumab has a terminal half -life of 21 days; 
therefore, its discontinuation results in slow elimination over several months. There is no 
available antidote for bevacizumab.  
  
 Subjects should be asse ssed clinically for toxicity prior to, during, and after each 
infusion. Blood pressure should be checked prior to each bevacizumab infusion and 
standard practice guidelines followed for determining initiation and continued 
infusion of Bevacizumab If resting systolic blood pressure is >140 and or resting 
diastolic blood pressure >[ADDRESS_458589] 5 minutes 
apart, Bevacizumab should be deferred until the h ypertension is managed with 
appropriate antihypertensive medication .  Treatment may be initiated once the criteria for 
blood pressure outlined above are met. If unmanageable toxicity including events such as 
medically uncontrolled hypertension or hypertensive encephalopathy occurs because of 
bevacizumab at any time during the  study, treatment with bevacizumab should be 
discontinued.  
 
 Infusion Reaction : Infusion of bevacizumab should be interrupted for subjects who 
develop dyspnea or clinically significant hypotension. Subjects who experience a NCI 
CTCAE v. 4.0 Grade 3 or 4 a llergic reaction / hypersensitivity, adult respi[INVESTIGATOR_366888]: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 37 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
37 
 syndrome, or bronchospasm (regardless of grade) will be discontinued from bevacizumab 
treatment.  
 
 The infusion should be slowed to 50% or less or interrupted for subjects who experience 
any infusion-associated symptoms not specified above. When the subject‚Äôs symptoms 
have completely resolved, the infusion may be continued at no more than 50% of the rate 
prior to the reaction and increased in 50% increments every 30 minutes if well tolerated. 
Infusions may be restarted at the full rate during the next cycle.  
 
 Adverse events requiring delays or permanent discontinuation of bevacizumab are listed 
in Table 1.  
  
 Regardless of the reason for holding study drug treatment, the maximum allowable length 
of treatment interruption is 4 weeks.  
 
 
Table1: 
Bevacizumab Dose Management Due to Adverse Events  
Event Action to be Taken  
Hypertension  
 
No dose modifications for grade 1/2 events  
Grade 3  If not controlled to 140/90 mmHg with medication, discontinue 
bevacizumab.  
 
Grade 4 (including 
hypertensive 
encephalopathy)   
Discontinue bevacizumab.  
Hemorrhage  
 
No dose modifications for grade 1/[ADDRESS_458590] bevacizumab held until all of the 
following criteria  are met: 
ÔÇ∑ The bleeding has resolved and hemoglobin is stable.  
ÔÇ∑ There is no bleeding diathesis that would increase the risk of 
therapy. 
ÔÇ∑ There is no anatomic or pathologic condition that significantly 
increases the risk of hemorrhage recurrence.  
 
Subjects who experience a repeat Grade 3 hemorrhagic event will 
be discont inued from receiving bevacizumab.  
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 38 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
[ADDRESS_458591] bevacizumab held until all of the 
following criteria  are met: 
ÔÇ∑ The bleeding has resolved and hemoglobin is stable. as clinically 
determined  
ÔÇ∑ There is no bleeding diathesis that would increase the risk of 
therapy. 
 
There is no anatomic or pathologic condition that significantly 
increases the risk of hemorrhage recurrence.  
 
Grade 2, 3, or 4 
pulmonary or CNS 
hemorrhage   
Discontinue bevacizumab  
Venous Thrombosis  
No dose modifications for grade 1/2 events  
 
Grade 3 or 4  Hold study drug treatment.  If the planned duration of full -dose 
anticoagulation is <2  weeks, bevacizumab  should be held until the 
full-dose anticoagulation period is over.  If the planned duration of 
full-dose anticoagulation is >2 weeks, bevacizumab may  be 
resumed during the period of full -dose anticoagulation if all of the 
following criteria  are met: 
ÔÇ∑ The subject must have an in -range INR (usually between 2 and 
3) if on warfarin; LMWH, warfarin, or other anticoagulant 
dosing must be stable prior to rest arting bevacizumab treatment.  
ÔÇ∑ The subject must not have had a Grade 3 or 4 hemorrhagic 
event while on anticoagulation.  
Arterial Thromboembolic event  
 
(New onset, worsening, or unstable angina, myocardial infarction, transient ischemic attack, 
cerebrovascular accident, and any other arterial thromboembolic event)  
 Any grade  Discontinue bevacizumab.  
Congestive Heart Failure (Left ventricular systolic dysfunction)  
 
No dose modifications for grade 1/2 events  
 
Grade 3  
Hold bevacizumab until resolution to Grade ‚â§ 1.  
Grade 4 Discontinue bevacizumab.  
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 39 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
39 
 Proteinuria  
 
No dose modifications for grade 1/2 events  
 
Grade 3 
(UPC> 3.5, urine 
collection > 3.5 g/24 
hr)    
Hold bevacizumab treatment until ÔÇ£ Grade 2, as determined by [CONTACT_200952] ‚â§ 3.5 or 24 hr collection ‚â§ 3.5 g  
 
 
Grade 4 (nephritic 
syndrome)   
Discontinue bevacizumab  
GI Perforation  Discontinue bevacizumab.  
Fistula   
 
Any grade (TE fistula)  Discontinue bevacizumab.  
 
Grade 4 fistula   
Discontinue bevacizumab.  
Bowel Obstruction  
 
Grade 1  
 
Continue patient on study for partial obstruction NOT requiring 
medical intervention.  
Grade 2 Hold bevacizumab for partial obstruction requiring medical 
intervention.  Patient may restart upon complete resolution.  
 
Grade 3/4   
Hold bevacizumab for complete obstruction.  If surgery is necessary, 
patient may restart bevacizumab after full recovery from surgery, and 
at investigator‚Äôs discretion.  
Wound dehiscence Any 
grade (requiring 
medical or surgical 
therapy) Discontinue bevacizumab.  
Reversible Posterior Leukoencephalopathy   
 
Any grade  
(confirmed by [CONTACT_9268])   
Discontinue bevacizumab.  
Other Unspecified Bevacizumab -Related Adverse Events  
Grade 3 
 
Grade 4 Hold bevacizumab until recovery to ‚â§ Grade 1 
 
Discontinue bevacizumab.  
  
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 40 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
40 
 6.4.2 Vorinostat Dose Modification and Toxicity Management  
 
Vorinostat will be administered from day 1 to day 7 and day 15 to day 21 in each 28 -day 
cycle in arm receiving vorinostat and bevacizumab. Treatment will be initiated at the 
MTD dose determined in the phase I component of the trial. This dose will be maint ained 
as long as there are no vorinostat related toxicities > grade 2. For grade 2 vorinostat 
related toxicities, treatment will be withheld and the patients will be monitored until 
toxicities resolve to < grade 2 (except for deep venous thrombosis as note d in section 
5.3). For subsequent treatment the dose will be unchanged provided the recovery occurs 
within 2 weeks of treatment hold; if it is longer than [ADDRESS_458592] period will be required. Subsequently, 
patients will restart treatment at one dose level less than the one that resulted in the 
toxicity as indicated below after the toxicities resolve to < grade 2 (except for deep 
venous thrombosis as noted in section  6.4). 
  
 Dose adjustments for the subsequent cycles:  dose will be one level below the dose that 
produced toxicity of grade 3 or greater per dose schedule changes indicated below. If 
grade 3 or 4 toxicity recurs, patients will again discontinue the vorinostat until toxicity 
returns to grade 1 or less. The estimated dose levels below are shown for various MTD 
that may be determined in the phase I study.  
 
Dose Level  -2 -1 0 
Drug: Vorinostat  N/A 100 mg/day  200 mg/day  
 100 mg/day  200 mg/day  300 mg/day  
 200 mg/day  300 mg/day  400 mg/day  
 300 mg/day  400 mg/day  500 mg/day  
 
Only 2 dose reductions of vorinostat are permitted as above. If the patient experiences 
grade 3 or greater toxicity after 2 dose reductions, he/she will be taken off   treatment . If 
starting dose is 200 mg once daily, only 1 dose reduction of vorinostat is  allowed.  
 
Regardless of the reason for holding study drug treatment, the maximum allowable length 
of treatment interruption is 4 weeks after which the patient will be taken off the study.  
 
6.5 CONCOMITANT ASPI[INVESTIGATOR_366889]-dose aspi[INVESTIGATOR_248] (‚â§ 325 mg/d) may be co ntinued in subjects at higher risk for arterial 
thromboembolic disease. Subjects developi[INVESTIGATOR_366890] 1, Bevacizumab Dose 
Management Due To Adverse  Events. 
 
6.[ADDRESS_458593] the Study Chair or the MD 
ANDERSON CANCER CENTER  OMCR at UT MD ANDERSON CANCER CENTER  at (713) 
792-8519 or [EMAIL_7056] . 
 
 
 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 41 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
41 
  
7.0 PRETREATMENT EVALUATION  
 
General Requirements  
 
7.1 A complete history  and physical (including baseline blood pressure measurement) and 
neurological examination (include documentation of the patients height, weight and 
Karnofsky Performance Status), as well as documentation of measurable and/or evaluable 
disease shall be performed on all patients  within 14 calendar days (+ 3 working days) of 
study entry .   
 
7.[ADDRESS_458594] enhanced  MRI scan done prior to study 
entry documenting progression . For non-surgical arm patients, a baseline scan should be 
performed within 14 calendar days (+ 3 working days) of registration, with day 
0=registration date. The baseline on -study MRI should be pe rformed on a steroid dosage 
that has been stable or decreasing for at least 5 days. If the steroid dose is increased 
between the date of imaging and the initiation of therapy (or at that time), a new baseline 
MRI is required.  
 
7.[ADDRESS_458595] MRI scan (with T1, T2, DWI, and T2 FLAIR images 
sequences and when feasible, T2* and DTI sequences) will be done in all patients within 
[ADDRESS_458596] enhanced 
(DCE) and dynamic suscept ibility contrast  (DSC) are preferred if individual sites can 
obtain the same but are not required. If DCE/DSC sequences can be obtained, it is 
important to obtain them at baseline and at each imaging follow -up.   
7.4 Pre-treatment laboratory tests will include CBC, differential, platelets, , total protein, 
albumin, calcium, , , glucose, BUN, creatinine, sodium, potassium,  total bilirubin, 
alkaline phosphatase, LDH, SGPT (ALT), SGOT (AST), Urine protein: Creatinine rat io 
or urine dipstick and a pregnancy test for women of child bearing potential. PT, PTT, 
INR, phosphorus, magnesium and uric acid will be done at the discretion of the treating 
physician.  Blood tests must be performed within 14 calendar days (+ 3 working days) of 
registration, with day 0 = registration date. Pregnancy test must be obtained 14 calendar 
days (+ 3 working days) of registration before treatment starts. Patient‚Äôs whose clinical 
condition has significantly changed between the time of these tests  and the initiation of 
treatment in the judgment of the treating physician, will have a repeat chemistry panel 
prior to the start of treatment.  
7.[ADDRESS_458597] consented to the optional procedures.   
 
7.6  About 7 cc of blood for isolation of peripheral blood monocytes will be collected for 
circulating endothelial cells (CEC) and circulating endothelial progenitor cells (CEPC) 
analysis at baseline before starting treatment  in those patients that have consented to the 
optional procedures. . 
 
7.7  If available, unstained paraffin tissue from surgical samples will be obtained. A 
representative paraffin tissue block (at least 5 mm x 5 mm) will be obtained from recent 
surgery to confirm the recurrence and original surgery, before entry into the clinical trial. 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 42 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
[ADDRESS_458598] the 9 gene signature [CONTACT_366991] q RT-PCR. 
These will be correlated with response.  
           
7.8  Documentation of tumor diagnosis  by [CONTACT_366948]‚Äôs initial or most 
recent surgery or biopsy  
  
 
7.9 (*) Patients will complete  a baseline MD Anderson Symptom Inventory -Brain Tumor 
Module (MDASI -BT) (Appendix 18.12) after registration but before init iating treatment 
on the clinical trial (*). The MDASI -BT will be completed only by [CONTACT_102], unless 
changes in vision or weakness make this difficult. If this occurs, then the caregiver or 
research assistant may read the questions to the patient or assist with marking the severity 
number or score as described by [CONTACT_102]. A patient caregiver may complete the 
questionnaires as a pa tient-preference proxy if the patient‚Äôs deficits preclude self report.  
 
* Note: 7.9 is an optional procedure, and will be obtained if the patient gives his or her informed 
consent. 
 
 
8.0 EVALUATION S DURING STUDY  
 
General Requirements  
 
8.1  Blood pressure monitoring every 2 weeks prior to bevacizumab infusion.  
 
8.2   Proteinuria will be monitored by [CONTACT_39701]: creatinine (UPC) ratio or dipstick every [ADDRESS_458599] cycle then prior to every subsequent cycle.  
 
8.3 CBC, differential and platelets will be performed every  two weeks (¬± 3 days) during 
treatment and prior to each new cycle. In addition, all patients will have the following 
tests every  4 weeks (¬± 3 days) prior to each new cycle if no significant toxicitie s are 
noted: total protein, albumin, calcium, glucose, BUN, creatinine, sodium, potassium, total 
bilirubin, alkaline phosphatase, LDH, SGPT, SGOT, urine protein: creatinine. Patients 
may also be evaluated with labs at any time clinically indicated.   PT, PTT, INR, 
phosphorus, magnesium, and uric acid will be done at the discretion of the treating 
physician.  
 
8.[ADDRESS_458600] MRI scan (with T1, T2, DWI, and T2 FLAIR images sequences 
and when feasible, T2* and DTI sequences) shall be done pretreatme nt, and subsequently 
after each 2 cycles of treatment. MRI scans may also be done at any time clinically 
indicated. Optional DCE/DSC MRI scans will be obtained at baseline, after cycle 2 (at 
week 8) and subsequently every 2 cycles prior to initiating the n ext cycle (or within 3 
working days of starting the cycle).   
 
8.5  About 5 cc of blood for measuring VEGF, PI[INVESTIGATOR_12252], bFGF, SDF1 Œ±, angiopoietin 1 and 2, 
will be drawn at baseline before treatment, cycle 1 day 2, day 15 (pre -infusion and post -
infusion)  and cy cle 2 (pre -infusion) in those patients that have consented to the optional 
procedures . The post -infusion blood will be drawn between 12 -24 hr after infusion.  
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 43 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
43 
  
8.6  About 7 cc of blood will be collected for CEC and CEPC  analysis at baseline, on cycle 1 
day 2 (post -infusion), and day 15 (pre -infusion and post -infusion) in those patients that 
have consented to the optional procedures . The post -infusion blood drawn between [ADDRESS_458601] 2 
cycles and subsequently after each 2 cycles of treatment prior to initiating the next cycle.  
Patients will also be evaluated anytime their clinical situation demand s an assessment.  
 
8.8  All relevant information regarding drug doses, concomitant medications, and doses, 
measurable lesions with measurements, tumor response, laboratory examinations, and 
treatment -related toxicities shall be documented in the patient‚Äôs m edical record and flow 
sheets. 
 
8.9  Pregnancy testing for FCBP (Appendix  18.11) 
 
8.10 (*)The patient will complete the MDASI -BT (Appendix 18.12) at the time of clinical 
evaluation with MRI as long as the clinical therapy is being administered, unless clinical 
deterioration makes self -report not possible before that time.  The time when patients are 
unable to complete the self - report questionnaires will be used as part of the study 
analysis.  The MDASI -BT will be completed only by [CONTACT_102], unless c hanges in vision 
or weakness make this difficult. If this occurs, then the caregiver or research assistant 
may read the questions to the patient or assist with marking the severity number or score 
as described by [CONTACT_102]. A patient caregiver may comple te the questionnaires as a 
patient-preference proxy if the patient‚Äôs deficits preclude self - report. 
 
* Note: 8.[ADDRESS_458602] two 
cycles and subsequently after each two cycles of treatment prior to initiating the next 
cycle. In addition all serious adverse events will be reported to the OMCR an d the study 
chair as directed in section 15. 7. 
 
8.12 After treatment on protocol is discontinued patients will be followed for overall survival, 
when possible.  
 
a) Patients who discontinue treatment due to progression will be followed for 
survival every 3 months.  
 
b) Patients who come off therapy for reasons other than progression will be 
followed every 2 months with an MRI until progression or institution of new 
anti-tumor therapy.  They will then be followed for survival  every three 
months. 
 
 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 44 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
44 
 9.0 CRITERIA FOR EVALUA TION AND ENDPOINT DEFINITIONS  
 
9.1 The primary efficacy endpoint for BTTC studies will be progression free survival (PFS) 
at six months from patient registration.  However, objective response status should be 
measured and recorded. For this and for all other t ime to event analyses that use 
registration date, if a patient is registered on the pre -operative portion of the study, the 
start date for calculation of time to event will be the date of first post -operative study 
drug administration . 
 
9.2 Definitions of Response  
 
9.2.1. Measurable Disease:  Bidimensionally measurable lesions with clearly defined 
margins by [CONTACT_212690].  
 
9.2.2 Evaluable Disease:  Unidimensionally measurable lesions, masses with margins 
not clearly defined. Patients with only this kind of imagin g will not be allowed to 
enter this study unless they have recently undergone surgery and have 
histologically proven recurrent disease.  
 
9.2.3 Non-Evaluable Disease:  Not Applicable for response evaluation . 
 
9.2.4. Objective Status, To Be Recorded at Each E valuation:  If there are too many 
measurable lesions to measure at each evaluation, choose the largest two to be 
followed before a patient is entered on study.  The remaining lesions will be 
considered evaluable for the purpose of objective status determina tion.  Unless 
progression is observed, objective status can only be determined when ALL 
measurable and evaluable sites and lesions are assessed.  
 
Response Criteria (Modified MacDonald Criteria)  
 
[IP_ADDRESS] Complete Response (CR):   Complete disappearance of all measurable 
and evaluable disease.  No new lesions.  No evidence of non -evaluable 
disease.  All measurable, evaluable and non -evaluable lesions and sites 
must be assessed using the same techniques as baseline.  Patients must be 
on none or only physiologic doses of  steroids. 
 
[IP_ADDRESS]. Partial Response (PR):   Greater than or equal to 50% decrease under 
baseline in the sum of products of perpendicular diameters of all 
measurable lesions.  No progression of evaluable disease.  No new 
lesions.  All measurable and evaluable lesions and sites must be assessed 
using the same techniques as baseline.  Responders must be on the same 
or decreasing doses of dexamethasone and have stable or improved 
neurological exams.  
 
[IP_ADDRESS]. Partial Response, Non -Measurable (PRNM):  Not applicable.  
 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 45 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
45 
 [IP_ADDRESS]. Stable/No Response:  Does not qualify for CR, PR, or progression.  All 
measurable and evaluable sites must be assessed using the same 
techniques as baseline.  Responders must be on the same or decre asing 
doses of dexamethasone and have stable or improved neurological 
exams. 
 
[IP_ADDRESS]. Progression:  25% increase in the sum of products of all measurable 
lesions over smallest sum observed (over baseline if no decrease) using 
the same techniques as baselin e, OR clear worsening of any evaluable 
disease, OR appearance of any new lesion/site, OR failure to return for 
evaluation due to death or deteriorating condition (unless clearly 
unrelated to this cancer).  
. 
[IP_ADDRESS]. Unknown:  Progression has not been documented and one or more 
measurable or evaluable sites have not been assessed  
 
 
9.[ADDRESS_458603] Response:  This will be calculated from the sequence of objective statuses.  
 
For patients with all disease sites assessed every evaluation p eriod, the best response will 
be defined as the best objective status as measured according to Section 9.3.  If the 
response does not persist at the next regular scheduled MRI, the response will still be 
recorded based on the prior scan, but will be design ated as a non -sustained response.  If 
the response is sustained, e. g. still present on the subsequent MRI, it will be recorded as 
a sustained response, lasting until the time of tumor progression.   Best response is 
unknown if the patient does not qualify for a best response or increasing disease and if all 
objective status determinations before progression are unknown.  
 
9.4 Neurological Exam:  Although not used for determining response, it is useful to evaluate 
improvement in the neurologic exam, (as compar ed to the baseline assessment), that 
should coincide with objective measurement of tumor size.  
     
    +2 Definitely Better  
    +1 Possibly Better  
      0 Unchanged  
    -1 Possibly Worse  
    -2 Definitely Worse  
    
    
    
    
    
 
 
9.5 Performance Status: Patients will be graded according to Karnofsky Performance Status  
(see Appendix 18.2). 
 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 46 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
46 
 9.6 Time to Treatment Failure:  From date of   registration to the date of first observation of 
progressive disease (as defined in Section 9.3), non -reversible neurologic progression or 
permanently increased steroid requirement (applies to stable disease only), death due to 
any cause, or early discontinuation of treatment. If a patient is registered on the pre -
operative portion of the study, the start date for ca lculation of time to event will be the 
date of first post -operative study drug administration.  
 
9.7 Time to Death:  From date of registration to date of death due to any cause.  
 
9.8 Documenting FLAIR: Although not part of M acdonald criteria, investigators w ill be 
asked to measure tumor related changes on FLAIR sequence as best as possible, as non -
enhancing patterns of recurrence can occur.   If this occurs within the setting of clinical 
decline, the patient will be considered to have progressive disease. Inve stigators will also 
be asked to document if recurrence of disease is multifocal.  
 
 
10.[ADDRESS_458604] DISCONTINUATION  
 
10.1 Criteria for Removal from Protocol Treatment:  
 
a. After administration of 12 cycles (unless there is clear evidence of clinical 
benefit to justify  continuation of treatment)  . 
 
b. Progression of disease as defined  in Section 9.3 , after 1 cycle of treatment .  
  
c. Unacceptable toxicity (including the following ). 
ÔÇ∑ Grade 4 hypertension or Grade 3 hypertension not controlled with 
medication  
ÔÇ∑ Nephrotic syndrome  
ÔÇ∑ Grade ‚â• 2 pulmonary or CNS hemorrhage; any Grade 4 hemorrhage  
ÔÇ∑ Symptomatic Grade 4 venous thromboembolic event  
ÔÇ∑ Any grade arterial thromboembolic event  
ÔÇ∑ Grade 4 congestive heart failure  
ÔÇ∑ Gastrointestinal perforation  
ÔÇ∑ Tracheoesophageal fistula (any grade) or Grade 4 fistula  
ÔÇ∑ Grade ‚â• 2 bowel obstruction that has not fully recovered despi[INVESTIGATOR_366891]  
ÔÇ∑ Wound dehiscence requiring medical or surgical intervention  
ÔÇ∑ Determinat ion by [CONTACT_138683]  
ÔÇ∑ Grade 4 events thought to be related to bevacizumab by [CONTACT_093]  
 
d. The patient may withdraw from the study at any time for any reason.  
 
e. Medical or psychiatric  illness which in the investigator's judgement renders the 
patient incapable of further therapy.  
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 47 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
[ADDRESS_458605] an ongoing bevacizumab  related Grade 4 or serious adverse event at 
the time of discontinuation from study treatment will continue to be followed until 
resolution of the event or until the event is considered irreversible . 
 
Patients may remain on treatment as long as disease progression is not observed and the 
patient is not experiencing unacceptable toxicity (see Section 10.1) .  Although therapy is 
planned for one year, the patient may remain on treatment beyond this time if both the 
patient and physician agree that further therapy is in the patient‚Äôs best interests.           
 
10.2 Criteria from Removal from the Study  
 
ÔÇ∑ Protocol Defined Follow -up Completed  
ÔÇ∑ Patient Lost to Follow -up 
ÔÇ∑ Patient Refused Follow -up 
ÔÇ∑ Death  
 
10.3 All reasons for discontinuation of treatment  and/or removal from the study must be 
documented in the source records and the BTTC study database .  
 
 
11.[ADDRESS_458606]. Ying Yuan , 
Department of Biostatistics at MD Anderson Cancer Center.  
11.1  Statistical Analysis  
 
11.1.1 Phase I component:  The phase I component will assess the MTD of Vorinostat in 
combination with Bevacizumab as shown in the table.  A conventional phase I design will be 
used and the MTD will be selected using a 3+3 accrual design at each dose level until MTD is 
determined.  A maximum of 18 patien ts will be recruited to this component of the study.  
 
11.1.2 Phase II component:  This is a randomized phase II trial to Bevacizumab to Vorinostat+ 
Bevacizumab in patients with recurrent GBM. The primary outcome is progression free survival. 
Patients will b e randomized between the two arms using a Bayesian adaptive algorithm. Patients 
will be randomized fairly between the two arms at the start of the trial (for the first 20 patients).  
Thereafter, as the trial progresses and data accrue, the randomization wi ll become unbalanced in 
favor of the treatment that, on average, has better results in terms of failure time.  Therefore, each 
successive patient is more likely to receive the treatment with better results, on average. A 
minimum of 20 and a maximum of 90 p atients will be accrued .  Based on an anticipated accrual 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 48 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
48 
 rate between 3 and 5 patients per month, the maximum trial accrual period will be between 12 
and 24 months.  
The table given below summarizes the operating characteristics of the design.  The histor ical 
median progression free survival is 4 months.  The tables below assume an accrual rate of either 3 
or 5 patients per month. The trial will be stopped early and a treatment selected as being ‚Äúbetter‚Äù 
if the probability that one treatment‚Äôs median PFS i s larger than the other‚Äôs PFS exceeds 0.995.  If 
the trial does not stop early and the maximum 90 patients are accrued, a treatment is selected as 
being ‚Äúbetter‚Äù if the probability that one treatment‚Äôs median PFS is larger than the other‚Äôs PFS 
exceeds 0.97 5.  A treatment arm will be dropped at any point during the trial if the probability 
that the treatment‚Äôs median PFS is larger than 4 months is less than 0.01.    The ‚Äú# of patients 
treated‚Äù row is the average number of patients treated on a given arm unde r the given scenario.  
When the medians are equal, the probability of selecting either of the two arms (i.e., a false 
positive result) is 8% for both accrual rates. The probability of selecting the better treatment (i.e., 
a true positive result) for a doub ling in the median PFS is 82% for 3 per month and 80% for 5 per 
month. 
 
Accrual Rate: 3 Per Month    Accrual Rate: 5 Per Month  
             
  Treatment      Treatment  
  BEV BEV+V     BEV BEV+V 
True Median PFS   4* 4   True Median PFS   4 4 
# Patients Treated 42.3 41.6   # Patients Treated  41.4 41.6 
Pr(Selected)  0.04 0.04   Pr(Selected)  0.04 0.04 
Pr(Selected Early)  0.02 0.01   Pr(Selected Early)  0.01 0.02 
       
       
True Median PFS  4 6   True Median PFS  4 6 
# Patients Treated  25.7 53.9   # Patients Treated  27.5 54.1 
Pr(Selected)  0.00 0.42   Pr(Selected)  0.00 0.42 
Pr(Selected Early)  0.00 0.23   Pr(Selected Early)  0.00 0.20 
          
          
True Median PFS  4 8   True Median PFS  4 8 
# Patients Treated  18.8 47.4   # Patients Treated  20.9 51.2 
Pr(Selected)  0.00 0.82   Pr(Selected)  0.00 0.80 
Pr(Selected Early)  0.00 0.60   Pr(Selected Early)  0.00 0.50 
         
 
  *True median failure times are given in month; V: vorinostat; BEV: bevacizumab  
 
At each evaluation when a new patient comes in the study, the data for patients who have been 
followed till that time and not yet progressed are accounted in the analysis. The trial will be 
conducted using a web based program developed by [CONTACT_366949]: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 49 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
[ADDRESS_458607] the ability to randomize patients, update the current patients‚Äô 
status. The results of randomization are displayed for user to review. When a  patient is 
randomized the calculations are based on all available data entered into the website.  The results 
of the randomization are displayed to the screen for the user to view.  All data is stored in a 
secure SQL server database.  
 
Time-to-event outcom es, including PFS and OS will be estimated using Kaplan -Meier method. 
The log rank test will be performed to test the difference in time -to-event distributions between 
two groups. Cox proportional hazards model will be utilized as regression technique to a djust the 
covariates in the time -to-event analysis.  
 
11.1.3 Correlative studies:  
 
[IP_ADDRESS] Gene Profile analysis :  Tumor tissue will be collected for qRT -PCR analysis to 
determine the established 9 gene profile and identify the presence of mesenchyme/angiogenic 
(poor prognosis) genotype versus the proneural (good prognosis) genotype. The response for each 
of the treatment arms will be correlated with the two expected genotypic prognostic groups of 
patients.  Because this is an optional proce dure and the trial is powered to detect differences in 
clinical outcome and not for biomarker analysis, these data will be used to generate preliminary 
data regarding identification of specific patient populations who may benefit from the treatments 
and for a future genomic -profile driven personalization of treatment in future studies.  
 
[IP_ADDRESS] Biomarker analysis:  measurement of plasma angiogenic proteins including VEGF, PI[INVESTIGATOR_12252], 
bFGF, SDF1Œ±, angiopoeitin 1 and 2 by [CONTACT_366941] 1 pretreatment, cycle 1 day 2, day 15 
(pre- and post-infusion) and cycle 2 (pre -infusion). 
 
[IP_ADDRESS] Blood circulating cells study:  blood cells experiment will be enumerated by [CONTACT_366950]31, CD 34, CD 45 and CD 133 using fluorescence -labeled monoclonal 
antibodies (Duda et al., 2006, 2007). Cell concentration will be calculated  as percentage of total 
number of mononuclear cells. The quantitative analyses end point will be the change in fraction 
of CD31+ CD34+CD45 - and CD133+CD34+ within the mononuclear blood cell po pulation in 
patients receiving treatment. Percent value will be obtained at baseline prior to every treatment 
cycle, and in addition on cycle 1 day 2 (post -infusion), and day 15 (pre - and post-infusion). 
Subsequently, pretreatment samples will be drawn on cycle 2.Post-treatment values in cycle [ADDRESS_458608].  
 
[IP_ADDRESS] Imaging study  (for MDACC patients: other sites may participate if interested and able 
to): Imaging parameter ana lysis and statistical analysis, based on the published study by 
[CONTACT_366951]. (Batchelor et al., 2007) , will be conducted in collaborati on with Dr. E d Jackson, 
imaging physicist.  
 
-Volumetrics: Enhancing lesion and areas of T2 abnormality on FLAIR imaging will be 
quantified by a neuroradiologist. The lesions will be outlined by [CONTACT_2329] a volumetric approach 
(Sorensen et al., 2 001). 
 
-Diffusion imaging assessment: Apparent diffusion coefficient are created from high  and low b 
value image using the standard Steskjal -Tanner diffusion approximation (Oh et al., 2005) . This 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 50 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
50 
 provides an estimate of relative water moti lity on a voxel -by-voxel basis.  The units of the map 
are in area/time, mm2/s. 
 
- Permeabil ity: DCE-MRI data will be processed following published approach, including Ktrans 
(Tofts et al., 1999)  and Ve (extracellul ar-extravascular  volume fraction).  
 
 - Statistical analysis:  The comparison between the MRI parameters, protein level and cell counts 
that measured on the different days will be performed with a two tailed paired Wilcoxon test 
(Hollander and Wolge, 1973).  
 
11.2 Determina tion of Sample Size  
 
11.2.1 Phase I component:  The Phase I component will assess the MTD of vorinostat in 
combination with bevacizumab as shown in the table.  A conventional phase I design will be used 
and the MTD will be selected using a 3+3 accrual desi gn at each dose level until MTD is 
determined.   A maximum of  18 patients will be recruited into this part of the study.  
 
11.2.2 Phase II component:  This is a randomized phase II trial to bevacizumab to vorinostat+ 
bevacizumab in patients with recurrent GBM. The primary outcome is progression free survival. 
Patients will be randomized between the two arms using a Bayesian adaptive algorithm. Patients 
will be randomized fairly between the two arms at the start of the trial (for the first 20 patients). 
Thereafter, as the trial progresses and data accrue, the randomization will become unbalanced in 
favor of the treatment that, on average, has better resul ts in terms of failure time.  Therefore, each 
successive patient is more likely to receive the treatment with better results, on average. A 
minimum of 20 and a maximum of 90 patients will be accrued .  Based on an anticipated accrual 
rate between 3 and 5 pa tients per month , the maximum trial accrual period will be between 12 
and 24 months.  
 
The table given in Section 10 summarizes the operating characteristics of the design.  The 
historical median time to progress is 4 months.  The tables below assume an ac crual rate of either 
3 or 5 patients per month. The trial will be stopped early and a treatment selected as being 
‚Äúbetter‚Äù if the probability that one treatment‚Äôs median PFS is larger than the other‚Äôs PFS exceeds 
0.995.  If the trial does not stop early an d the maximum 90 patients are accrued, a treatment is 
selected as being ‚Äúbetter‚Äù if the probability that one treatment‚Äôs median PFS is larger than the 
other‚Äôs PFS exceeds 0.975.  The number of patients treated row is the average number of patients 
treated on a given arm under the given scenario.  When the medians are equal, the probability of 
selecting either of the two arms (i.e., a false positive result) is 9% for both accrual rates. The 
probability of selecting the better treatment (i.e., a true positive  result) for a doubling in the 
median PFS is 85% for 3 per month and 83% for [ADDRESS_458609] the ability to randomize patients, 
update the current patients‚Äô status. The results of randomization are displayed for user to review.  
  
If the study reaches the total enrollment specified in section 11 , allowance will be made for the 
enrollment of 10 or more additional patients in the phase II component to be treated in order to 
fulfill the minimal number for the pre-operative study for tissue correlates . 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 51 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
51 
  
11.3  SAFETY PLAN   
 
 11.3.1 GENERAL PLAN TO MANA GE SAFETY  
 
A number of measures will be taken to ensure the safety of patients participating in this 
trial.  These measures will be addressed through exclusion criteria (see Section  4.0) and 
routine monitoring as follows.  
 
Patients enr olled in this study will be evaluated clinically and with standard laboratory 
tests before and at regular intervals during their participation in this study.  Safety 
evaluations will consist of medical interviews, recording of adverse events, physical 
examinations, blood pressure, and laboratory measurements.  Patients will be evaluated 
for adverse events (all grades), serious adverse events, and adverse events requiring study 
drug interruption or discontinuation at each study visit for the duration of thei r 
participation in the study.  Patients discontinued from the treatment phase of the study for 
any reason will be evaluated ~30  days (28‚Äì42 days) after the decision to discontinue 
treatment .  
 
A.  Bevacizumab -Specific 
 
Specific monitoring procedures are as  follows: 
 
ÔÇ∑ Hypertension will be monitored through routine evaluation of blood pressure prior 
to each bevacizumab treatment.  Optimal control of blood pressure according to 
standard public health guidelines is recommended for patients on treatment with or 
without bevacizumab.   
 
ÔÇ∑ Proteinuria will be monitored by [CONTACT_39701]: creatinine (UPC) ratio or dipstick 
every [ADDRESS_458610] cycle then prior to every subsequent cycle.  
 
ÔÇ∑ If patients on treatment with bevacizumab require elective major surgery, it is 
recommended that bevacizumab be held for 4 -8 weeks prior to the surgical 
procedure. Patients undergoing a major surgical procedure should not begin/restart 
bevacizumab until 4 weeks after that procedure (in the case of high risk procedures 
eg.  liver resection, or thoracotomy, it  is recommended that chemotherapy be 
restarted no earlier than 6 wk and bevacizumab no earlier than 8 wk after surgery).   
 
ÔÇ∑ If the surgery is not due to tumor progression or due to adverse event attributable to 
study drugs, the patient may resume treatment once medically stable and per 
guidelines above. The provision to continue treatment after surgery will constitute 
an exception to the provision in secti on  6.4.1 and permits the patient to continue 
on the study despi[INVESTIGATOR_040] a 4 weeks or greater break from treatment if this is considered 
in the patient‚Äôs best interest. A new baseline scan will be necessary before beginning 
such treatment. If the patient has dis ease progression on this scan, the date of this 
scan will be considered as the progression date for the purposes of PFS calculation.    
 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 52 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
52 
 B.  Vorinostat -Specific 
 
Specific monitoring procedures are as follows:  
 
Anorexia and other constitutional symptoms, in cluding weight loss, fatigue will be 
monitored through routine evaluation including body weight at every clinic follow up 
visit during the vorinostat treatment.   
 
Cytopenia, especially thrombocytopenia will be monitored by [CONTACT_366952] 2 weeks.  
 
Gastrointestinal symptoms, such as nausea, vomiting, diarrhea, constipation will be 
monitored through routine evaluation at week 4 then every 8 weeks during the treatment 
with vorinostat. Patients are also encouraged to communicate with the clinical nurse to 
report severe GI symptoms.  
 
12.0 DISCIPLINE REVIEW   
 
 
12.1 Pathology Review  
 
Not Applicable  . 
 
12.2 Radiology Review  
 
Not Applicable  
 
 
13.0 PHARMACOKINETICS  
 
N/A 
 
 
14.0 LABORATORY CORRELATES  
  
See Appendices 18. 4 and 18.5 
 
 
15.0 MULTICENTER PROCEDURES  
 
15.1 General Procedures  
 
The BTTC Operations Manual and Data Submission Forms, on file at all BTTC 
institutions, document the data management and quality assurance programs for this 
collaboration.  BTTC institutions will follow the guidelines as addressed below  and 
throughout this protocol.  
 
15.2 Principal Investigators  
 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 53 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
53 
 The principal investigator(s) will be responsible for the conduct of the study and 
monitoring its progress.  The responsibility for all reports and forms required by [CONTACT_366953](s).  
 
15.[ADDRESS_458611] 
complete the following steps:  
 
ÔÇ∑ Submit all required regulatory documents to the MD ANDERSON CANCER 
CENTER  Office of Multicenter Cli nical Research (OMCR) as outlined in the 
BTTC Operations Manual  
ÔÇ∑ Participate in a site initiation visit, webcast, or conference call  
ÔÇ∑ Receive training regarding study specific CRF‚Äôs and/or databases  
ÔÇ∑ Execute all relevant contractual agreements  
 
After these requirements have been fulfilled, the participating institution will 
receive by [CONTACT_6791], e -mail, or hard copy memo a Site Activation Notification.  Once 
the Site Activation Notification has been received, the participating institution 
may begin to register pat ients to the protocol   
 
15.3.2  Patient Registration Procedures  
 
BTTC patients will be registered with the MD ANDERSON CANCER CENTER  
OMCR by [CONTACT_6791] & phone at UT MD ANDERSON CANCER CENTER .  All 
eligibility requirements will be checked prior to registration.  The status of all 
regulatory documents will be checked prior to registration. No patient will be 
entered on protocol if they do not satisfy all regulatory document and eligibility 
requirements. Gener ic MD ANDERSON CANCER CENTER  OMCR 
registration procedures  are also described in the BTTC Operations Manual.  
 
Informed Consent/Authorization  
 
Prior to protocol enrollment and initiation of treatment, subjects must sign and 
date an Institutional Review Board (IRB) approved consent form.  
 
Patient Registration Proce dures 
 
Participating institutions must register patients via EDMS, fax, and phone with 
the MD ANDERSON CANCER CENTER  Office of Multicenter Clinical 
Research at:  
 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 54 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
54 
 EDMS: https://iview.mdanderson.org/  
Fax: ([PHONE_7589] 
Phone: (713) 792 -8519 
 
Registration hours are 8:00 a.m. to 5:[ADDRESS_458612] be completed a fter the patient has signed the informed 
consent and has been determined to be eligible by [CONTACT_16533].  
 
At the time of registration the following information will be requested by [CONTACT_366954] 
(OMCR):  
 
ÔÇ∑ A copy of a completed and signed, protocol specific, Eligibility Checklist  
form  
ÔÇ∑ One copy of a Pathology report from the patient‚Äôs most recent surgery or 
biopsy 
ÔÇ∑ One copy of  the signed and dated Informed Consent/Authorization.  
 
The eligibili ty checklist form should be prepared and signed prior to sending to 
the MD ANDERSON CANCER CENTER  OMCR. The submission  should be 
followed by a phone call to the MD ANDERSON CANCER CENTER  OMCR to 
verify receipt.  If the patient fails eligibility screening do not proceed to the 
registration process.  
 
Patient Number for Participating Institutions  
 
Once eligibility has been established during Registration, the patient from the 
participating institution is assigned a six character MD ANDERSON CANCER 
CENTER  OMCR patient ID number and a protocol specific Accession Number .  
The patient ID  number is unique to the patient and , except for SAE reports, must 
be used for registrations onto subsequent protocols and written on al l data and 
correspondence for the patient.  The SAE reports must use the protocol specific 
Accession Number. 
 
Verification of Registration  
 
For participating institutions, a Registration Verification Letter for patients 
registered to BTTC protocols will be faxed or emailed to the registering 
institution within one working day after the registration  is received . The OMCR 
must be notified in adv ance of patient cases that may require an expedited 
registration.    
 
Initiation of Therapy  
 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 55 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
55 
 Treatment may not be initiated until the participating institution receives a faxed 
or emailed copy of the patient‚Äôs Registration Verification Letter from the MD 
ANDERSON CANCER CENTER  OMCR.  
 
All Patients that are eligible to receive therapy must initiate treatment within [ADDRESS_458613] be notified in writing 
of any exceptions to this policy.  
 
Eligibility  Exceptions  
 
Eligibility Exceptions will not be granted.  
 
 
15.4 Data Management  
 
All data will be entered into the computerized web accessible data management system 
located at the MD ANDERSON CANCER CENTER  OMCR at MD ANDERSON 
CANCER CENTER .  Designated research staff from the registering institution will enter 
the data.  The protocol specific electronic forms are to be used by [CONTACT_77954].  
All investigators will utilize these forms for Baseline, Treatment , Tumor Evaluation, Off  
Treatment, Survival, and  Off-study data.    
 
Confidentiality   
 
All documents, investigative reports, or information relating to the patient are strictly 
confidential. Any patient specific reports (i.e. Pathology Reports, MRI Reports, 
Operative Reports, etc.) submitted to the MD ANDERSON CANCER CENTER  OMCR 
must have th e patient‚Äôs full name & social security number ‚Äúblacked out‚Äù and the 
assigned MD ANDERSON CANCER CENTER  patient ID number, protocol number and 
event time point written on every page of the document . Patient initials may be included 
or retained for cross ve rification of identification.  
 
 
15.5 Data Monitoring  
 
All submitted data will be monitored by [CONTACT_366955].  Requests for correction of data 
deficiencies will be sent via email to the  Institutional Coordinator.  Any major 
deficiencies will be corrected by [CONTACT_366956] .  All data will be monitored for completeness.  Key parameters such 
as drug dosages including attenuations and es calations, toxicity documentation and tumor 
measurements will be analyzed.  All data deficiencies will be corrected within two 
weeks. 
 
The schedule for data & source document submission is outlined as follows.  Source 
document requirements are subject to in crease for a given participating institution  or 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 56 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
[ADDRESS_458614], data quality , and/or non -
compliance with the following submission schedule.  
 
 
 
 
 
  
Data Set / Source Documents  Schedule for Submission  
Regulatory Documents  
(as described in the BTTC Operations 
Manual) Prior to Patient Registration  
Eligibility Checklist  Prior to Patient Registration  
Copy of signed & dated Informed Consent 
w/ HIPAA Authorization  Prior to Patient Registration  
Pathology Report (from the most recent 
pre-registration diagnostic biopsy or 
surgery) Prior to registration  
Baseline Data  
(To include prior disease/treatment history, 
and baseline clinical evaluation 
information)  Within 14 days after the registration 
date 
Baseline Source  Documents  
(To include all source documents that 
support all data reported on the Baseline 
form and Eligibility Checklist/s)  Within 14 days after the registration 
date 
Baseline MDASI ‚Äì BT Questionnaire  Within 14 days after the registration 
date 
Treatment  (Cycle) Data  
(To include treatment, AE, concurrent 
medications, and clinical evaluation 
information)  Within [ADDRESS_458615] day of 
each treatment cycle.  
Treatment (Cycle) Source Documents  
(To include Infusion records, Physician 
Orders, Prescripti ons, Patient Diaries, Pi[INVESTIGATOR_366892] ) Within [ADDRESS_458616] day of 
each treatment cycle.  
Disease Evaluation Data  
(To include response, measurements, and 
clinical evaluations used to determine the 
response)  Within 14 days after registration (for 
baseline) and then REAL TIME  after 
each protocol defined on -therapy 
assessment time point.  
Disease Evaluation Source Documents  
(To include MRI Scans or any other 
assessment used to determine the patients 
baseline status and/or response to protocol 
therapy) Within 14 days after registration (for 
baseline) and then  REAL TIME  after 
each protocol defined assessment time 
point. 
Off Treatment Data  REAL TIME  after the last date of any 
modality of protocol treatment  
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 57 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
57 
 Off Treatment Source Documents  Within 10 days after off treatment 
decision has been made.  
Follow-up (Survival) Data  Within [ADDRESS_458617] treatment 
date and then every 90 days until Off 
Study (unless otherwise specified by 
[CONTACT_760])  
Follow-up Source Documents  On Request  
Non-Treatment Data  
(May include Quality of Life questionnaires 
(MDASI_BT), Specimen Tracking 
information, Pathology Specimen 
Submission, etc.  when applicable ) Within 10 days after each scheduled 
assessment, event, or activity  
Off Study Data  Within 10 days after the date the patient 
is removed from the study.  
Off Study Source Documents   Within 10 days after the date the 
patient is removed from the study.  
 
15.6 Safety Assessments and Toxicity Monitoring  
 
All patients receiving  study agents will be evaluated for safety.  The safety parameters 
include all laboratory tests and hematological abnormalities, CNS observations, physical 
examination findings, and spontaneous reports of adverse events reported to the 
investigator by [CONTACT_338419].  All toxicities encountered during the study will be evaluated 
according to the NCI Common Terminology  Criteria for Adverse Events (CTCAE) 
version 4.[ADDRESS_458618] two cycles and 
subsequently after eac h two cycles  of treatment and prior to initiating the next cycle  .  
Life-threatening toxicities that are unexpected and assessed to be possibly related to the 
study agent/s should be reported immediately to the study Coordinator, Institutional 
Review Board  (IRB), and those that are unexpected and assessed to be possibly related to 
the study agents should also be reported to the FDA.  MD Anderson Cancer Center 
OMCR will notify Genentech Drug Safety and [COMPANY_006] Sharp and Dohme Corp 
Worldwide safety of ANY serious treatment emergent adverse event (STEAE) as 
soon as possible.  
 
Information about all adverse events, whether volunteered by [CONTACT_423], discovered by 
[CONTACT_424], or detected through physical examination, laboratory test or 
other means, will be collected and recorded on the Adverse Event Case Report Form and 
followed as appropriate. An adverse event is any undesirable sign, symptom or medical 
condition occurring after starting study drug (or therapy) even if the event is not 
considered to be related to study drug.  
 
Medical conditions/diseases present before starting study treatment are only considered 
adverse events if they worsen after starting study treatment (any procedures specified in 
the protocol). Adverse events occurring bef ore starting study treatment but after signing 
the informed consent form are recorded on the Baseline Evaluations_Adverse Events 
Case Report Form. Abnormal laboratory values or test results constitute adverse events 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 58 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
[ADDRESS_458619] (DSM B) of MD 
Anderson Cancer Center. All adverse events submitted to the IRB will also be reviewed 
by [CONTACT_4318]. In addition, the principal investigator [INVESTIGATOR_366893]. 
 
Safety Monitoring and Early Stoppi[INVESTIGATOR_366894] [ADDRESS_458620] completed 
one cycle of treatment and subsequently for every 20 patients enrolled until study 
completion.   This will ensur e identification of any unexpected toxicities.  If unexpected 
toxicities are seen in more than 30% of the patients at the time of any of the periodic 
reviews noted above, the trial will be placed on hold and the dosing and schedule of the 
treatment re -evaluated.   
 
A serious adverse event is any adverse drug experience at any dose that results in any of 
the following outcomes: Death, a life -threatening adverse drug experience, inpatient 
hospi[INVESTIGATOR_1081], a persiste nt or significant 
disability/incapacity, or a congenital anomaly/birth defect.  Important medical events that 
may not result in death, be life -threatening, or require hospi[INVESTIGATOR_47022], based upon appropriate medical  judgment , they may jeopardize the patient 
or may require medical or surgical intervention to prevent on e of the outcomes listed in 
this definition.  Examples of such medical events include allergic bronchospasm 
requiring intensive treatment in an emergency room or a t home, blood dyscrasias or 
convulsions in a patient who has never had seizure activity in the past that do not result in 
inpatient hospi[INVESTIGATOR_059], or the development of drug dependency or abuse.  
 
Events not considered to be serious adverse events are hospi[INVESTIGATOR_366895]:  
 
ÔÇ∑ Routine treatment or monitoring of the studied indication not associated with any 
deterioration in condition.  
ÔÇ∑ Treatment, which was elective or p re-planned, for a pre -existing condition that did 
not worsen  
ÔÇ∑ Treatment on an emergency, outpatient basis for an event not fulfilling any of the 
definitions of serious given above and not resulting in hospi[INVESTIGATOR_063].  
 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 59 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
59 
 Pregnancy, although not itself a se rious adverse event, should also be reported on a 
serious adverse event form and be followed up to determine outcome, including 
spontaneous or voluntary termination, details of birth, and the presence or absence of 
any birth defects or congenital abnormali ties. 
 
The study will utilize the Cancer Therapy Evaluation Program ( BTTC) Common 
Terminology  Criteria for Adverse Events (CTCAE) Version 4.0 for Toxicity and Adverse 
Event reporting.  A copy of the CTCAE version 4.0 can be downloaded from the BTTC 
home page ( (http://BTTC.cancer.gov/reporting/ctc.html) .  All appropriate treatment areas 
should have access to either a hard copy of the CTCAE version 4.0 or the www version.  
 
Serious Adverse Event s will be reported via the BTTC SAE reporting process . See 
section 15. 7 for BTTC SAE reporting guidelines.  
 
Notification of Investigators of Expedited Adverse Events Reported to the FDA  
 
Safety Reports  or Updates  ‚ÄìInvestigators will be sent a copy of expedited adverse 
events, which BTTC has sent to the FDA  or that BTTC receives from the agent suppliers . 
BTTC will notify consortium investigators via the MD ANDERSON CANCER 
CENTER  Office of Multicenter Clinical Resea rch. Within [ADDRESS_458621] the 
reports to the participating members with protocol specific instructions for IRB 
submissions, patient notifications, etc. For routine IND Safety Reports BTTC does not 
generally require an immediate revision to the master protocol and/or model informed 
consent documents maintained at the MD ANDERSON CANCER CENTER  Office of 
Multicenter Clinical Research . The investigators are to file a copy with thei r protocol file 
and send a copy to their IRB according to their local IRB‚Äôs policies and procedures.  
 
IND AE Action Letters  - These letters are issued by [CONTACT_366957], which warrant an immediate change in the informed consent form and/or 
protocol. Investigators will be sent a copy of expedited adverse events, which BTTC has 
sent to the  FDA or that BTTC has received from the agent supplier/s . BTTC will notify 
consortium investigators via the MD ANDERSON CANCER CENTER  Office of 
Multicenter Clinical Research  with the requirement that the model informed consent and 
or master protocol be amended to include the new event. Immediately upon receipt of the 
notification the MD ANDERSON CANCER CENTER  OMCR will forward the letters to 
the participating members with protocol specific instructions for IRB submissions, 
patient notifications, etc. BTTC provides a time frame for which to submit the 
amendment to the BTTC Protocol and Information Office. The letter from BTTC will 
specify if accrual  to the protocol is to be suspended until the revision is made and 
whether patients already on study require re -consenting.  
 
 
 
 
 
 
  
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 60 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
60 
 15.7 Guidelines for Reporting Serious Adverse Events to BTTC  
 
All patients receiving agents will be evaluated for safety. Both local IRB and BTTC SAE 
reporting procedures are to be followed by [CONTACT_366958].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Participating 
Institution Coordinating 
Center
(MDACC)Lead PI[INVESTIGATOR_366896]
(If applicable)
MDACC IRB
(Lead IRB)Participating IRBAll SAE
ReportsAll SAE 
ReportsSAE ReportsUnexpected & Related SAEs
SAEs per
Local SOPBTTC 
Routine SAE Report 
Processing WorkFlow All SAEs
(if applicable)FDA
(If Applicable)Unexpected & 
Related SAEs
Lead IRBAll SAE
Reports
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 61 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
61 
 BTTC SAE reporting requirements and time frames for reporting to the BTTC Coordinating 
Center are described below:  
 
What to Report?  When to Report?  How to Report?  
   
Serious Adverse Events (SAE‚Äôs)  
1. All Deaths occurring from 
the time the consent is signed 
through [ADDRESS_458622] 
day of active treatment  Within 1 working day (24 
hours) from the time the 
research team  becomes 
aware of event  
 
 
 
 Unless otherwise specified  in 
the protocol use the MD 
ANDERSON SAE Report 
Form for Multicenter 
Reporting (Multicenter 
Participants outside MD 
ANDERSON)  
 
 
 
2. Other SAE‚Äôs (that did not 
result in death) that are serious 
AND unexpected AND 
related occurring from the 
time the consent is signed 
through [ADDRESS_458623] 
day of active treatment  Within 5 working days from 
the time the research team  
becomes aware of event  Unless otherwise specified in 
the protocol use the MD 
ANDERSON SAE Report 
Form for Multicenter 
Reporting (Multicen ter 
Participants outside MD 
ANDERSON)  
 
3.  Other SAE‚Äôs (that did not 
result in death) that do not meet 
the above criteria occurring 
from the time the consent is 
signed through [ADDRESS_458624] day of active treatment 
(the SAE is unrelated ) Within 5 working days from 
the time the research team  
becomes aware of event  Unless otherwise specified in 
the protocol use the MD 
ANDERSON SAE Report 
Form for Multicenter 
Reporting (Multicenter 
Participants outside MD 
ANDERSON)  
 
 
Serious Adverse Events are to be reported to the local IRB in accordance with local 
policy and procedures. However, all SAE‚Äôs are to be reported to the OMCR in 
accordance with BTTC policy even when the local IRB does not require a report, or does 
not require a prompt report.  In these cas es a formal memo explaining the local policy 
must accompany the report that is submitted to the OMCR.  
 
The BTTC Coordinating Center will maintain documentation of all Serious Adverse 
Events from each institution. The BTTC Coordinating Center will notify al l investigators 
of any serious and unexpected adverse experiences that are possibly related to the study 
agent/s.  The investigators are to file a copy with their protocol file and send a copy to 
their IRB according to their local IRB‚Äôs policies and procedures.  
 
All serious adverse events that are unexpected and assessed to be possibly related to the 
study agents must  be reported to the FDA by [CONTACT_7613] (or their designee) as a 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 62 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
[ADDRESS_458625]-marketing ‚ÄòAlert Report‚Äô. An unexpected adverse event is one that is not 
already described in the study agent Investigator Brochure(s) . The lead principal 
investigator (o r their designee) also has the obligation to report serious adverse events to 
their IRB, Genentech Drug Safety and [COMPANY_006] Sharp and Dohme Corp Worldwide safety .   
 
The BTTC Coordinating Center will forward all SAE reports to the lead IRB via the lead 
investigator, FDA (when applicable), and , Genentech Drug Safety and [COMPANY_006] Sharp and 
Dohme Corp Worldwide safety . 
 
Genentech Drug Safety and [COMPANY_006] 
Sharp and Dohme Corp Worldwide 
safety FDA MedWatch 15 -day Alert Report  
  
Genentech Drug Safety  
Fax: ([PHONE_166] or (650) 225 -
5288 
(Using the safety reporting fax cover 
sheet attached to this document)  
 
[COMPANY_006] Sharpe and Dohme Corp.   
(Attn: Worldwide Product Safety)  
 
Fax: [PHONE_833] 
 
AND: 
 
Study Coordination Center/Principal 
Investigator  
[INVESTIGATOR_366897] # (713) 792 -
2883  and (713) 794 -4999 
 Phone: 1-800-FDA-1088 
FAX: 1-800-FDA-0178 or by [CONTACT_366959] 200N 1401 Rockville Pi[INVESTIGATOR_366898], MD [ZIP_CODE] -1448  
FAX: 1-800-FDA-[ADDRESS_458626], Rockville, MD 
[ZIP_CODE]- 
9787 
 
SAEs should be recorded on a Multicenter Serious Adverse Event Form (Appendix 
18.8).The completed SAE form  is to be imported or faxed to : 
 
MD ANDERSON CANCER CENTER  Office of Multicenter Clinical Research  
Attn: BTTC Project  
EDMS: https://iview.mdanderson.org/  
Fax: [PHONE_7588] 
 
Follow-up information:   
 
Additional information may be added to a previously submitted report by [CONTACT_38311]:  
 
ÔÇ∑ Adding to the original SAE report and submitting it as follow -up. 
ÔÇ∑ Adding supplemental summary information and submitting it as follow -up 
with the original SAE report.  
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 63 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
[ADDRESS_458627] for whom an adverse event was 
reported.  
 
Assessing Causality:  
 
Investigators are required to assess whether there is a reasonable possibility that 
the study agen t/s caused or contributed to an adverse event.  The following 
general guidance may be used.  
 
Yes: If the temporal relationship of the clinical event to the study agent/s 
administration makes a causal relationship possible, and other drugs, 
therapeutic interventions or underlying conditions do not provide a 
sufficient explanation for the observed event.  
 
No: If the temporal relationship of the clinical event to the study agent/s 
administration makes a causal relationship unlikely, or other drugs, 
therapeutic interventions or underlying conditions provide a sufficient 
explanation for the observed event.  
 
15.8 Guidelines & Procedures for reporting Violations, Deviations and Unanticipated 
Problems  
 
Neither the FDA nor the ICH GCP guidelines define the terms ‚Äúprotocol violation‚Äù or 
‚Äúprotocol deviation.‚Äù  The definition is often left to the Lead Institution IRB.  
Accordingly, since MD ANDERSON CANCER CENTER  is the Coordinating Center 
and the Protocol C hair must adhere to those policies set by [CONTACT_366960], the definitions for protocol violation and deviation as described 
by [CONTACT_366961]-
center Project. Definitions, reporting guidelines and procedures for reporting violations, 
deviations and/or unanticipated problems are described in the BTTC Operations Manual.  
 
Protocol violations/deviations/unanticipa ted problems occurring at a participating 
institution will be submitted to that institution‚Äôs own IRB.   A copy of the participating 
institution‚Äôs IRB violation/deviation/unanticipated problem report will be forwarded to 
the BTTC Coordinating Center by  [CONTACT_366962] 7 calendar 
days after the original submission.  
 
MD ANDERSON CANCER CENTER  Office of Multicenter Clinical Research  
 
EDMS: https://iview.mdanderson.org/  
Fax: [PHONE_7588] 
 
BTTC Coordinating Center:   Upon receipt of the violation/deviation/unanticipated 
problem report from the participating institution, the BTTC Coordinating Center will 
submit the report to the lead Protocol Chair for review. Subsequently, the participating 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 64 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
64 
 institution‚Äôs IRB violation/deviation/unanticipated problem report will be submitted to 
the MD Anderson Cancer Center IRB for review.  
 
15.9 Institutional Review  
 
Each cooperating center will submit the protocol to its own IRB.  Documentation of the 
IRB approval will be forwarded to the MD ANDERSON CANCER CENTER  OMCR at 
UT MD ANDERSON CANCER CENTER  before a patient from that institution can be 
registered on protocol .  No changes in the protocol will be allowed unless approved by 
[CONTACT_458] [INVESTIGATOR_264300]. 
 
15.10 Protocol Revisions and Closure  
 
Non life-threatening revisions : BTTC investigators will receive written notification of 
protocol revisions regardin g non life -threatening events.  
 
Life-threatening revisions : BTTC investigators will receive telephone notification of life -
threatening revisions with follow -up by [CONTACT_96924]/or e -mail.  Life -threatening protocol 
revisions will be implemented immediately.  
 
Protocol closures and temporary holds : BTTC investigators will receive email 
notification of protocol closures and holds.  Closures and holds will be effective 
immediately.  Centers will be updated on an ongoing basis about protocol accrual data so 
that they will be aware of imminent protocol closures.  
 
15.11 Quality Assurance  
 
The BTTC Quality Assurance procedures and reports are described in detail in the BTTC 
Operations Manual. However, an abbreviated description is provided below.  
 
BTTC Quality assurance measures are provided by [CONTACT_294432]: ongoing in -house 
monitoring of protocol compliance, on -site audits, and response reviews.  All data 
submitted to the MD ANDERSON CANCER CENTER  OMCR at UT MD ANDERSON 
CANCER CENTER  will be mo nitored in -house for timeliness of submission, 
completeness, and adherence to protocol requirements.  Data monitoring will begin at the 
time of patient registration and will continue during protocol performance and 
completion.  The MD ANDERSON CANCER CENTE R Protocol Manager will perform 
the ongoing protocol compliance monitoring with the support of the BTTC study 
investigators.  
  
In the absence of a sponsor monitoring requirement, or agency, institutions participating 
in BTTC Protocols may be subject to on -site auditing conducted by [CONTACT_366963]‚Äôs Multi -Center Audit Plan for the BTTC consortium.  The 
Multi-Center Audit Plan does not replace the in -house monitoring described in this 
manual. On -Site auditing combined with the in -house monitoring are intended to enhance 
the reliability and validity of clinical tri al data from BTTC institutions through the use of 
routine monitoring & auditing procedures.  
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 65 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
[ADDRESS_458628] 2 years after the investigation is 
completed.  
 
15.13  Data confidentiality Plan  
 
The investigator will assure that subjects‚Äô anonymity will be maintained and that their 
identities are protected from unauthorized parties. The Informed Consent Form will 
incorporate (or, in some cases, be accompanied by a separate document incorporating) 
wording that complies with relevant data protection and privacy legislation. Pursuant to 
this wording, patients will authorize the collection, use and disclosure of their study data 
by [CONTACT_366964].  
 
The use of the samples for research will be done in accordance with the guidelines 
defined by [CONTACT_366965] ‚ÄúGuidance on Informed Consent for In Vitr o Diagnostic 
Device Studies Using Leftover Human Specimens that are Not Individually Identifiable‚Äù 
(issued 25 April 2006). The subject‚Äôs personal information will be removed before the 
research samples are used. The research samples will be de -identified b y setting a study 
code /initials . If a subject requests destruction of their banked research tissue and blood 
samples, and the samples have not yet been de -identified, the investigator will destroy the 
samples as described in this FDA guidance.  
 
 
16.0 PATIENT RELATED OUTCOMES MEASURES  
 
This study seeks to establish effective therapi[INVESTIGATOR_366899].  We hypothesize that using a combination of  vorinostat and bevacizumab  will result in 
improved outcome compared to bevacizumab alone .  However, given the intensive nature of this 
regimen, it will be important to determine whether if any determined survival benefit is 
associated with improvements in symptoms or does a worsening of these parameters offset the 
increase in  survival.  
 
Precedence for measuring ‚Äúnon -therapeutic‚Äù endpoints exists in oncology research.  For example, 
Gemcitabine was approved by [CONTACT_264330] a consequence of the decrease in pain 
reported in pancreatic patients who were treated, not on the  basis of survival improvement which 
was modest, at best1 (Carmichael, Fink et al. 1996) .  There have been efforts in neuro -oncology to 
evaluate secondary endpoints using validated instruments as an additional indicator of benefit.   
 
The MD Anderson  Symptom Inventory -Brain Tumor Module (MDASI -BT) allows the self-
reporting of symptom severity and interference with daily activities.  The MDASI -BT has 
demonstrated reliability and validity in the adult primary brain tumor patient population2 
(Armstrong, M endoza et al. 2006) . This tool represent s a modification of the widely used and 
validated MDASI, with particular attention to symptoms common in patients with brain tumors.   
The availability of validated instruments provides an opportunity to prospectively assess the 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 66 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
[ADDRESS_458629] toxicity.  
 
16.1 Patient Related Outcome Objectives:  
 
1. To evaluate longitudinal changes in symptom measures and determine the impact of 
the therapy on these parameters.  
2. To measure symptom burden over the course of therapy to evaluate differences 
between patients individual symptom severity, overall mean symptom  severity, and 
difference in scores on the interference items between responders and non -responders.  
3. To describe the variability  of symptom severity longitudinally over the treatment 
course and follow -up period.  
 
16.2 Patient Related Outcome Methods:  
 
16.2.1 Patient Related Outcome Instruments:  
 
The MDASI -BT will be utilized for this portion of the study. Full instruments are 
provided in the appendix.  In addition, information regarding demographics and 
treatment history will be collected as part of the la rger study and used in this 
analysis.    
 
The MDASI -BT consists of 23 symptoms rated on an 11 -point scale (0 to 10) to 
indicate the presence and severity of the symptom, with 0 being ‚Äúnot present‚Äù 
and 10 being ‚Äúas bad as you can imagine.‚Äù Each symptom is rated at its worst in 
the last 24 hours. Sy mptoms included on the instrument include those commonly 
associated with cancer therapi[INVESTIGATOR_014], those associated with increased intracranial 
pressure, and those related to focal deficits.  The questionnaire also includes  
ratings of how much symptoms interfered with different aspects of a patient‚Äôs life 
in the last 24 hours. These interference items include: general activity, mood, 
work (includes both work outside the home and housework), relations with other 
people, walki ng, and enjoyment of life. The interference items are also measured 
on 0 - 10 scales. The average time to complete these instruments is 5 minutes. 
The MDASI -BT has been translated into 18 languages ( Armstrong, Mendoza et 
al. 2006). 
 
16.2.2  Patient Related Outcome Data collection:   
 
After enrollment on the clinical trial, patients will complete as baseline measures 
the MDASI -BT.  The patient will continue to complete the MDASI -BT at the 
time of clinical evaluation with MRI  as long as the clinical therapy is being 
administered, unless clinical deterioration makes self -report not possible before 
that time.  The time when patients are una ble to complete the self-report 
questionnaires will be used as part of the study analysis.  The MDASI -BT will be 
completed only by [CONTACT_102], unless changes in vision or weakness make this 
difficult. If this occurs, then the caregiver or research assista nt may read the 
questions to the patient or assist with marking the severity number or score as 
described by [CONTACT_102]. A patient caregiver may complete the questionnaires as 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 67 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
67 
 a patient-preference proxy if the patient‚Äôs deficits preclude self-report. These 
reports will be used for descriptive purposes only.  
 
16.3 Patient Related Outcome Statistical Section:  
 
The sample size for this trial was based on the primary end point of the study.  
 
Received MDASI -BT forms will be checked versus the timing schedule an d considered 
as valid if they fall within ten days of the scheduled assessment.  Compliance rates will 
be calculated as the number of received valid forms over the number of expected forms. 
Differences between groups in compliance will be tested by [CONTACT_264348]‚Äôs exact test at 
every time point.  
 
We will use descriptive statistics to describe how patients rate symptom severity and 
interference with function at each time point.  Error bar graphs for each of the symptoms 
will be constructed at each time point .  The proportion of patients rating their symptoms 
to be 7 or greater (on a 0 -10 scale) will also be reported.  We will construct individual 
patient profiles for each of the selected symptoms to describe the individual patients‚Äô 
patterns of change over ti me. We will calculate the mean core symptom severity, mean 
severity of the MDASI -BT and mean symptom interference at the time of clinical 
evaluation . Estimates of differences in the mean symptom severity and mean symptom 
interference between responders and  non-responders will be estimated in the intent to 
treat population.  All patients with at least one valid questionnaire  will be included in the 
analyses.  Questionnaires completed at study registration will be considered baseline.  All 
questionnaire data received after randomization will be used in the primary analyses.  
 
Differences of at least 2 points will be classified as the minimum clinically meaningful 
change in the symptom severity and symptom interference measures. For example, an 
increase of 2 poi nts or more would mean a moderate improvement, whereas a decrease of 
2 points or more would be interpreted as moderate worsening. For individual symptoms, 
a rise in a symptom score means deterioration, whereas a reduced score means 
improvement of the speci fic symptom.  
 
  
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 68 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
68 
 17.0 REFERENCES  
 
ÔÇ∑ Carmichaeil, J., et al (1996).  Phase II study of gemcitabine in patients with advanced pancreatic 
cancer.  British Journal of Cancer, 73 (1), 101-105. 
ÔÇ∑ Chinnaiyan et al. (2012). Phase I trial of vorinostat  combined with bevacizumab and CPT -11 in 
recurrent glioblastoma.  Neurooncology . 2012 Jan;14(1):93 -100. 
ÔÇ∑ Armstrong, T.S., Mendoza, T., Gning, et al (2006).  Validation of the MD Anderson  Symptom 
Inventory Brain Tumor Module (MDASI -BT).  Journal of Neuro -Oncology, 80 (1), 27-35. 
ÔÇ∑ Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W. T., D uda, D. G., Cohen, K. S., 
Kozak, K. R., Cahill, D. P., Chen, P. J., Zhu, M. , et al. (2007). AZD2171, a pan -VEGF receptor 
tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma 
patients. Cancer Cell  11, 83-95. 
ÔÇ∑ Bergers, G., and Hanahan, D. (2008). Modes of resistance to anti -angiogenic therapy. Nat Rev 
Cancer 8, 592-603. 
ÔÇ∑ Bergers, G., Song, S., Meyer -Morse, N., Bergsland, E., and Hanahan, D. (2003). Benefits of 
targeting both pericytes and endothelial cells in the tumor va sculature with kinase inhibitors. J 
Clin Invest  111, 1287-1295. 
ÔÇ∑ Bolden, J. E., Peart, M. J., and Johnstone, R. W. (2006). Anticancer activities of histone 
deacetylase inhibitors. Nat Rev Drug Discov  5, 769-784. 
ÔÇ∑ Calvani, M., Rapi[INVESTIGATOR_57195], A., Uranchimeg, B., Shoemaker, R. H., and Melillo, G. (2006). Hypoxic 
induction of an HIF -1alpha-dependent bFGF autocrine loop drives angiogenesis in human 
endothelial cells. Blood  107, 2705-2712. 
ÔÇ∑ Casanovas, O., Hicklin, D. J., Bergers, G., and Hanahan, D. (2005). Drug resist ance by [CONTACT_366966] -stage pancreatic islet tumors. Cancer Cell  8, 
299-309. 
ÔÇ∑ Ceradini, D. J., Kulkarni, A. R., Callaghan, M. J., Tepper, O. M., Bastidas, N., Kleinman, M. E., 
Capla, J. M., Galiano, R. D., Lev ine, J. P., and Gurtner, G. C. (2004). Progenitor cell trafficking 
is regulated by [CONTACT_192089] -1 induction of SDF -1. Nat Med  10, 858-864. 
ÔÇ∑ Du, R., Lu, K. V., Petritsch, C., Liu, P., Ganss, R., Passegue, E., Song, H., Vandenberg, S., 
Johnson, R. S., Werb, Z., and Bergers, G. (2008). HIF1alpha induces the recruitment of bone 
marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer 
Cell 13, 206-220. 
ÔÇ∑ Fernando, N. T., Koch, M., Rothrock, C., Gollogly, L. K., D 'Amore, P. A., Ryeom, S., and Yoon, 
S. S. (2008). Tumor escape from endogenous, extracellular matrix -associated angiogenesis 
inhibitors by [CONTACT_25764] -regulation of multiple proangiogenic factors. Clin Cancer Res  14, 1529-1539. 
ÔÇ∑ Folkman, J. (1971). Tumor angiogenesi s: therapeutic implications. N Engl J Med  285, 1182-
1186. 
ÔÇ∑ Folkman, J. (2006). Angiogenesis. Annu Rev Med  57, 1-18. 
ÔÇ∑ Glusker, P., Recht, L., and Lane, B. (2006). Reversible posterior leukoencephalopathy syndrome 
and bevacizumab. N Engl J Med  354, 980-982; discussion 980 -982. 
ÔÇ∑ Gurney, J. G., and Kadan -Lottick, N. (2001). Brain and other central nervous system tumors: 
rates, trends, and epi[INVESTIGATOR_623]. Curr Opin Oncol  13, 160-166. 
ÔÇ∑ Holash, J., Maisonpi[INVESTIGATOR_11958], P. C., Compton, D., Boland, P., Alexander, C. R., Zagzag, D., 
Yancopoulos, G. D., and Wiegand, S. J. (1999). Vessel cooption, regression, and growth in 
tumors mediated by [CONTACT_366967]. Science  284, 1994-1998. 
ÔÇ∑ Jain, R. K., di Tomaso, E., Duda, D. G., Loeffler, J. S., Sorensen, A. G., and Batchelor, T. T.  
(2007). Angiogenesis in brain tumours. Nat Rev Neurosci  8, 610-622. 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 69 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
69 
 ÔÇ∑ Karp, J. E., Gojo, I., Pi[INVESTIGATOR_45769], R., Gocke, C. D., Greer, J., Guo, C., Qian, D., Morris, L., Tidwell, M., 
Chen, H., and Zwiebel, J. (2004). Targeting vascular endothelial growth factor for re lapsed and 
refractory adult acute myelogenous leukemias: therapy with sequential 1 -beta-d-
arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clin Cancer Res  10, 3577-3585. 
ÔÇ∑ Kim, M. S., Kwon, H. J., Lee, Y. M., Baek, J. H., Jang, J. E., Lee, S. W., Moo n, E. J., Kim, H. S., 
Lee, S. K., Chung, H. Y. , et al. (2001). Histone deacetylases induce angiogenesis by [CONTACT_366968]. Nat Med  7, 437-443. 
ÔÇ∑ Kim, S. H., Jeong, J. W., Park, J. A., Lee, J. W., Seo, J. H., Jung, B. K., Bae, M . K., and Kim, K. 
W. (2007). Regulation of the HIF -1alpha stability by [CONTACT_366969]. Oncol Rep  17, 647-
651. 
ÔÇ∑ Kopp, H. G., Ramos, C. A., and Rafii, S. (2006). Contribution of endothelial progenitors and 
proangiogenic hematopoietic cells to vasculariz ation of tumor and ischemic tissue. Curr Opin 
Hematol 13, 175-181. 
ÔÇ∑ Lamszus, K., Kunkel, P., and Westphal, M. (2003). Invasion as limitation to anti -angiogenic 
glioma therapy. Acta Neurochir Suppl  88, 169-177. 
ÔÇ∑ Mahon, P. C., Hirota, K., and Semenza, G. L. (2001). FIH -1: a novel protein that interacts with 
HIF-1alpha and VHL to mediate repression of HIF -1 transcriptional activity. Genes Dev  15, 
2675-2686. 
ÔÇ∑ Mancuso, M. R., Davis, R., Norberg, S. M., O'Brien, S., Sennino, B., Nakahara, T., Yao, V. J., 
Inai, T., Brooks, P., Freimark, B. , et al. (2006). Rapid vascular regrowth in tumors after reversal 
of VEGF inhibition. J Clin Invest  116, 2610-2621. 
ÔÇ∑ Marks, P. A., Richon, V. M., Miller, T., and Kelly, W. K. (2004). Histone deacetylase inhibitors. 
Adv Cancer Res  91, 137-168. 
ÔÇ∑ Mastronardi, L., Puzzilli, F., Couldwell, W. T., Farah, J. O., and Lunardi, P. (1998). Tamoxifen 
and carboplatin combinational treatment of high -grade gliomas. Results of a clinical trial on 
newly diagnosed patients. J Neurooncol  38, 59-68. 
ÔÇ∑ Miller, D. L., Dou, C., and Armstrong, W. F. (2005). The influence of agent delivery mode on 
cardiomyocyte injury induced by [CONTACT_366970]. Ultrasound Med 
Biol 31, 1257-1263. 
ÔÇ∑ Munster, P. N., Rubin, E. H., Van Belle, S., Friedman,  E., Patterson, J. K., Van Dyck, K., Li, X., 
Comisar, W., Chodakewitz, J. A., Wagner, J. A., and Iwamoto, M. (2009). A Single 
Supratherapeutic Dose of Vorinostat Does Not Prolong the QTc Interval in Patients with 
Advanced Cancer. Clinical Cancer Research  15, 7077-7084. 
ÔÇ∑ Norden, A. D., Young, G. S., Setayesh, K., Muzikansky, A., Klufas, R., Ross, G. L., Ciampa, A. 
S., Ebbeling, L. G., Levy, B., Drappatz, J. , et al. (2008). Bevacizumab for recurrent malignant 
gliomas: efficacy, toxicity, and patterns of recurr ence. Neurology  70, 779-787. 
ÔÇ∑ Oh, J., Cha, S., Aiken, A. H., Han, E. T., Crane, J. C., Stainsby, J. A., Wright, G. A., Dillon, W. 
P., and Nelson, S. J. (2005). Quantitative apparent diffusion coefficients and T2 relaxation times 
in characterizing contrast e nhancing brain tumors and regions of peritumoral edema. J Magn 
Reson Imaging  21, 701-708. 
ÔÇ∑ Okuyama, H., Krishnamachary, B., Zhou, Y. F., Nagasawa, H., Bosch -Marce, M., and Semenza, 
G. L. (2006). Expression of vascular endothelial growth factor receptor 1 in  bone marrow -derived 
mesenchymal cells is dependent on hypoxia -inducible factor 1. J Biol Chem  281, [ZIP_CODE]-[ZIP_CODE]. 
ÔÇ∑ Ozcan, C., Wong, S. J., and Hari, P. (2006). Reversible posterior leukoencephalopathy syndrome 
and bevacizumab. N Engl J Med  354, 980-982; discussion 980 -982. 
ÔÇ∑ Petit, I., Jin, D., and Rafii, S. (2007). The SDF -1-CXCR4 signaling pathway: a molecular hub 
modulating neo -angiogenesis. Trends Immunol  28, 299-307. 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 70 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
70 
 ÔÇ∑ Phillips, H. S., Kharbanda, S., Chen, R., Forrest, W. F., Soriano, R. H., Wu, T. D., Misra , A., 
Nigro, J. M., Colman, H., Soroceanu, L. , et al. (2006). Molecular subclasses of high -grade glioma 
predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. 
Cancer Cell  9, 157-173. 
ÔÇ∑ Qian, D. Z., Wang, X., Kachh ap, S. K., Kato, Y., Wei, Y., Zhang, L., Atadja, P., and Pi[INVESTIGATOR_45769], R. 
(2004). The histone deacetylase inhibitor NVP -LAQ824 inhibits angiogenesis and has a greater 
antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine 
kinase inhibitor PTK787/ZK222584. Cancer Res  64, 6626-6634. 
ÔÇ∑ Rossig, L., Urbich, C., Bruhl, T., Dernbach, E., Heeschen, C., Chavakis, E., Sasaki, K., Aicher, 
D., Diehl, F., Seeger, F. , et al. (2005). Histone deacetylase activity is essential for the expression  
of HoxA9 and for endothelial commitment of progenitor cells. J Exp Med  201, 1825-1835. 
ÔÇ∑ Scappaticci, F. A., Fehrenbacher, L., Cartwright, T., Hainsworth, J. D., Heim, W., Berlin, J., 
Kabbinavar, F., Novotny, W., Sarkar, S., and Hurwitz, H. (2005). Surgical  wound healing 
complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol  91, 
173-180. 
ÔÇ∑ Sorensen, A. G., Patel, S., Harmath, C., Bridges, S., Synnott, J., Sievers, A., Yoon, Y. H., Lee, E. 
J., Yang, M. C., Lewis, R. F. , et al. (2001). Comparison of diameter and perimeter methods for 
tumor volume calculation. J Clin Oncol  19, 551-557. 
ÔÇ∑ Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J., Belanger, 
K., Brandes, A. A., Marosi, C., Bogdahn, U. , et al. (2005). Radiotherapy plus concomitant and 
adjuvant temozolomide for glioblastoma. N Engl J Med  352, 987-996. 
ÔÇ∑ Tofts, P. S., Brix, G., Buckley, D. L., Evelhoch, J. L., Henderson, E., Knopp, M. V., Larsson, H. 
B., Lee, T. Y., Mayr, N. A., Parker, G. J. , et al. (1999). Estimating kinetic parameters from 
dynamic contrast -enhanced T(1) -weighted MRI of a diffusable tracer: standardized quantities and 
symbols. J Magn Reson Imaging  10, 223-232. 
ÔÇ∑ Tso, C. L., Shintaku, P., Chen, J., Liu, Q., Liu, J., Chen, Z., Y oshimoto, K., Mischel, P. S., 
Cloughesy, T. F., Liau, L. M., and Nelson, S. F. (2006). Primary glioblastomas express 
mesenchymal stem -like properties. Mol Cancer Res  4, 607-619. 
ÔÇ∑ Vredenburgh, J. J., Desjardins, A., Herndon, J. E., 2nd, Marcello, J., Reardon , D. A., Quinn, J. A., 
Rich, J. N., Sathornsumetee, S., Gururangan, S., Sampson, J. , et al. (2007). Bevacizumab plus 
irinotecan in recurrent glioblastoma multiforme. J Clin Oncol  25, 4722-4729. 
ÔÇ∑ Wong, E. T., Hess, K. R., Gleason, M. J., Jaeckle, K. A., Kyri tsis, A. P., Prados, M. D., Levin, V. 
A., and Yung, W. K. (1999). Outcomes and prognostic factors in recurrent glioma patients 
enrolled onto phase II clinical trials. J Clin Oncol  17, 2572-2578. 
ÔÇ∑ Yu, J. L., Rak, J. W., Coomber, B. L., Hicklin, D. J., and Ke rbel, R. S. (2002). Effect of p53 
status on tumor response to antiangiogenic therapy. Science  295, 1526-1528. 
 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 71 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
71 
 18.0 APPENDIX  
 
18.1 NCI Common T erminology  Criteria for Adverse Events  
 
18.2 Karnofsky Performance Status  and Neurologic Function  
 
18.3 EIAEDs and Non -EIAEDs 
 
18.4 Peripheral Blood Mononuclear Cell (PBMC) Isolation for Circulating Endothelial Cells 
Assays 
 
18.5 Blood and tissue biomarker collection and analysis  
 
18.6 Bayesian Adaptive Algor ithm: Technical Details  
 
18.7 Study Flow Chart / S chema 
 
18.8  Multicenter Serious Adverse Event Form  
 
18.9 [LOCATION_001] Heart Association (NYHA) Guidelines  
 
18.10 Procedure for Obtaining a Urine Protein: Creatinine Ratio  
 
18.11 Pregnancy Tests for Females of Childbearing Potential and Adequate Methods of 
Contraception  
 
18.12  MD Anderson Symptom Inventory for Brain Tumors (MDASI ‚Äì BT) 
 
18.13  Drug Accountability  
 
 18.14     Patient Study Drug Diary  
 
  
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 72 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
72 
  
 
 
18.1 NCI Common Terminology  Criteria for Adverse Events  
 
This study will utilize the CTCAE version 4.0 for Toxicity and Adverse Event reporting.  A copy 
of the CTCAE version 4.0  can be downloaded from the www at  
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm . 
 
18.2 Karnofsky Performance Status Score and Neurological Function  
 
Patient's performance status  and Neurologic Functions  will be graded according to the following 
scales: 
Karnofsky Performance Status  
 
KPS 100 Normal; no complaints; no evidence of disease  
KPS   90 Able to carry on normal activity; minor signs or symptoms of disease  
KPS   80 Normal activity with effort; some sign or symptoms of disease  
KPS   70 Cares for self; unable to carry on normal activity or do active work  
KPS   [ADDRESS_458630] personal  needs 
KPS   50 Requires considerable assistance and frequent medical care  
KPS   40 Disabled; requires special care and assistance  
KPS   30 Severely disabled; hospi[INVESTIGATOR_89648], although death no imminent  
KPS   20 Very sick; hospi[INVESTIGATOR_20545]; active support treatment is necessary  
KPS   10 Moribund; fatal processes progressing rapi[INVESTIGATOR_366900]     0 Dead 
 
 
Neurologic Function  
 
 
 
     
 +2 Definitely Better 
 +1 Possibly Better  
   0 Unchanged  
 -1 Possibly Worse  
 -2 Definitely Worse  
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 73 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
[ADDRESS_458631] OF ENZYME INDUCING & NON_ENZYME INDUCING ANTICONVULSANTS  
 
 
Enzyme inducing antiepi[INVESTIGATOR_366901]  (Tegretol, Tegretol XR, Carbatrol)  
Oxcarbazepi[INVESTIGATOR_050]  (Trileptal)  
Phenytoin  (Dilantin, Phenytek)  
Fosphenytoin  (Cerebyx)  
Phenobarbital  (Solfoton) 
Primidone  (Mysoline)  
 
Non enzyme inducing antiepi[INVESTIGATOR_366902]*  (Trileptal)  
Topi[INVESTIGATOR_052]*  (Topamax, Topi[INVESTIGATOR_366903])  
Ethosuximde  (Zarontin)  
Gabapentin  (Neurontin , Fanatrex, Gabarone, Horizant ) 
Lacosamide  (Vimpat) 
Lamotrigine*  (Lamictal) 
Levatiracetam  (Keppra) 
Pregabalin  (Lyrica) 
Tiagabine  (Gabatril)  
Valproic acid**  (Depakote, Depakene, Epi[INVESTIGATOR_266118], Stavzor)  
Vigabatrin  (Sabril) 
Zonisamide  (Zonegran)  
Clonazepam  (Klonopin , Klonipin Wafer, Ceberclon, Valpax ) 
Clobazam (Frisium, Urbanol ) 
 
* Weak inducers of Cyp3A4 and only at higher doses  
 
35,9,/(*('&[ZIP_CODE],&$7,21 )25,19(67,*$7,21$/86(21/< 
  %77&
 
3DJHRI

%HYDFL]XPDE9RULQRVWDW3URWRFRO   



 3HULSKHUDO%ORRG0RQRQXFOHDU&HOO3%0&,VRODWLRQIRU&LU FXODWLQJ(QGRWKHOLDO&HOOV
$VVD\V

$,QVWUXFWLRQVIRU6DPSOH&ROOHFWLRQDQG3URFHVVLQJ 
x$SSUR[LPDWHO\FFRIYHQRXVEORRGZLOOEHFROOHFWHGLQWRD%' 9DFXWDLQHU&37¬åWXEHZLWK
6RGLXP&LWUDWH%HFWRQ'LFNLQVRQSURGXFW,I\RXUFH QWHUZLOOSDUWLFLSDWHLQWKLVSDUW
RIWKHVWXG\SOHDVHHQVXUHDY DLODELOLW\RIWKHVHWXEHVLQDGYD QFHRISDWLHQWHQUROOPHQW

x7KHWXEHVKRXOGEHJHQWO\LQYHUW HGWLPHVWRHQVXUHPL[LQJZ LWKWKHDQWLFRDJXODQW

x:LWKLQWZRKRXUVWKH&37WXEHVKRXOGEHFHQWULIXJHG DWURRPWHPSHUDWXUH LQDKRUL]RQWDOURWRU
IRUPLQXWHVDWJ¬É&WR¬É&ZLWKRXWWKHEUDNH

x3UHSDUHDQGODEHOFU\RWXEHVDVVSHFLILHGEHORZ

x$IWHUFHQWULIXJDWLRQWKHPRQRQXFOHDUFHOOVZLOOEHYLVLEOHLQ DZKLWLVKOD\HUMXVWXQGHUWKH
SODVPD5HPRYHPORISODVPDWRSOD\HU FDUHIXOO\ZLWKRXWGLVWXUELQJWKHORZHUOD\HUXVLQJD
POSLSHWWHDQGSXWLQWRFU\RWXEH

x7KHQUHPRYHPRQRQXFOHDUOD\HUPODQGSXWLQWRFU\RWXEH 

x7KHQWUDQVIHUKDOIRIPRQRQXFOHDUFHOOVPLFUROLWHUVWRFU \RWXEH

x$GGPLFUROLWHUVRIIUHH]LQJ PHGLD530,PHGLDZLWK GLPHWK\OVXOIR[LGHWR
3%0&FU\RWXEHVDQG$OOWKU HHFU\RWXEHVVKRXOGLPPHGLDW HO\EHSODFHGLQD¬±GHJUHH
IUHH]HU




PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 75 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
75 
 
B.  Labeling and Storage of Samples:  Cryotubes should be labeled with the following information  
(do not include any patient identifiers other than the ones indicated below) : 
 
Patient  BTTC Number  
Protocol number  BTTC 11 -02 
Collection date  
Tube number  
Cells (PBMC) or plasma  
 
ÔÇ∑ Samples should be stored at -70¬∞ to -80¬∞C and shipped as soon as possible ‚Äì specimens have to be 
analyzed within 3 months  of collection . Shippi[INVESTIGATOR_366904]-color flow cytometry.  Briefly, analysis will be conducted with using a panel of antibodies to 
identify different cellular populations such as: CD146 as a marker of mature ECs; CD133 as a 
marker of EC precursors; CD45 to exclude hematopoeitic cells; and anti -KDR as a marker of 
both precursor and mature endothelial cells.  Ap optosis markers (i.e. annexin V) will also be 
incorporated. Standard analysis gates will be used to exclude dead cells and platelets. The number 
of mature CECs, expressed as a percentage of PBMCs, will be recorded and the absolute number 
of CECs and CEPCs (number per microliter of blood) will be derived using the patients white 
count and differential.   
C.  Packaging of Blood Specimens : For clinical blood samples, the following four layers of 
packaging should be included:  
1. Primary watertight inner recepta cle. Use watertight containers for liquid specimens with a 
positive closure such as a screw -on, snap-on or push -on lid, taped for an additional seal. If you 
place multiple fragile primary receptacles in a single secondary receptacle, they must be 
individually wrapped or separated to prevent contact [CONTACT_76058].  
2. Absorbent material. Place absorbent material such as paper towels or cotton balls between the 
primary and secondary receptacles, using enough material to absorb the entire contents of al l 
primary receptacles.  
3. Secondary watertight inner receptacle. Use a watertight sealed plastic bag or plastic canister  
4. Sturdy outer packaging. Use rigid outer packaging constructed of corrugated fiberboard 
appropriately sized for the contents.  
D.  Shippi[INVESTIGATOR_335]: The samples should be shipped to the following address ON DRY ICE in 
appropriately labeled package (include dry ice label ‚Äì ensure that sufficient amount of dry ice is 
included to maintain samples frozen) in accordance with local and  federal regulations for 
biological material . (Note: The samples may be batched with the PBMC/CEC samples from 
section 18. 5)  
    
Jihong Xu/Puduvalli Lab  
Room [ADDRESS_458632]  
Columbus ,OH [ZIP_CODE]  
Ph : [PHONE_7590] or [PHONE_7591] 
Email : [EMAIL_7060]  
  
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 76 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
[ADDRESS_458633] . Xu by [CONTACT_366971].  Samples can be batched and sent as a single 
shipment Mondays through Wednesdays by [CONTACT_366972] a weekend . 
 
18.4.   Alternative Method of PBMC Processing (If BD Vacutainer CPT Tubes are not procurable)  
 
1.   Collect 7 cc of whole blood in a Sodium citrate blood collection tube and gently invert to ensure good    
mixing. Pi[INVESTIGATOR_366905] a 50 -ml conical centrifuge tube and add 13 ml room 
temperature PBS  
2.  Using a 10 -ml pi[INVESTIGATOR_8459], underlay with 5 ml room temperature Ficoll -Hypaque solution.  
3.  Separate cells by [CONTACT_366973] 20 min at 800 √ó g (2000 rpm in H -1000 rotor), at 20¬∞C, with the 
brake off. 
4.  Gently aspi[INVESTIGATOR_366906] - and platelet -containing supernatan t above the interface band 
(granulocytes and erythrocytes will be in red pellet; see Fig below ‚Äì A. Before centrifugation; B: After 
centrifugation).  
Aspi[INVESTIGATOR_366907] (which includes 
the monocytes) along with no more than 2 ml 
of fluid above the pellet into a 10 -ml pi[INVESTIGATOR_8459], 
then transfer to a new 50 -ml conical 
centrifuge tube, Add PBS to 50 -ml mark.  
 
 
 
 
 
 
 
 
 
5.  Centrifuge 10 min at 600 √ó g (1500 rpm in H -1000 rotor), 20¬∞C, with the brake on.  
6.  Aspi[INVESTIGATOR_366908] 10 ml room temperature PBS.  
7.  Centrifuge 15 min 300 √ó g (750 rpm in H -1000 rotor), 20¬∞C, with brake on. This low -speed 
centrifugatio n permits as many platelets as possible to remain above the pellet of monocytes.  
8.  Prepare and label cryotubes as specified in protocol 18.[ADDRESS_458634] nearly all the overlying  plasma (about 7 ml) leaving about 1 ml of plasma behind 
in the tube ( as the top layer); carefully extract this 1 ml of plasma  without disturbing the lower layer 
using a 3 ml pi[INVESTIGATOR_366909] #1.  
10.  Then remove ALL of the mononuclear layer (1.5 ml) and put into cryotube #2.  
11.  Then transfer half of mononuclear cells from cryotube 2 (750 microliters) to cryotube #3.   
12.  Add 750 microliters of freezing media (RPMI -1640 media with 20% dimethyl sulf oxide) to PBMC 
cryotubes (#2 and #3). All three cryotubes should immediately be placed in a ‚Äì80 degree freezer.   
 
monocytes  
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 77 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
77 
 
18.5 Blood and Tissue biomarker collection and analysis   
A. Guidelines for Collection , storage and shipment of Blood Samples for Biomarkers  
ÔÇ∑ Collect 5 mL of whole blood into a CTAD (B ecton-Dickinson Cat #[ADDRESS_458635], 4.5 mL 
tubes) vacutainer tube, being careful to minimize agitation of the sample and using the largest -
bore needle that is feasible for the patient.   
ÔÇ∑ Mix by [CONTACT_166117] 4 times.    
ÔÇ∑ Centrifuge at 2000 x g for 15 minutes at room temperature within 1 hour of draw.  
ÔÇ∑ Within 30 minutes after centrifugation, draw off plasma very slowly with transfer pi[INVESTIGATOR_366910] 0.5 cm of the buffy coat, tak ing great care not to disturb the buffy coat.  (NOTE: Any 
contamination may invalidate the assay.  If there is inadvertent mixing of these layers, please 
indicate this in the shipment paperwork )    
ÔÇ∑ Pi[INVESTIGATOR_366911]-chilled plastic cryovials.  Do not 
transfer more than 1.5 mL into each tube.   
ÔÇ∑ All specimens must be stored frozen at -20ÀöC (or colder) in a freezer.   
ÔÇ∑ One vial is labeled VEGF/bFGF and the other vial is labeled as reserve.  These reserve tubes will 
be used to measure soluble VEGFR -1 and -2, placental growth factor (PlGF), SDF1Œ±,  
angiopoeitin -1 and 2. 
ÔÇ∑ Labeling of samples :  All samples should be labeled with  the following information:  (do not 
include any patient identifiers other than the ones indicated below ): 
Patient  BTTC Number  
Protocol number  
Collection date  
Tube number  
Cells or plasma  
ÔÇ∑ Packaging and Shippi[INVESTIGATOR_3931]:  The samples should be packaged as described in Section 
18.4 C and shipped to the following address ON DRY ICE in appropriately labeled package 
(include dry ice label  shown‚Äì ensure that sufficient  amount of dry ice is added to cover the 
sample and keep it frozen for overnight shipment ) in accordance with local and federal  
regulations for biological material . (Note: The samples may be batched with the PBMC/CEC 
samples from section 18.4)  
    
Hong Xu/Puduvalli Lab  
Room [ADDRESS_458636] 
Columbus, OH [ZIP_CODE]  
Ph: [PHONE_7590] or 614 -688-7592 
Email: [EMAIL_7060]  
 
  
Prior to shippi[INVESTIGATOR_366912],  please contact [INVESTIGATOR_124] . Xu by [CONTACT_366971].  Samples can be batched and sent as a single 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 78 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
78 
 shipment Mondays through Wednesdays by [CONTACT_366974] a weekend . 
 
 
B. Guidelines for Collection , Processing and Shipment of Tissue and Intraoperative Blood 
Samples 
 
1. Presurgical Tissue Sample - Surgical Arm : Patients who are candidates for surgery (in MDACC 
or other participating sites ) and consent to taking part in the pre -surgical portion of the phase II 
study will be assessed under the following  guidelines to ensure uniform tissue collection and 
processing  
 
ÔÇ∑ After a patient has consented  for the pre-surgical portion of the study, the laboratory 
personnel ([EMAIL_7060]) at [PHONE_7590] or 614 - 688-7592, should be notified by 
[CONTACT_366975].  
  
ÔÇ∑ Following surgery and verification of tumor recurrence , two specimens of tissue will be 
collected  
1. Snap Frozen:  One part (1 cm3) will be collected as soon as possible after resection and 
snap frozen  for genomic profiling (see instructions below). To ensure that the highest 
quality data can be obtained, it is essential that tissue should be processed in an expedited 
manner. If this tissue cannot be processed right after resection, it should be transpo rted to 
the lab on ice as soon as possible and snap-frozen and stored as indicated below . 
Standard Instructions for Collecting Snap Frozen  Tissue  
 Pre-label one cryovial according to the specimen labeling requirements indicated in 
the Labeling Instructions below.  
 Pre-chill cryovial by [CONTACT_195142].  
 Tissue specimen should be a minimum of 1 cm3 in size. If needed, remove any blood 
from the spec imen by [CONTACT_366976] a sterile swab.  
 Snap freeze tissue as soon as possible  after resection on dry ice or in the vapor phase 
liquid nitrogen (do not submerge the tissue in liquid nitrogen).  
 Transfer frozen specimen to pre -chilled tube to prev ent thawing of the tissue  
 Store snap frozen tissue in a -70¬∞C to -80¬∞C freezer until ready to ship.  
2. FFPE Specimen:  A second part will be  obtained from the  routinely processed  formalin 
fixed and paraffin -embedded (FFPE) block s generated for immunohistochemical studies , 
This part can either be provided as 20 unstained slides or an equivalent section from the 
paraffin block and should be verified to contain non -necrotic tumor tissue .   
 
ÔÇ∑ Intraoperative blood samples  should be processed as descri bed in Section 18.5  A above 
ÔÇ∑ Contact [CONTACT_366977]/Puduvalli Lab             
Room [ADDRESS_458637],                                     
Columbus, OH [ZIP_CODE]   
Ph: [PHONE_7590] or 614 -688-7592     
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 79 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
79 
  
3. Tissue samples from  PRIOR surgeries  
Samples from prior surgeries ( sections of paraffin blocks) should be collected whenever available 
from patients who consented to optional procedures . If paraffin blocks are unavailable, 20 
unstained slides can be provided. The samples should be shipped to  OSU and will be stored in the   
Puduvalli  Lab for correlative studies . These specimens  will not be used to determine treatment or 
procedures ; hence, they can be procured whenever feasible from the initial surgery source (e.g. 
outside hospi[INVESTIGATOR_600]) and any subsequent surgeries (from participating centers or outside center by a 
formal request based on this IRB approved protocol).  
 
ÔÇ∑ Labeling Instructions  for tissue specimens  
Labels on all samples should include the following information  (Do not include any other 
personal identification details) :  
 
Patient  BTTC Number  
Protocol number  BTTC 11 -02 
Collection date  and time 
Vial # and type of specimen (e.g.snap frozen tissue)  
Number of tubes, specimens  or slides 
   
ÔÇ∑ Instructions for Packaging and Shippi[INVESTIGATOR_366913]  (The following are general 
guidelines ‚Äì Each institution should  ensure that all required regulation for clinical sample 
shipment are followed)  
Packaging:  To eliminate the possibility of thawing of frozen samples during packaging and 
shipment, prepare packaging material in advance  
ÔÇ∑ The cryovial must be wrapped in absorbable material such as paper towels  and secured 
with a rubber band .  
ÔÇ∑ Place the specimen in an secondary container such as a sealable plastic bag compatible 
with frozen specimens and seal the same .  
ÔÇ∑ Place packaged specimen in an appropriate shippi[INVESTIGATOR_7788] (composed of an inner 
styrofoam and outer cardboard layer) contain ing dry ice.  Surround the package with dry 
ice.  
ÔÇ∑ Mark the outside shippi[INVESTIGATOR_366914] "Exempt Human Specimen" label and a 
dry ice label.  
 Shippi[INVESTIGATOR_007]:  
a. Ship frozen tissue on DRY ICE  using Federal Express Priority Overnight service  in 
accordance with the  required regulations. Use of other courier services may delay 
package receipt.  
b. Frozen specimens may only be shipped Monday through Wednesday using only overnight 
delivery to arrive on weekdays . Do NOT ship frozen specimens on Friday for Saturday 
delivery. 
c. The samples should be shipped to the following address in appropriately labeled package in 
accordance with local and federal regulations for biological material. Prior to shippi[INVESTIGATOR_366915], please contact  [INVESTIGATOR_124]. Xu by [CONTACT_366978]: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 80 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
80 
 receipt of the sample. Samples can be batched and sent as a single shipment by [CONTACT_366979]. 
 
Jihong Xu/Puduvalli Lab              
Room [ADDRESS_458638].                                    
Columbus, OH [ZIP_CODE]                                       
Ph: [PHONE_7590] or 614 -688-7592         
Email jihong .[EMAIL_7061]   
 
ÔÇ∑ Standard Instructions for Packaging a nd Shippi[INVESTIGATOR_366916]  (The following are 
general guidelines ‚Äì Each institution should  ensure that all required regulation for clinical sample 
shipment are followed)  
 
Packaging  
ÔÇ∑ The specimen should be in a plastic container (for blocks) or in a slide container (for 
unstained slides). It must be wrapped in absorbable material such as paper towels and secured 
with a rubber band.  
ÔÇ∑ Place the specimen in an AIRTIGHT container (must hav e a primary and secondary 
container, ex a Saf -T-Pak).  
ÔÇ∑ Place packaged specimen in an appropriate shippi[INVESTIGATOR_7788] (ex. FedEx box or clinical 
pack).  
ÔÇ∑ Mark the outside shippi[INVESTIGATOR_366914] "Exempt Human Specimen" label.  
 
Shippi[INVESTIGATOR_007] 
ÔÇ∑ The samples should b e shipped to the following address in appropriately labeled package in 
accordance with local and federal regulations for biological material.  
ÔÇ∑ Prior to shippi[INVESTIGATOR_366912], please contact  [INVESTIGATOR_124]. Xu/Puduvalli Lab by [CONTACT_366980].   
ÔÇ∑ Samples can be batched and sent as a single shipment by [CONTACT_366981].  
 
 
Jihong.Xu/Puduvalli Lab          
Room [ADDRESS_458639].                                     
Columbus, OH [ZIP_CODE]                                       
Ph: [PHONE_7590] or 614 -688-7592         
Email: [EMAIL_7062]      
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 81 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
81 
 18.6 BAYESIAN ADAPTIVE ALGORHYTHM: TECHNICAL DETAILS  
Approved  by [CONTACT_366982]#3 on December 17, 2003  
 
Denote the time to progression for the patients as T1,T2,‚Ä¶and index the two treatment arms by t 
= 1,2.  Assume that the T‚Äôi are independent, [Ti |t]~ exponential with median ÔÅ≠ÔÄ™t , for t = 1,2 and 
that a priori  {ÔÄ†ÔÅ≠ÔÄ™1ÔÄ¨ÔÄ†ÔÅ≠ÔÄ™2} are independent following an inverse gamma distribution with parameters 
ÔÅ°ÔÄ†= 2.016 and ÔÅ¢ÔÄ†= 4.064.  This parameterization was chosen to set the mean of the prior equal to 4 
(the historical median TTP in months) and a variance of 1000.  This gives a 95%  credible interval 
for the median TTP of (0.73, 16.44).  For each patient, the randomization probability for treatment 
t=[ADDRESS_458640] median TTP, that is  ÔÅ∞1(data) = Pr( ÔÅ≠1 > 
ÔÅ≠2| data); the randomization probabi lity for treatment t =2 is ÔÅ∞2(data) = Pr( ÔÅ≠2 > ÔÅ≠1| data).  If at any 
point during the trial ÔÅ∞i(data) > 0.995 (< 0.005) the trial will be terminated and treatment i will be 
selected as superior (inferior).  If the maximum accrual is reached and  ÔÅ∞i(data) > 0.975 (< 0.025), 
treatment i will be selected as superior (inferior).  A treatment arm will be dropped at any point 
during the trial if Pr( ÔÅ≠i > 4 |data) < 0.01, for i=1,2.  
 
Prior Distribution (Time -To-Event Trial)  
The time -to-event (TTE) variable, Tji, for each arm j is assumed to be Exponential  with mean 
ÔÅ≠jÔÄªÔÄ†p( Tji | ÔÅ≠j)  = 1/ (ÔÅ≠iDi ) exp(Tj+ / ÔÅ≠i).  However, since most of the time we are interested in the 
median tte,  ÔÅ≠ÔÄ™jÔÄ†ÔÄΩ
log(2) * ÔÅ≠j,  therefore, p( Tji | ÔÅ≠ÔÄ™j) = ( log(2)Dj ) / (ÔÅ≠ÔÄ™jDj ) exp( ( log (2) * Tj+ ) 
/ÔÅ≠ÔÄ™j ).  Where Tj+  = ÔÅìi Tji =event or censoring times for arm j and Dj = # of events for arm j.  
a priori ÔÅ≠ÔÄ™jÔÄ†ÔÅæÔÄ†Inverse Gamma (ÔÅ°jÔÄ¨ÔÄ†ÔÅ¢jÔÄ©ÔÄÆÔÄ†
E(ÔÅ≠ÔÄ™j) = ÔÅ¢j / (ÔÅ°j- 1) ; ÔÅ°> 1  
Var(ÔÅ≠ÔÄ™j) = ÔÅ¢j2 / [(ÔÅ°j - 1)2 (ÔÅ°j - 2)] ; ÔÅ° > 2  
Therefore; ÔÅ≠ÔÄ™j | Tji ~ Inverse Gamma ( ÔÅ°j + Dj
ÔÄ†ÔÅ¢j + log(2 )*Tj+  ÔÄ©ÔÄÆ
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 82 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
82 
 18.7 STUDY FLOW CHART/SCH EMA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 83 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
83 
 Study Flow Chart  
 
Phase I/II Adaptive Randomized Trial of Bevacizumab versus Bev acizumab plus Vorinostat Adults with Recurrent Glioblastoma  
 
 
 BL Cycle 1 Cycle 2 Subsequent every 2 Cycles  Off Treatment  
Procedure   Wk 
1 Wk  
2 Wk 
3 Wk 
4 Wk 
1 Wk 
2 Wk 
3 Wk 
4 Wk 
2 Wk 
4 Wk 
6 Wk 
8  
Informed Consent  X              
Medical History  X              
Physical Exam1 X    X    X    X X 
BP Recorded9 X  X  X  X  X X X X X  
MDASI-BT8 X        X    X X 
MRI (with 
DCE/DSC7) X        X    X 7  X 
Hematology2 X  X  X  X  X X X X X X 
Chemistry3 X    X    X  X  X X 
Urine protein: 
creatinine ratio   
X  
  
X  
  
X     
X   
X   
X  
Pregnancy Test 4  X    X    X  X  X X 
Tumor Pathology  X              
Paraffin Tissue 
block5  X              
Biomarker 
measurement6  X D2  D1  D1         
 
1. Physical examination includes vital signs, neurological exam, neurological function score, Karnofsky performance score ., 
2. Includes CBC with differential  
3. Includes: Total protein, albumin, Ca,   glucose, BUN, creatinine, Na, K, , total bilirubin, alkaline phosphatase, LDH, SGPT (ALT), 
SGOT (AST) . 
4. Only for women of childbearing potential as defined by [CONTACT_76798] 18.11. To be performed before each new cycle of therapy.  
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 84 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
84 
 5. Optional procedur e.  
6. Optional procedure. Including 5 cc blood sample for VEGF, PI[INVESTIGATOR_12252], bFGF, SDF1 Œ±, angiopoietin 1 and 2 and 7 cc of blood for isolation 
of peripheral blood monocytes will be collected for CEC and CEPC, at baseline before  treatment, cycle 1 day 2, day 15 (p re-infusion 
and post-infusion)  and cycle 2 (pre -infusion). The post -infusion blood drawn between [ADDRESS_458641] to be obtained every 2 cycles during treatment and every other cycle  until disease progression if  
treatment is discontinued for reasons other than progressive disease and no other new treatment is started.  Optional DCE/DSC studies 
are preferred but not required.  
8. MDASI-BT at Baseline, prior to results of each MRI Evaluation  are shared with  the patient , and at end of therapy  (optional procedure) . 
9. Blood Pressure monitoring every 2 weeks prior to Bevacizumab infusion.  
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 85 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
85 
 18.8 Multicenter SAE Form  
 
 
 
 
SPONSOR:  
UT MD ANDERSON 
CANCER 
CENTER/BRAIN TUMOR 
TRIALS 
COLLABORATION  
 
IND#:  NA SITE‚ÄôS PROTOCOL NO.       PROTOCOL TITLE:      
PRINCIPAL INVESTIGATOR        
 [INVESTIGATOR_366917]  
 F/U REPORT  
(CHECK ONLY ONE ) PROTOCOL STATUS (CHECK ONE ):       
    ACTIVE   TERMINATED  
  CLOSED TO NEW PATIENT  ENTRY AND PATIENTS ON TREATMENT  
  CLOSED TO NEW PATIENT  ENTRY AND  PATIENTS OFF TREATMENT  
DATE  
RESEARCH 
TEAM 
NOTIFIED OF 
EVENT OR 
FOLLOW -UP       DATE 
SUBMITTED 
TO LOCAL 
IRB       SITE 
NAME        [CONTACT_366992] . OF 
PT‚ÄôS ON 
PROTOCOL 
AT THIS SITE        
PATIENT REACTION INF ORMATION  
MEDICAL RECORD 
NUMBER         REACTION OUTCOME : 
DEATH (PROVIDE 
DATE OF DEATH )       
PATIENT STUDY  NUMBER        HOSPI[INVESTIGATOR_366918] 
(MO/DAY/YEAR )       
 IMPORTANT MEDICAL 
EVENT        
PLEASE WRITE A SHORT  SUMMARY DESCRIBING THE EVENT (S) IF NEEDED  
 Event/Reaction (use appropriate Title from 
NCI CTC for all events reported) (More than 
one event may be listed if related and 
occurs around same time)   Attribution(s):   
Event 
Grade 
(1-5) 
Definite  
Probable 
Possible 
Unlikely  
Unrelated  IS EVENT 
EXPECTED ? 
(NOTED IN THE DRUG 
INFORMATION ) 
      
      
      
      
            
      
      
      
               
         
         
         
         YES   NO  
YES   NO  
YES   NO  
YES   NO  
YES   NO  
MULTICENTER SERIOUS ADVERSE EVENT REPORT  
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 86 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
[ADDRESS_458642] OR ATTACH ALL C ONCOMITANT 
MEDICATIONS PT TAKIN G AT TIME OF 
THE EVENT        
 
 
NAME [CONTACT_366993] 
(LIST MANUFACTURER AN D LOT 
# #)       DID REACTION ABATE A FTER STOPPI[INVESTIGATOR_366919]? 
YES       DATE       
DOSE  
( LIST FREQUENCY OR  
SCHEDULE )       NO       
NOT KNOWN        
ROUTE OF ADMINISTRAT ION       DID REACTION REAPPEA R AFTER REINTRODUCTI ON? 
DATE(S) OF ADMINISTRATION        
 
HAVE YOU ALSO REPORT ED THIS 
REACTION TO THE 
MANUFACTURER ?  
      YES       DATE:       
NO       
NA       
 
 
PRINTED NAME [CONTACT_366994]   
[INVESTIGATOR_366920] # 
 
COMPLETED SAE  REPORT FORMS FOR MULTICENTER REPORTING ARE TO BE S UBMITTED TO THE OMCR  VIA EDMS  OR FAX AT : 
 
EDMS:  HTTPS ://IVIEW .MDANDERSON .ORG/ 
FAX: [PHONE_7588]  
 
THE SITE REPORTING TH E SAE  MUST IMMEDIATELY AL ERT THE OMCR  VIA EMAIL OR PHONE THAT AN SAE  HAS BEEN SUBMITTED . 
 
FOR PROBLEMS SENDING THE FORM OR OTHER QU ESTIONS , PLEASE CONTACT [CONTACT_366983] . 
 
 
 
 
 
 
 
 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 87 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
87 
 18.9 [LOCATION_001] Heart Association (NYHA) Guidelines  
 
 
 
18.10  PROCEDURE FOR OBTAINING A URINE PROTEIN: CREATININE RATIO  
 
1)  Obtain at least 4 ml of a random urine sample (does not have to be a 24 hour urine)  
2)  Determine protein concentration (mg/dL)  
3)  Determine creatinine concentration (mg/dL)  
4)  Divide #2 by #3 above:   urine protein / creatinine ratio =  protein concentration (mg /dL) / 
creatinine concentration (mg /dL)  
 
The UPC directly correlates with t he amount of protein excreted in the urine per 24 hrs (i.e. a 
UPC of 1 should be equivalent to 1g protein in a 24hr urine collection)  
                                            
Protein and creatinine concentrations should be available on standard reports of urinalyses, not 
dipsticks. If protein an d creatinine concentrations are not routinely reported at an Institution, their 
measurements and reports may need to be requested.  
  
 
 
 
 

PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 88 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
88 
 18.11 Pregnancy tests for females of childbearing potential and adequate methods of 
contraception  
 
A female of childbearing potential (FCBP) is a sexually mature female who: 1) has not undergone 
a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at 
least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive 
months). 
 
Pregnancy tests must occur within [ADDRESS_458643] before each new cycle; at discontinuation of vorinostat and at Day [ADDRESS_458644]: Serum ÔÅ¢-HCG  
 
Adequate method of contraception: one highly effective method or more than one additional 
methods. 
 
Highly effective methods:  
ÔÇß Intrauterine device (IUD)  
ÔÇß Hormonal (birth control pi[INVESTIGATOR_3353], injections, implants)  
ÔÇß Tubal ligation  
ÔÇß Partner‚Äôs vasectomy  
 
Additional effective methods:  
ÔÇß Latex condom  
ÔÇß Diaphragm  
ÔÇß Cervical Cap  
 
 
  
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 89 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
89 
 18.12 MD ANDERSON SYMPTOM  INVENTORY FOR BRAIN  TUMORS (MDASI -BT) 
 
 (The MDASI ‚Äì BT is created by [CONTACT_366984]. 
The standard MDASI ‚Äì BT questionnaire is used as a template. This form will contain coding  
‚Äúlandmarks‚Äù   that enable the data to be scanned into the MD ANDERSON CANCER CENTER  
data repository for MDASI results. Please contact [CONTACT_366985] .) 
 
 (Rest of this page is left blank on purpose)  
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 90 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
90 
 

PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 91 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
91 
  

PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 92 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
92 
 18.13   Drug Accountability  
  
BTTC11-02      DRUG ACCOUNTABILITY DOCUMENTATION:     
 
TO BE COMPLETED BY [CONTACT_366986]: ________________________                         BTTC I.D. # _________        Cycle #  ________  
 
 
DOSE OF VORINOSTAT PRESCRIBED: __________ MG  _____ CAPSULES (DAILY)  
 
VORINOSTAT CAPSULES  are 100MG EACH.  
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx  
 
 
DATE DISPENSED: _____________ (mm/dd/yy)  
 
 
QUANTITY OF BOTTLES DISPENSED OF 100 MG : ________     QUANTITY OF 100 MG T ABLETS PER BOTTLE: ___________  
 
NUMBER OF 100  MG TABLETS  PER DAY REQUIRED TO ACHIEVE PRESCRIBED DOSE: _____________  
 
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx  
 
**********DO NOT RETURN UNUSED TABLE TS TO THE PATIENT*************  
 
RETURN PI[INVESTIGATOR_93601]/BOTTLE COUNT DATE: ___________  (mm/dd/yy)     Has the patient taken the dose scheduled for this date?  YES     N O  
         
QUANTITY OF EMPTY BOTTLES RETURNED: _____________  QUANTITY OF CAPSULES RETURNED: ______ ________  
 
Please document any discrepancies between number of capsules returned and patient‚Äôs diary, or any other discrepancies: ______ ______________  
 
_________________________________________________________________________________________________________ ____________  
 
Study Coordinator Name:_______________________________       Signature [CONTACT_3670]: ____________________________________________ _ 
 
 
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 93 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
93 
 18.14   BTTC11-02 Patient Study Drug Diary   
 
PATIENT INITIALS: _______________________                     BTTC I.D. # _________         Cycle# ______ Start Date: _________  
    
This calendar is for you to indicate that you took the study drug as instructed.  Please put a check mark or your initials a fter each dose.  If not taken, write 0 mg. 
Please sign this calendar at the end of the cycle and bring the calendar and all study drug bottle(s) back to your next clini c visit. 
  
 DOSE prescribed:  Vorinostat   ______mg (_____ capsules) by [CONTACT_366987] [ADDRESS_458645] be administered whole.  
 
Day 1 __________  
 
____________ mg  
 
 Day 2 __________  
 
____________ mg  
 
 Day 3  __________  
 
_____________ mg  
 
 Day  4 __________  
 
______________mg  
 
 Day 5 __________  
 
______________mg  
 
 Day 6 __________  
 
______________ mg  
 
 Day 7 __________  
 
______________mg  
 
 
Day 8 __________  
 
 
 Day 9 __________  
 
 
 Day 10 __________  
 
 
 Day 11 __________  
 
 
 Day 12 __________  
 
 
 Day 13 __________  
 
 
 Day 14 __________  
 
 
Day 15  
 
____________ mg  Day 16 _ 
 
___________ mg  
 
 Day 17 __________  
 
____________ mg  
 
 Day 18 __________  
 
____________ mg  
 
   Day 19 __________  
 
____________ mg  
 
 Day 20 __________  
 
______________ mg  
 
 Day 21 __________  
 
______________mg  
 
 
Day 22 
__________  
 
 Day 23 
__________  
 
 Day 24 __________  
 
 
 Day 25 __________  
 
 Day 26 
___________  
 
 Day 27 ___________  
 
 Day 28 __________  
 
 
Day 29 
___________  
 
 Day 30 
__________  
 
 
 My signature [CONTACT_366995]: _________________________________________  Date: _____________________  
 
 
 
  
PRIVILEGED COMMUNICATION: FOR INVESTIGATIONAL USE ONLY  
                                                                                                           BTTC11-02   
  9.22.2014  
Page 94 of 94    
                              
Bevacizumab  + Vorinostat Protocol        
 
94 
  